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Methods to Increase Efficiency in Clinical Trials with Restricted Sample Size
by Kristian BROCK
Efficiency is a perennial motivation of statistical analysis and clinical trials. This is
most pertinent when sample size is constrained. When trials and their analyses are
more efficient, results can be more precise, can be disseminated quicker, and impact
the clinical pathway faster.
This thesis describes methods developed and investigated by the author in three
trials at the Cancer Research UK Clinical Trials Unit. Methods for seamless phase
I/II trials that conduct dose-finding by efficacy and toxicity outcomes are studied.
A repeated measures analysis in an ultra-rare disease yields a feasible trial where
standard approaches do not. Finally, this thesis develops methods for a phase II trial
with co-primary outcomes and predictive covariate information.
We conclude that two common goals to increase efficiency are: i) use more out-
comes to answer trial questions; and ii) use all available information. In our exam-
ples, analysing efficacy and toxicity in dose-finding lets these trials simultaneously
achieve phase I and II objectives. However, this thesis highlights operational is-
sues that can impair efficiency. We show that statistical performance is improved
by analysing the information in repeated measures and predictive baseline covari-
ates. Methods developed herein help to achieve conventional error rates without
prohibitive increases in sample size.
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1.1 Aims of this thesis
There are instances in clinical trials where innovative or uncommon methods are
used to increase efficiency, particularly when the feasible sample size is smaller than
would generally be desirable. This thesis describes in detail a number of methods
that have been used and developed by the author in three clinical trials at the Cancer
Research UK Clinical Trials Unit of the University of Birmingham.
In this section, we proceed with a brief introduction to clinical trials. We define
efficiency in this scientific context, elaborating on the significance of a restricted sam-
ple size. We then give a brief overview of the chapters in this thesis, highlighting the
novel elements of each.
1.2 Clinical trials
Clinical trials are medical experiments on human subjects. They are generally se-
quential in nature, with treatments typically passing through trials at phases I, II
and III before being accepted as part of the standard of care. The collective aim is to
learn about clinical interventions so that the conditions that impair our health may
be treated and the overall health of the population may be maintained or improved.
The objectives of the individual trial phases are specialised to reflect that this oner-
ous task is tackled in stages. The trial phases are not particularly well defined, so
considerable heterogeneity is seen. However, a generally accepted pathway to mar-
ket authorisation for a drug could be described as follows.
1
Chapter 1. Introduction
Pre-clinical and animal studies yield information on the range of doses that might
be tolerable and active in humans. The typical objective of a phase I trial is to select
from this dose range the most attractive dose for further investigation in subsequent
trials. What constitutes attractive varies by scenario, but it usually entails being tol-
erable to most patients. It might also entail being sufficiently active, in some clinical
or pharmacological sense. Sometimes phase I trials are genuinely “first in man”
scenarios.
In phase II, a typical objective is to assess early signs of efficacy at the dose se-
lected at phase I. The dose may yet be adjusted as safety data continues to be col-
lected, but the primary focus is to establish the presence of some therapeutic ben-
efit. Trials may or may not be randomised, and the use of shorter-term predictive
outcomes is relatively common to make trials quicker. Crucially, this step affords
investigators the opportunity to assess whether an expensive and lengthy phase III
trial is warranted.
If the treatment looks to hold promise, it is then typically tested at phase III
against the standard of care. Phase III trials are usually randomised, and often
blinded. Generally, in the case of drugs, the results of phase III trials are used to
support applications for marketing authorisation so that the treatment may become
part of the standard of care.
1.3 Efficiency in Clinical Trials
In their recent review “Improving Clinical Trial Efficiency: Thinking Outside the
Box”, Mandrekar et al.[62] describe some novel approaches to clinical trials that seek
to increase efficiency. They identify that efficiency equates to “reduced sample size
requirements”. This is probably the most common interpretation of efficiency in the
clinical trial context. Simon & Maitournam[83] also use this definition in their article
evaluating the efficiency of trial designs that seek to allocate patients to treatments
based on the presence of molecular targets. If trial design A can expect to arrive
at a conclusion subject to given statistical error rates, requiring fewer patients than
design B, then A can be said to be more efficient than B.
2
1.3. Efficiency in Clinical Trials
However, sample size is not the sole resource that is sought to be optimised in
the pursuit of increased efficiency in trials. In this thesis, we define efficient methods
in clinical trials to be those that reduce the expected resource required for a trial or
sequence of trials to achieve their objectives. In addition to patients, two other re-
sources invariably required in clinical trials are time and money. Thus, for instance,
an approach that reduces the expected amount of time required to satisfactorily con-
duct a sequence of trials may also be regarded as efficient.
Efficiency is a perennial motivation in the design and analysis of clinical trials
because we want to share the benefits of health research as quickly as possible. The
sooner that good treatments are approved, the sooner they may benefit the diseased
population. The sooner that unacceptable treatments are discarded, the more re-
sources will be dedicated to investigating alternatives that could provide benefit.
Broadly speaking, efficiency can be imparted on clinical trials in two main ways:
through operational and statistical methods. Operational methods are those that al-
ter the way clinical trials are conducted. Efficiency is garnered when a trial is able
to achieve its objective faster, or achieve the objectives of several trials faster than
conducting them separately.
PICO, a mnemonic that lists the core defining elements of a comparative clinical
trial, stands for Population, Intervention, Comparison, Outcome. In this section, it may
serve to illustrate how clinical trials have typically been conducted, as a hypothetical
traditional trial would have a single response to each item. The article by Mandrekar
et al.[62] focuses on so-called basket and umbrella trials. These augment the PICO
approach by investigating a single novel intervention in several disease populations,
and multiple novel interventions in a single population, respectively. The rationale
is that several similar questions can likely be more quickly answered in a single
larger trial than separate parallel trials, when we consider the fixed costs in time
and money required to conduct a clinical trial. The marginal cost of adding to an
existing protocol an extra patient population or novel intervention, keeping the other
elements of PICO constant, is likely to be less than those required to run a completely
new trial. These examples demonstrate how operational efficiency can be achieved.
Another example of operational efficiency comes from achieving the objectives of
two consecutive trial phases in a single over-arching seamless trial. So-called phase
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I/II trials conduct dose-finding whilst assessing efficacy in addition to toxicity in
an experimental treatment, thus achieving the objectives of trials at phases I and II.
There have been a number of designs proposed in this area[12, 92, 98, 112]. These de-
signs are the subject of Chapters 2 and 3 in this thesis. Further examples of seamless
methodology are multi-arm multi-stage (MAMS) trials[77], that fuse the traditional
objectives of phases II and III. However, these are not a particular focus of this work.
There are typically many possible ways to analyse a dataset. In the context where
a decision must be made on the acceptability of a treatment, the type of decision
generally made in trials, statistical methods may be considered efficient when they
achieve given error rates with a smaller sample size. In a clinical trial, those errors
typically involve concluding a novel treatment is superior to a comparator when it
truly is not; and rejecting a novel treatment when it truly is superior. Error rates are
expected to reduce as sample size is increased and more information is provided to
the analysis algorithm. Some algorithms are able to incorporate information from
other sources to increase efficiency and outperform alternatives that have no such
facility. This is the focus of Chapters 4, 5 and 6.
1.4 Restrictions on Sample Size
Sample sizes are constrained in clinical trials for many reasons. The most intuitive
is that the number of patients that may be required to conduct a conventional anal-
ysis simply does not exist. Obviously, this is particularly pertinent in rare diseases.
However, it can be very difficult to recruit to trials in relatively common diseases
like lung cancer and leukaemia, if a particular disease subtype or patient character-
istic is sought. In this regard, every disease has the capacity to suffer from a small
recruitment pool.
Elsewhere, the feasible recruitment level in a trial can be constrained for reasons
other than patient availability. For instance, with novel therapeutics that are difficult
or expensive to manufacture, it may transpire that only a small number of patients
can be treated. If research funds are constrained, as they so often are, only a small
trial may be possible. Finally, time is often a limited commodity. There is a strong
motivation to conduct phase I and II trials quickly so that the time novel treatments
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spend in trials can be reduced and effective new treatments delivered to patients in
a timely manner.
There are many reasons that sample sizes are restricted and we will encounter
several of them in this thesis. When sample sizes are restricted, trialists have strong
motivation to use efficient methods to make the most of the available information.
1.5 Chapters in this thesis
It is preferable to pass through the trial phases as quickly as possible. A seamless
phase I/II trial that achieves both the traditional objectives of separate phase I and
II trials is efficient if it is faster and cheaper than separate trials. Seamless phase I/II
trials are the focus of Chapters 2 and 3.
In Chapter 2, we describe our experiences using the EffTox dose-finding de-
sign[92] in the Matchpoint trial. The design estimates the rates of binary efficacy
and toxicity events at a range of different doses using logit models. The probabil-
ity model uses six parameters in total. A feature of dose-finding trial designs is
that they must make inferences when very few patient outcomes are observed. For
example, in typical dose-finding scenarios, patients are treated in cohorts of three.
Once the first cohort is treated and assessed, the trial design advises the dose for
the second cohort based on the outcomes observed hitherto. In this scenario with
the EffTox model, there are fewer patients than parameters so inferences are subject
to great amounts of uncertainty. We introduce the phenomenon of dose ambivalence
where the design can recommend different doses in response to identical outcomes,
and advocate a simulation-based method to overcome the ensuant uncertainty. We
also describe the challenge arising from outcome ambiguity, and advocate a practical
solution using dose-transition pathways in the phase I/II setting. Our methods pro-
mote efficiency by aiding the selection of the optimal dose and overcoming delays
in the assessment of outcomes.
Chapter 3 introduces a novel design for seamless phase I/II clinical trials. It fuses
elements from EffTox and an alternative design by Wages & Tait[98] that uses adap-
tive randomisation to explore the doses under investigation. Wages & Tait’s method
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uses a simpler probability model that requires fewer parameters than EffTox. How-
ever, randomisation brings potential operational complexity. Our motivation was
to create a hybrid design that uses fewer parameters than EffTox in the hope that
this would maintain statistical efficiency, whilst abrogating the need for randomisa-
tion and reducing possible administrative inefficiency. We present the design and
investigate performance in Matchpoint scenarios in Chapter 3.
The desire for efficiency is not unique to early phase trials. It is important when-
ever sample size is constrained, and felt particularly acutely in rare diseases in piv-
otal settings. This is the topic of Chapter 4, where we describe a design for a ran-
domised controlled trial in an ultra-rare disease. A traditional experiment where
outcomes are compared at the end of an intervention period would require a sample
size that exceeds the total number of patients in the UK to achieve conventional error
rates. We describe an approach using repeated measures, linear hierarchical models,
and simulation to design a trial that is feasible and defensible. Key to achieving this
was using all of the information in the repeated measures. The flexibility of the sim-
ulation method allowed us to examine expected power under different patterns of
missing data. Our motivation for this level of scrutiny was the severely constrained
sample size. Our literature review shows that this approach is novel in clinical trials
of visual acuity, and indicative of other scenarios where repeated measures analyses
are possible but generally not conducted.
Patient numbers might be constrained in otherwise common diseases because of
specific eligibility criteria. This is the focus of Chapter 5 where we introduce a novel
adaptation to the design of Thall, Nguyen & Estey[89] to assess an immunother-
apy drug in a specific subgroup of non-small-cell lung cancer patients. Lung cancer
is a regrettably common disease but subgroups can be quite small once molecular
stratifiers are included. Our design incorporates baseline predictive information to
increase efficiency when simultaneously assessing efficacy and toxicity outcomes
in a phase II trial. It achieves statistical operating performance superior to bench-
mark designs that assess treatment cohort-by-cohort. One of the goals of stratified
medicine is to tailor treatments by patient subgroup. We use predictive categorical
variables, presented and validated in a trial of a related patient group, to increase
efficiency in estimating the event rates of our co-primary outcomes. The design
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satisfies an otherwise unmet need that will become more common as biomarker-
associated therapies are further investigated.
In Chapter 6, we extend further the scenario in Chapter 5 by considering alterna-
tive model specifications. Our chosen model forms were motivated by the available
literature and our feasible sample size. However, the implicit assumptions were po-
tentially undesirable. We research the implications of more complex model forms,
and discuss the trade-off of a more flexible model with the attendant greater re-
source requirements. We describe how marginal further efficiencies are available at
relatively little marginal cost.
Finally, in Chapter 7 we discuss the broad themes spanned by the topics in the




Implementing EffTox in the
Matchpoint Trial
Background: Methods for phase I/II dose-finding use efficacy outcomes in ad-
dition to toxicity outcomes to identify the most attractive dose. EffTox is one of
the earliest and best-known. The Matchpoint trial uses EffTox to search for an ef-
fective and tolerable dose of ponatinib to combine with FLAG-IDA chemother-
apy.
Notable methods in this chapter: We describe a nomenclature for succinctly
describing outcomes in phase I/II dose-finding trials. We use dose-transition
pathways in the phase I/II setting, where doses are calculated for each feasible
set of outcomes in future cohorts. We introduce the phenomenon of dose ambiva-
lence, where EffTox can recommend different doses after observing the same
outcomes. We also describe our experiences with outcome ambiguity, where the
categorical evaluation of some primary outcomes is temporarily delayed.
The implications on efficiency: Phase I/II trials are efficient because they allow
the objectives of two trial phases to be addressed at once. However, phenomena
like dose ambivalence and outcome ambiguity stand to erode that efficiency by
allowing sub-optimal doses to be selected and causing delays in the assessment
of outcomes. The methods we introduce show how those complications can
be managed and overcome. Furthermore, our methods facilitate efficient trial
planning and conduct.
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2.1 Introduction
The introduction of BCR-ABL tyrosine kinase inhibitors (TKIs; imatinib, dasatinib,
nilotinib, bosutinib and ponatinib) has revolutionised the treatment of chronic myeloid
leukaemia (CML). The great majority of patients with chronic phase (CP)-CML ob-
tain a durable complete cytogenetic response and the rate of progression to blast
phase (BP) is 1 to 2% per annum in the first few years after diagnosis, falling sharply
when major molecular response is obtained[34, 47, 58]. A minority of patients (<10%)
present with de novo BP-CML and of these two-thirds are myeloid and one-third
lymphoid BP[43]. Despite the use of TKIs, median survival after the diagnosis of
BP-CML is between 6.5 and 11 months[33, 41, 71, 78], with the majority of long-term
survivors being recipients of allogeneic stem cell transplant in second chronic phase
of disease[48]. This poor survival is often due to patients developing new mutations,
most frequently within the BCR-ABL kinase domain, resulting in resistance to TKIs
and further rapid disease progression[85]. Therefore, novel therapies to improve
and prolong therapeutic responses in BP-CML are urgently sought.
In the Matchpoint trial (EudraCT 2012-005629-65) we plan to simultaneously as-
sess co-primary safety and efficacy outcomes for the combination of a novel TKI,
ponatinib, with conventional FLAG-IDA chemotherapy. We believe this to be the
first such study in blastic phase CML. It is envisaged that the data will be the first
step to improve the treatment of this difficult clinical problem.
Historically, dose-finding trials in oncology have sought to find the maximum
tolerable dose (MTD) of a treatment under the cytotoxic assumption. Rule-based de-
signs like 3+3 change dose based on the number of dose-limiting toxicities (DLTs)
observed. Using a model-based design like the seminal continual reassessment
method[69] (CRM), dosage is increased to find the dose with an associated probabil-
ity of toxicity that is less than (or close to) a pre-specified threshold. The rate of effi-
cacy does not directly affect the dose selection decision. Instead, it is assumed to in-
crease monotonically with the probability of toxicity and dose. This has been a valid
assumption in treatments like chemotherapy, that kill diseased and non-diseased
cells alike. A notable advantage of the cytotoxic assumption is that it simplifies the
mathematics when calculating the ideal dose.
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Increasingly, modern treatments like molecularly targeted agents and immunother-
apies are being investigated for their therapeutic effects in oncology. Targeted ther-
apies work by altering the behaviour of cells at a molecular level to slow or stop
the malignant proliferation. Immunotherapies work by instigating a response from
the patient’s immune system to fight disease. A positive outcome like longer sur-
vival may be achieved whilst containing the aggregate disease burden, rather than
reducing it. With each of these classes of treatment, the cytotoxic assumption is
not necessarily valid so we can no longer assume that the most toxic dose is the
most efficacious dose. This presents a methodological challenge to investigators in
dose-finding trials. The goal here is to find the optimal dose rather than merely the
maximum tolerable dose. We may regard the optimal dose as that which provides
the most attractive trade-off between the probabilities of efficacy and toxicity, or that
which offers maximal chance of efficacy with the chance of toxicity less than some
critical value. Generally, these targeted therapies and immunotherapies are less toxic
than cytotoxic therapies, so the optimal dose may be much lower than the MTD[1].
In the so-called cytostatic setting, dosing decisions should be guided by patients’
outcomes with regard to efficacy and toxicity, yielding designs for joint phase I/II
trials.
Published clinical trial designs in this arena include extensions of CRM. Braun’s
bivariate CRM[12] models separate toxicity and disease progression events. Zhang
et al.’s variant of CRM[112] uses an ordered trinary outcome that incorporates re-
sponse and toxicity. More recently, Wages & Tait[98] introduced a method that uses
a latent CRM model to monitor toxicity and selects amongst candidate efficacy mod-
els using Bayes factors. Amongst non-CRM alternatives, Wang & Day [99] introduce
a utility-maximising approach that assumes responses and toxicity occur in patients
according to log-normally distributed patient thresholds.
Thall & Cook[92] introduced EffTox, the method we chose to use in Matchpoint.
EffTox is a Bayesian adaptive dose-finding trial design that models correlated binary
efficacy and toxicity outcomes. A search of PubMed on 17th October 2016 for articles
that have cited Thall & Cook[92] returned 54 items. Of these, 36 were methodolog-
ical in nature, detailing extensions or alternative designs. A further 14 were review
articles. Only four articles pertained to the design or reporting of a specific clinical
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trial. Three of these used the EffTox design[4, 23, 81]. The first author is based at the
MD Anderson Cancer Center for two of these papers[4, 81], and at the University
of Washington for the third[23]. The fourth trial article[13] cites the EffTox paper
but uses a randomised trial design. It is not our intention to give a full systematic
review but this scoping search suggests that EffTox is not widely used, and scarcely
used at all outside the USA. Thall[88] himself admitted that “[Bayesian models for
early phase clinical trials] have seen limited use in clinical practice”. In describing
our experience using this important dose-finding clinical trial design, we hope to en-
courage others to use it too. Our proposed solutions to the problems we encountered
will expedite the trial design process.
In Section 2.2 we recap the EffTox design. Section 2.3 details our rationale for
choosing EffTox and our experience using it in Matchpoint, the problems we faced
and the solutions we proposed. We provide some discussion in Section 2.4, culmi-
nating in some conclusions on the impact on clinical trial efficiency in Section 2.5.
2.2 The EffTox Design
Thall & Cook[92] introduced the adaptive Bayesian design EffTox to facilitate seam-
less phase I/II dose-finding. EffTox uses logit models for the marginal probabilities
of efficacy and toxicity at each dose and utility contours to measure the attractive-
ness of each dose based on the posterior probabilities of efficacy and toxicity.
Let y = (y1, ..., yn) be the n doses under investigation. Thall & Cook use the
codified doses x = (x1, ..., xn):






For example, a trial of 4 doses, 10mg, 20mg, 30mg and 50mg, would have y =
(10, 20, 30, 50), and x = (−0.85,−0.16, 0.25, 0.76). These values are used as explana-
tory variables so it is desirable that they are centralised and relatively small in mag-
nitude.
Using the notation of Thall & Cook[92], let Y = (YE , YT ) be indicators of binary
efficacy and toxicity events. Let πa,b(x, θ) = Pr(YE = a, YT = b|x, θ) for a, b ∈ {0, 1}.
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The marginal probabilities of efficacy and toxicity at dose x are given by
logitπE(x, θ) = µE + βE,1x+ βE,2x
2 (2.2)
and
logitπT (x, θ) = µT + βTx (2.3)
When βT > 0, the toxicity probabilities increase monotonically in dose. In contrast,
the efficacy curve is not necessarily monotonically increasing. The presence of βE,2
allows for non-linearity and possibly a turning point.
The joint probability model is
πa,b(x, θ) = (πE)
a(1− πE)1−a(πT )b(1− πT )1−b




where ψ is an association parameter and (x, θ)-notation has been suppressed in
each function for brevity. Here, a, b are binary patient-specific variables that denote
whether efficacy and toxicity events occurred. For a given patient, a = 1 means the
patient experienced efficacy and b = 1 means they experienced toxicity.
The EffTox design requires several pieces of information to be elicited from the
investigators. Firstly, the statistician must elicit the prior probability of efficacy
and toxicity at each dose. Let us label the vector of efficacy probabilities ηE , and
the toxicity analogue ηT . The EffTox software[45] published by the MD Ander-
son Cancer Center will take these prior beliefs and a desired effective sample size
(ESS) and convert them into univariate normal priors on each component of θ =
(µT , βT , µE , βE,1, βE,2, ψ). Thall et al.[94] detail the algorithm and advise that ESS
should be between 0.5 and 1.5. High values for ESS reflect stronger prior infor-
mation. The preference is for priors that are strong enough to sensibly guide early
dosing decisions but weak enough to be overridden by patient outcomes where they
diverge from prior beliefs.
Secondly, the statistician must elicit parameters to calculate the utility contours.
Thall et al. discuss one particular method for this task[92, 93]. The points (π∗1,E , 0),




3,T ) are elicited from the investigator such that the pairs are
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equally attractive. The quantity π∗1,E is the minimum required probability of efficacy
when toxicity is impossible. The quantity π∗2,T is the maximum permissible proba-
bility of toxicity when efficacy is guaranteed. The point (π∗3,E , π
∗
3,T ) is chosen in the
first quadrant (i.e. not lying on the x- or y-axis), representing a pair of probabilities
for efficacy and toxicity that are of equal attractiveness as the two other points.
EffTox originally used inverse quadratic functions to model the utility contours
but, after observing that the design was reticent was escalate to more efficacious
doses, the authors later advocated using Lp norms[27]. An Lp norm is a mathemati-
cal tool for generally measuring the distance between two points. The best known is
L2, the Euclidean norm, that measures the length of a hypotenuse c in a right triangle
to satisfy c2 = a2 + b2, where a and b are the lengths of the other two sides.
Thall et al.[94] stressed the importance of using contours that are steep enough
to encourage the design to accept slightly higher probabilities of toxicity when they
are compensated with materially higher probabilities of efficacy. This point was de-
veloped in detail in Yuan et al.[111]. In Figure 2.1, we see that the neutral utility
contour in bold is practically vertical when the probability of toxicity belongs to
(0, 0.2), illustrating what we mean by a steep contour. Here, an equal absolute per-
centage increase in the probabilities of efficacy and toxicity will increase the utility
score. In contrast, the neutral utility contour is flatter, or more horizontal, where the
probability of efficacy belongs to (0.8, 1.0). Here, an identical increase in the prob-
abilities of efficacy and toxicity results in a decrease in utility. When the contours
are too flat, pathological behaviour can manifest where the design becomes stuck at
a sub-optimal dose. This point was unfortunately missed in earlier publications on
EffTox[92, 93]. Furthermore, the illustrative example in the original EffTox paper[92]
inadvertently uses a family of contours that exhibit pathological behaviour. In order
to achieve a design with good properties, Thall advocates selecting three equivalent
points that yield a reasonably steep contour, and not trying to elicit points of equal
utility from clinicians. Fundamentally, trialists should note that EffTox has evolved
since its original 2004 publication[92].
14
2.2. The EffTox Design
The utility of a dose with associated posterior efficacy and toxicity probabilities
πE and πT is











In (2.5), p determines the extent of the curvature of the utility contours. For p > 1,
the contours are convex and for p = 1, the contours are simply straight lines[27].
The value for p is calculated by the EffTox software so that the neutral utility curve
intersects (π∗1,E , 0), (1, π
∗





EffTox uses decision criteria to determine the set of admissible doses based on
posterior beliefs. Given trial data for the first j patients,D = {(x1, a1, b1), ..., (xj , aj , bj)},
dose x is admissible if
Pr {πE(x,θ) > πE |D} > pE (2.6)
and
Pr {πT (x,θ) < πT |D} > pT (2.7)
where πE is a lower bound on the acceptable efficacy rate and πT an upper bound on
the toxicity rate. In order to resolve (2.6) and (2.7), a prior-to-posterior analysis must
be carried out to combine the investigators’ priors with D. This involves solving a
six-dimensional integral. The details are given in Thall et al.[92].
The investigators provide values for πE , πT , pE and pT . The set of doses that
are admissible is said to be the admissible set. When a dose selection decision is
required (e.g. at the end of a cohort), the admissible set is recalculated. If no dose
is admissible, the trial stops and no dose is selected for further research. This may
occur if all of the doses are too toxic or insufficiently efficacious, or both. If the
admissible set is non-empty, the dose with maximal utility, subject to rules about not
skipping untested doses, is recommended to be given to the next cohort or patient.
This iterative process is repeated until the maximum sample size or some pre-
defined stopping criteria is reached. The dose recommended after all patients have
been treated and evaluated is the dose selected for further research in a later phase
trial.
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2.3 EffTox in the Matchpoint trial
The EffTox design was originally selected for use in Matchpoint by Christina Yap
(CY), working with the chief investigator and co-investigators. She was aided in
early trial design work by Josephine Khan (JK). The trialists chose to use a seamless
phase I/II dose-finding design in Matchpoint because it would be more efficient that
running separate trials in phases I and II. We wanted the observed efficacy events
to influence the doses selected because there was clinical justification in suspecting
cytostatic behaviour with respect to the experimental agent, discussed below. CY
chose to use EffTox because of the readily-available MD Anderson software[45] with
which to conduct a trial using the EffTox design. Critically, the software performs
simulation studies, allowing trialists to hone parameter choices.
This section details the parameters chosen for EffTox in the Matchpoint trial, the
practical issues we faced and how we surmounted them. A summary of our param-
eter choices appears in Table 2.1. These are discussed further below.
TABLE 2.1: EffTox parameters chosen in the Matchpoint trial. These
are discussed in the main text.
Notation Interpretation Value
N Total number of patients 30
m Cohort size 3
pE Certainty required to infer dose is threshold efficable 0.03
pT Certainty required to infer dose is threshold tolerable 0.05
πE Minimum efficacy threshold 0.45
πT Maximum toxicity threshold 0.40
π∗1,E Required efficacy probability if toxicity is impossible 0.40
π∗2,T Permissible toxicity probability if efficacy guaranteed 0.70
The values pE and pT may seem unconventionally small. Recall that their func-
tion is to define a list of doses appropriate for experimentation. It may be more
intuitive to interpret 1 − p. as the posterior certainty required to omit a dose from
consideration. In their original demonstration, Thall & Cook[92] used values pE =
pT = 0.1.
In Matchpoint, the binary efficacy event is achieved when patients experience
at least a minor cytogenetic response (i.e. <65% Philadelphia chromosome-positive
cells), or haematological response with platelets > 50 × 109/L, neutrophils > 1.0 ×
109/L and blasts< 5% in the peripheral blood and bone marrow. The binary toxicity
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outcome is defined by the occurrence of a range of pre-specified adverse events,
including any grade 3 or 4 clinically significant non-haematological adverse event,
related to ponatinib, that cannot be managed with optimal medical care and likely
to endanger the life of the patient or result in long term effects. Both co-primary
outcomes are assessed over the eight-week period following the commencement of
the first cycle of treatment. The first cycle lasts for 28 to 56 days, depending on how
long it takes for blood counts to recover.
Of practical importance when using a seamless phase I/II design is that the co-
primary outcomes can be assessed over a similar time horizon. It was felt that re-
sponses to treatment could be expected after just one cycle if the treatment could
be successfully administered to patients. If toxicity was frequent and treatment dis-
continuation common, the capacity for response is diminished. In a scenario where
outcomes are assessed over materially different horizons, the trial would proceed at
the speed determined by the outcome with the longest assessment period, increasing
the risk of incomplete data and eroding the scope for operational efficiency.
2.3.1 Parameters
We investigate four doses of ponatinib: 15mg every second day, 15mg daily, 30mg
daily and 45mg daily, referenced as dose-levels 1, 2, 3, 4 respectively, as shown
in Table 2.2. For a tractable analysis, we use y = (7.5, 15, 30, 45), and thus x =
(−0.97,−0.27, 0.42, 0.82).
Generally, the clinicians were comfortable providing their prior beliefs on the
probability of efficacy and toxicity. These were elicited by CY and JK. The clinicians
believed a-priori that all doses would be tolerable. There was some debate about
the extent to which the probability of efficacy would improve when moving from
the third to the highest dose. On balance, it was felt that efficacy would be low at
the lowest doses, increase with dose throughout but begin to level-off at the highest
dose. This yielded the priors shown in Table 2.2.
The clinicians were also comfortable specifying πE and πT . Conventional chemother-
apy regimens like FLAG-IDA can induce complete cytogenetic responses in 20-40%
of patients who have progressed to blastic phase[97]. Cortes et al.[29] gave 45mg of
ponatinib daily as a monotherapy to CML patients and observed major cytogenetic
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TABLE 2.2: Doses under investigation in Matchpoint and the investi-
gators’ prior beliefs on rates of efficacy and toxicity. Note, the pona-
tinib dose labelled 7.5mg per day is actually 15mg every other day.
Dose-level Daily ponatinib dose (mg) Prior Pr(Eff), ηE Prior Pr(Tox), ηT
1 7.5 0.2 0.025
2 15 0.3 0.05
3 (start dose) 30 0.5 0.1
4 45 0.6 0.25
response in 23% of 62 patients in blast transformation phase. They also observed
very good response rates in chronic phase patients. By combining the treatments,
we hope to observe a response rate in excess of 45% so we used πE = 0.45. It was
the clinicians’ prior belief that only the highest two doses would exceed the mini-
mum efficacy threshold. To achieve this level of efficacy, it was felt that a toxicity
rate up to 40% would be acceptable thus we set πT = 0.40.
The first cohort will receive dose-level 3 (30mg) because this is the lowest dose
believed a-priori to be sufficiently active. From here, there is scope to escalate or
de-escalate dose as the outcomes dictate.
The values of pE and pT in (2.6) and (2.7) determine the posterior confidence
required to admit the doses as worthy of investigation. Low values are chosen so
that even relatively weak beliefs will render doses worthy of investigation in this
early phase clinical trial. CY and JK initially proposed using the values pE = pT =
0.05 but later, after the author (KB) became involved in this trial, this was altered this
to pE = 0.03. The process of refining these values is described in Section 2.3.2.6.
In contrast, the clinicians found it rather more challenging to specify (π∗1,E , 0) and
(1, π∗2,T ) because of the practical impossibility of a treatment where efficacy is guar-







and (π∗5,E , π
∗
5,T ), three points in the general efficacy-toxicity space (i.e. not at the ex-
tremes) such that the points had equal utility. Using an Lp norm to fit a curve like
(2.5) to these points requires u(π∗3,E , π
∗








5,T ) = 0. Thus,
we have three simultaneous, non-linear equations with three unknown values:et:
π∗1,E , π
∗
2,T and p. We used the multi-variate solver multiroot in the R[76] package
rootSolve[84] to find the simultaneous solution to these equations. The curve fit-
ted to the elicited points (50%, 40%), (45%, 30%) and (70%, 60%) intercepts the axes
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FIGURE 2.1: Utility contours in the Matchpoint trial. The neutral util-
ity contour in bold joins (0.4, 0) to (1.0, 0.7). Points inside this contour
have positive utility, increasing as they approach (1.0, 0.0).
at (39.6%, 0%) and (100%, 67.9%). We rounded to take π∗1,E = 0.40 and π
∗
2,T = 0.70.
The revised curve actually intersects the points (50%, 40%), (45%, 29.3%) and (70%,
61.4%), as illustrated in Figure 2.1.
Finally, the value of ESS was chosen by trial-and-error. Thall, Cook and Estey[93]
advise a value in the range (0.5, 1.5). Increasing ESS generally improves the per-
formance of the design in scenarios that broadly agree with the prior beliefs, and
vice-versa. Statisticians and investigators should, however, be mindful of the neces-
sity for the data to override the prior in the event that the priors are wrong. This
advocates exercising caution when using inflated ESS values. We arrived at ESS=1.3
because it yielded attractive simulated operating characteristics and sensible dose
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transitions, as described in the following sections.
2.3.2 Trial Conduct
2.3.2.1 Nomenclature for Describing Outcomes in Phase I/II Trials
To expedite the discussion of phase I/II clinical trial conduct, we introduce some
nomenclature, created by KB for succinct interim reporting. Each patient may expe-
rience one of four specific outcomes: efficacy without toxicity (E); toxicity without
efficacy (T); both (B); or neither (N). Let us string these symbols behind a numerical
dose-level to denote the outcomes of cohorts of patients. For instance, 2EET denotes
a cohort of three patients that were given dose-level 2, two of whom experienced
efficacy only and one who experienced toxicity. These strings can be concatenated
to describe the outcomes of several cohorts consecutively. For example the path
2EET 3EBB extends our previous scenario. After the first cohort, the trial escalated
to dose-level 3. The next cohort of three were treated at this dose and all three pa-
tients experienced efficacy. Unfortunately, two of them also experienced toxicities.
Using our notation, this information is unambiguously and efficiently conveyed in
8 characters.
In phase I/II, it is inadvisable to reduce patients’ outcomes to simple tallies of ef-
ficacy and toxicity events because of the complication that patients may experience
both events or neither. For instance, the design may recommend a different dose
after observing NTE than it would after observing NNB, even though both cohorts
contain a single efficacy event and a single toxicity event. In the first example, the
events are experienced by different patients whereas in the latter, they are experi-
enced by the same patient. The distinction is especially pertinent in EffTox because
the ψ parameter models the association between efficacy and toxicity.
The described notation combines simple codification of dose-levels and patient
outcomes to succinctly and unambiguously describe pathways through phase I/II
dose-finding trials. We use it in the next section to define dose transition pathways,
and in following sections to discuss the potential problems of outcome ambiguity
and dose ambivalence, and to aid trial planning.
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2.3.2.2 Dose Transition Pathways
We found it greatly beneficial to prospectively analyse how our dose-finding design
would behave with respect to cohorts by supposing each feasible set of future patient
outcomes and calculating the model advice in each. From a given starting point, we
look to identify the conditions under which the design would escalate dose, stay at
a dose, de-escalate dose, or recommend that the trial stops.
Dose-transition pathways (DTPs) were introduced by Yap et al.[108] in the context
of traditional phase I trials with DLT outcomes. A DTP is a single feasible pathway
through a dose-finding trial. It reflects the dose selections that a model would make
in response to given hypothetical future outcomes. We introduce here the novel
extension of Yap et al.’s idea to phase I/II trials with efficacy and toxicity outcomes.
The example in Table 2.3 shows the complete set of DTPs for cohort 2 having ob-
served 3TTT in cohort 1. We see that after observing 3TTT, the design unsurprisingly
TABLE 2.3: DTPs after observing 3TTT in cohort 1. Cohort 2 is recom-
mended to receive dose-level 2. The dose recommended for cohort 3
depends on the outcomes in cohort 2, as depicted by this table.





















de-escalates to dose-level 2. If a mix of only N and T events is observed in cohort
2, or three T events, the design recommends no dose for cohort 3, choosing to stop
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the trial due to excess toxicity and lack of efficacy. If 2NNN is observed, the design
chooses to re-escalate. In contrast to toxicity-only dose-finding methods, observing
no change is a bad outcome, and the lack of response motivates escalation. In every
other path, the design chooses to de-escalate to dose-level 1 in cohort 3. The EffTox
design is prevented from skipping doses. The effect of the level of toxicity observed
in cohort 1 endures to warrant further de-escalation in the majority of paths to seek
a tolerable dose. After 3TTT 2NNN, the design has simultaneously observed excess
toxicity and a complete absence of response. It is torn between the completing claims
of seeking efficacy and avoiding toxicity. In this particular path, the design chooses
to re-escalate to dose-level 3. After observing 3TTT, even before commencing cohort
2, we know from Table 2.3 that if the trial makes proceeds to cohort 3, it will probably
be at dose-level 1.
Table 2.3 shows DTPs for a single future cohort but that need not be a constraint.
We use DTPs in Matchpoint to analyse every feasible outcome of the next few co-
horts. DTPs can be calculated for several subsequent cohorts, or even an entire trial.
However, the number of possible paths grows geometrically with the number of co-
horts being considered. Each evaluable patient will experience exactly one of E, T, N
or B, independent of the other patients. With cohorts of three, the number of distinct
outcomes for a single cohort is 20, as shown in Table 2.3, hence the number of feasi-
ble DTPs for the next two and three cohorts are 202 and 203 respectively. Thus, the
limitation of what can be depicted on printed pages tends to limit our DTP analysis
to no more than the next two cohorts of three patients.
Our frequent use of DTPs contributed to the efficient conduct of the Matchpoint
trial. We were particularly interested to learn the outcomes that would have to man-
ifest to change dose or stop the trial and DTPs allowed us to make timely prepa-
rations. Furthermore, the method allowed us to convey to investigators and the
monitoring committee the behaviour of our design in many hypothetical scenarios,
emulating the familiar transparency of rule-based designs like 3+3.
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2.3.2.3 Outcome Ambiguity
Patients in the blastic transformation phase of CML under study in the Matchpoint
trial are particularly sick. The FLAG-IDA regimen is toxic and the addition of pona-
tinib only increases the potential for toxic adverse events. Periodic dose-selection
meetings are a feature of dose-finding studies, where early safety and efficacy out-
comes are reviewed and a new dose for the next patient or cohort is selected. Some-
times, because of the frail nature of the patients, efficacy assessments might be tem-
porarily delayed. This outcome ambiguity presents a challenge for dose-selection be-
cause the decision seemingly requires that full patient outcomes be available. How-
ever, we have already seen that this is not necessarily the case. From Table 2.3, we
know that at least one E or B event in cohort 2 is enough to know with certainty that
the trial will proceed to cohort 3 using dose-level 1. If one of the patients experiences
E or B in cohort 2, the dose-decision is independent of the other two patients so it
does not matter, purely from a dose-decision perspective, if some of the outcome
information is temporarily missing for the other patients in cohort 2.
Naturally, this phenomenon does not always occur and there are many occasions
when every patient’s outcomes will be required promptly to know the course of ac-
tion in the subsequent cohort. Furthermore, it is important that outcomes for cohort
2 are finalised before trying to establish doses for cohorts after cohort 3, for example,
because all patient outcomes affect the dosing decision in model-based dose-finding
designs. The described method merely offers short-term respite in some occasions if
a small number of data-points are temporarily missing.
2.3.2.4 Posterior Utility
Thall & Cook work with utility as a function of the mean posterior efficacy and toxic-
ity probabilities of the doses. In contrast, we consider here the posterior distribution
of utility scores. For example, the posterior mean utility of dose x is





whereL is the likelihood function given in EffTox[92] and f(θ) is the parameter prior
distribution.
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(A) After 3 patients with outcomes 3NTE
(B) After 15 patients with outcomes 2NNN 3ENN 4EBE 3TEE 4NEE
FIGURE 2.2: Posterior densities of utility at dose-levels 3 and 4. After
only three patients, the densities largely occupy the same space and
dose ambivalence is likely. However, after 15 patients, they are quite
distinct and dose ambivalence is much less likely.
24
2.3. EffTox in the Matchpoint trial
The posterior utility density curves in Figure 2.2 demonstrates the difficulty a
utility-maximising design like EffTox faces when few patient outcomes have been
observed and two doses have very similar utility scores. Figure 2.2a depicts the pos-
terior beliefs on the utilities of dose-levels 3 and 4 after observing 3NTE in cohort
1. For clarity in illustration, dose-levels 1 and 2 are not shown. Figure 2.2a shows
that the distribution for dose 4 has slightly greater variability but that the two utili-
ties have approximately equal mode. When the posterior utilities for the two doses
are so similar, it is difficult for the design to reliably choose between them and dose
ambivalence (expanded below) is the likely result. Figure 2.2b shows similar curves
after 15 patients with outcomes 2NNN 3ENN 4EBE 3TEE 4NEE. In contrast, the pos-
terior utilities are now quite distinct and a consistent dose decision is almost guar-
anteed. The EffTox implementation in the trialr[16] package offers functionality
to plot posterior utility densities.
2.3.2.5 Dose Ambivalence
The EffTox probability model has six parameters for which prior distributions are
specified. After patient outcomes are observed, posterior estimates of efficacy and
toxicity come from evaluating a six-dimensional integral, one dimension for each
parameter. Such integrals are approximated numerically rather than solved analyt-
ically and this leads to estimation error. Typically, early phase clinical trials do not
use a large number of patients so the amount of information in the trial will usually
be quite low, i.e. the number of patients divided by the number of parameters be-
ing estimated will be lower than a typical phase II or III trial. The combined effect
of these two sources of variability is that the EffTox outputs are subject to quite a
lot of uncertainty, especially in early cohorts. An unwelcome consequence of this
uncertainty is that the model can make different dose recommendations based on
the same patient outcomes. This is obviously undesirable in a clinical trial where a
categorical course of action is sought. KB identified this phenomenon and named it
dose ambivalence.
Consider, for example, our Matchpoint parameterisation and the posterior util-
ities depicted in Figure 2.2a. After observing outcomes 3NTE in the first cohort,
the design sometimes recommends dose-level 3 for the next cohort, and sometimes
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dose-level 4. This ambiguity manifests because the two doses are both admissible,
have similar utility scores, and the Bayesian update integral is imperfectly calcu-
lated. This happens when using the MD Anderson implementation of the EffTox
software[45] that uses the spherical radial method of Monahan and Genz[65] to es-
timate the posterior integrals, and our own implementation that uses Monte Carlo
Markov Chain methods.
It is possible to calculate the integral more precisely by increasing the number
of posterior samples or integration points but this risks missing an important mes-
sage. If the dose-recommendation is not consistent when calculated to a reasonable
numerical precision, the design is telling us that it is difficult to pick between the
doses. It could be that several doses have similar utility scores, as we have seen. Al-
ternatively, it could be that a dose is very close to the boundary for inclusion in the
admissible set. For instance, purely by chance, repeated invocations of the imperfect
statistical analysis may alternatively include or exclude a dose from the admissible
set. In the former, the dose is available for selection. In the latter, it is not. In these
circumstances, the dose recommended is likely to vary. When the design is ambiva-
lent about a dose, rather than rely on one invocation of the dose update decision,
it is more appropriate in our opinion to calculate the dose recommendation many
times (say, 1,000) using reasonable precision and analysing the distribution of the
selections. This presents the uncertainty of the dose recommended.
We give a further example in Table 2.4. Our design with pE = 0.05 was ambiva-
lent on the preferred action after observing 3TTT in the first cohort. This uncovered
a flaw in our design. In that particular instance, the reticence to take the logical
action and de-escalate motivated us to re-parameterise the model to pE = 0.03, as
described in the following section.
2.3.2.6 Changing pE to avoid premature stopping
We commenced the trial with both pE and pT set to 0.05 so that the design only had to
be at least 5% sure that a dose was efficacious and safe to include it in the admissible
set.
Table 2.4 summarises the decision in two dose transition scenarios for the first
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TABLE 2.4: Outcomes of 1,000 replicates for two possible dose-paths
in the first cohort receiving dose-level 3, calculated using EffTox pa-
rameterisations with different values for pE . Pr(Stop) is the probabil-
ity that the design recommends stopping and Pr(i) is the probability
that the design recommends selecting dose-level i for the next cohort.
Decision is the dose level most frequently recommended for the next
cohort in the replicates.
Using pE = 0.05 Using pE = 0.03
Path Pr(Stop) Pr(1) Pr(2) Pr(3) Pr(4) Decision Pr(Stop) Pr(1) Pr(2) Pr(3) Pr(4) Decision
3NEE 0.00 0.00 0.00 0.00 1.00 4 0.00 0.00 0.00 0.00 1.00 4
3TTT 0.45 0.00 0.18 0.37 0.00 Stop 0.09 0.00 0.85 0.06 0.00 2
Matchpoint cohort using two slightly different parameterisations of the EffTox de-
sign. The columns on the left show the behaviour of a design with pE = 0.05; the
right a design with pE = 0.03. Each row summarises 1,000 replicates of the dose-
transition decision. Pr(Stop) is the probability that the design recommends stopping
and Pr(i) is the probability that the design recommends selecting dose-level i for the
next cohort. Decision is the dose level most frequently recommended for the next
cohort in the replicates.
TABLE 2.5: EffTox posterior beliefs after observing 3TTT in cohort 1.
The values for pE and pT determine the admissible doses.
Dose 1 Dose 2 Dose 3 Dose 4
Utility -0.489 -0.534 -0.777 -0.817
Pr(πE > πE) 0.079 0.037 0.060 0.200
Pr(πT < πT ) 0.919 0.758 0.051 0.005
Admissible under pE = 0.05, pT = 0.05 1 0 1 0
Admissible under pE = 0.03, pT = 0.05 1 1 1 0
After observing 3NEE, both designs recommend escalating to dose-level 4 in all
iterations. This is sensible and consistent behaviour. In contrast, after observing
3TTT, the designs take different courses. The design using pE = 0.05 seems unsure
of its preferred behaviour. In approximately half of the iterations, it recommends
stopping and in the other half, it proposes to select dose-level 2 or 3. This is another
manifestation of the ambivalence previously described. The design using pE = 0.03
is rather more consistent because it recommends de-escalating to dose-level 2 in the
great majority of replicates.
Output from the official EffTox software in Table 2.5 reveals the cause. Having
observed three toxicities at dose-level 3, all doses are believed to be unattractive,
hence the negative utility scores. The most attractive dose is actually dose-level 1,
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so the design would like to de-escalate. However, the design cannot go straight to
dose-level 1. The restriction to not skip untried doses requires that dose-level 2 is
tested first. The software does not allow this feature to be turned off. However, with
pE = 0.05, dose-level 2 is actually inadmissible so the design cannot de-escalate.
The problem is potentially exacerbated by the fact that Pr(πT < πT ) is very close
to the value pT = 0.05 for dose-level 3. If this probability is estimated to be slightly
less than 0.05, as is possible with just 3 data-points and a six-dimensional Bayesian
integral solved numerically, then dose-level 3 becomes inadmissible also. Under
these circumstances, with dose-level 4 inadmissible too on account of excess toxicity,
the design cannot recommend a dose so it advocates stopping. This accounts for the
relatively large probability of stopping under pE = 0.05 in Table 2.4.
By reducing pE to 0.03, we made it much more reliable that the design would
de-escalate after 3TTT rather than stop. Observing three toxicities in the first three
patients is clearly a grave situation. However, we should be mindful of the play of
chance and the extent of our knowledge on the event rates. The lower bound of the
95% confidence interval for a binomial proportion having observed three events in
three trials is 29.2% using the exact method, and 43.9% using the Wilson method.
This implies that the true toxicity rate could plausibly be much lower than the 100%
rate observed with 3TTT. Also, we have no direct knowledge of the toxicity rates
at the other dose-levels, only the information extrapolated by our model from the
toxicities observed at dose-level 3. To stop the trial before even trying the lower dose-
levels seems hasty and wasteful. We had not noted the restriction of no-skipping,
and its implications, until we examined the DTPs more closely. We chose pE = 0.03
over pE = 0.05 so that our design would be more willing to de-escalate at early
trial stages when toxicities are observed. We advise fellow trialists to study DTPs
routinely, especially in early cohorts, to spot undesirable behaviour.
In the scenario in question, it is sensible to ask why we are tweaking a parameter
that pertains to efficacy when toxicity is the problem. The succinct answer is that
it was the posterior prediction of efficacy that rendered the doses inadmissible after
invocation of (2.6). In addition to observing the presence of toxicity, the design si-
multaneously observed the absence of response. Decreasing pE was one solution but
was likely not the only one. The same ends could have perhaps been achieved by
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increasing the effective sample size to give more weight to our priors, thus overrid-
ing the low efficacy and high toxicity rates observed. This seemed a less satisfactory
alteration to us.
It is important that investigators are aware of the circumstances under which
their design would recommend stopping because the official EffTox software (v4.0.12)
will not allow further patients to be added once the stop point has been reached. If
investigators are relying on this software, they could find themselves constrained
by a hitherto unknown feature of their design. It is better to address these issues in
set-up rather than when the trial is in progress. Nevertheless, KB developed an open
source implementation of EffTox[16]for research purposes only that will continue to
accept new patient outcomes even after the stop point has been reached.
This section has described a flaw in our EffTox parameterisation that was not ini-
tially evident to us, that could have led to undesirable behaviour and disruption in
our trial, that we discovered through novel analysis of dose transition pathways and
repeated simulation, and resolved via a minor adjustment to the parameterisation.
Efficient trial conduct is maintained when flaws like this are uncovered before they
become critical, or avoided altogether.
2.3.3 Operating Characteristics
Once a complete set of parameters has been proposed, we learn how the design
performs by simulation.
Blastic transformation phase CML is relatively rare. It was felt that 30 patients
was the feasible limit to recruit in a reasonable time frame. The trialists, including CY
and JK but not KB, selected 30 patients as the target sample size. This was chosen to
maximise the expected probability of identifying the optimal dose. The trialists also
chose to use cohorts of three, thus re-evaluating the recommended dose after every
third patient. Evaluating dose after every patient would allow maximum capacity
for adaptation. However, it would also require the maximum number of interim
analyses. Under the procedures of the trials unit, each analysis would be associated
with a monitoring visit, data cleaning and a meeting of the independent data moni-
toring committee. It was hoped that 10 dose decisions (i.e. cohorts of three) would
provide enough opportunity for dose adaptation whilst not coercing an undesirable
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administrative burden on those persons running and monitoring the trial. We inves-
tigated by simulation study the operating performance that could be expected with
30 patients treated cohorts of three.
The EffTox software provides the ability to simulate the outcome of thousands of
trials using the chosen design and some assumed true efficacy and toxicity curves.
In practice, of course, the true curves are unknown. We choose a variety of scenarios
for simulation that will provide pertinent information on the behaviour of the design
in real usage.
Trialists should assess performance in a set of clinically relevant scenarios. One
of the scenarios should closely resemble the investigators’ prior beliefs, as this repre-
sents the anticipated outcome. We would expect the probability of correctly selecting
the best dose to be high in the scenario that matches the investigators’ priors. The
setting for any clinical trial is that we are unsure of the truth so the range of scenarios
in which our design performs well should reflect our ignorance. We considered how
the design would perform if adverse circumstances prevailed. To these ends, we ad-
vocate analysing performance when (i) no doses are tolerable, and (ii) no doses are
efficacious. In these scenarios, the desirable behaviour is to stop. As the clinical sce-
nario dictates, we might also advocate analysing scenarios where the true efficacy
and toxicity curves are not monotonically increasing.
In Table 2.6 we analyse in six indicative scenarios the performance of our chosen
EffTox model in Matchpoint, labelled ESS=1.3. We have also given the performance
of two other models with priors on θ recalibrated using the EffTox software to give
ESS set to 0.5 and 1.5, being the recommended lower and upper limits on ESS ad-
vised by Thall & Cook[92]. These convey the feasible range of performance, holding
all other parameters constant. In every other regard, the three models are exactly the
same. 10,000 replicates were simulated for each model in each scenario. The Monte
Carlo standard error for probabilities estimated by simulation with this number of
replicates is up to
√
0.5× 0.5/10000 = 0.5% so that selection probabilities that differ
by more than 1% probably differ by more than can be regarded merely as simulation
error.
We naturally seek a design that selects the optimal dose most reliably. The op-
timal selection is shown in bold in Table 2.6. However, the design must reliably
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TABLE 2.6: Final dose-selection and stopping probabilities of EffTox
designs with 30 patients in cohorts of 3 and ESS=0.5, 1.3 and 1.5. In
rows pertaining to design performance, the optimal decision is in
bold and the admissible decisions are underlined. The EffTox soft-
ware gives selection probabilities to the nearest whole percent.
Scenario Dose 1 Dose 2 Dose 3 Dose 4 Stop
1
Pr(Eff) 0.20 0.30 0.50 0.60
Pr(Tox) 0.03 0.05 0.10 0.30
Utility -0.33 -0.17 0.16 0.22
ESS=0.5 0.01 0.01 034 0.63 0.01
ESS=1.3 <0.01 <0.01 0.22 0.76 <0.01
ESS=1.5 <0.01 <0.01 0.22 0.77 <0.01
2
Pr(Eff) 0.40 0.60 0.75 0.79
Pr(Tox) 0.10 0.25 0.55 0.60
Utility -0.01 0.25 0.12 0.08
ESS=0.5 0.06 0.59 0.32 <0.01 0.03
ESS=1.3 0.03 0.60 0.35 <0.01 0.01
ESS=1.5 0.03 0.57 0.39 <0.01 0.01
3
Pr(Eff) 0.25 0.40 0.60 0.60
Pr(Tox) 0.10 0.20 0.38 0.42
Utility -0.26 0.04 0.15 0.12
ESS=0.5 0.03 0.10 0.70 0.13 0.04
ESS=1.3 0.01 0.10 0.73 0.13 0.02
ESS=1.5 0.01 0.09 0.73 0.15 0.02
4
Pr(Eff) 0.50 0.60 0.70 0.80
Pr(Tox) 0.20 0.20 0.20 0.20
Utility 0.12 0.28 0.43 0.57
ESS=0.5 0.02 0.03 0.61 0.34 <0.01
ESS=1.3 <0.01 0.02 0.47 0.50 <0.01
ESS=1.5 <0.01 0.01 0.47 0.51 <0.01
5
Pr(Eff) 0.05 0.08 0.20 0.25
Pr(Tox) 0.05 0.08 0.12 0.14
Utility -0.58 -0.54 -0.34 -0.26
ESS=0.5 0.06 0.03 0.01 0.37 0.53
ESS=1.3 0.06 0.07 0.02 0.34 0.51
ESS=1.5 0.07 0.08 0.02 0.36 0.48
6
Pr(Eff) 0.05 0.08 0.12 0.25
Pr(Tox) 0.60 0.65 0.70 0.80
Utility -0.78 -0.78 -0.76 -0.67
ESS=0.5 0.09 0.01 0.01 0.01 0.88
ESS=1.3 0.06 0.01 0.01 0.01 0.91
ESS=1.5 0.04 0.01 0.01 0.01 0.93
stop when no dose satisfies (2.6) and (2.7). When stopping is the correct decision,
the stopping probability is shown in bold. Sometimes, there will be many admissible
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doses that satisfy (2.6) and (2.7), irrespective the fact that one generally dominates all
others by our utility metric. Admissible decisions are underlined in Table 2.6. When
stopping is the correct decision, stopping is the only admissible decision.
Scenarios 1 and 4 show the benefit of a modestly more informative prior. Through
the addition of prior information approximately equivalent to one patient (i.e. in-
creasing the effective sample size of the prior from 0.5 to 1.3 or 1.5), the probability
that the design selects the optimal dose is increased by up to 17%. Investigators will
naturally ponder the existence of the opposite effect, i.e. an increased propensity to
do the wrong thing when the prevailing scenario disagrees with the prior. Scenario 3
shows that this is not necessarily the case. The designs with more informative priors
actually perform slightly better, despite a shape of efficacy curve that disagrees with
the prior.
TABLE 2.7: Mean probabilities of performing the optimal decision in
the scenarios presented in Table 2.6.




Table 2.7 shows the mean probability that each design variant identifies the op-
timal decision, given the six scenarios in Table 2.6. We see that our design is the
superior of the three presented. The variant with ESS=0.5 has inferior performance,
mostly for the reasons discussed. The variant with ESS=1.5 is only modestly inferior
but provides no reason to be preferred to our design.
We investigated by simulation the larger sample size n = 60. The extra patients
greatly improve performance in some scenarios. In scenario 2, the probability of se-
lecting dose 2 increases by 20% to 80%. Similarly, the chances of correctly stopping
early in scenario 5 increase by 27% to 78%. In many clinical scenarios, recruiting a
higher number of patients is warranted in a phase I-II trial because of the associ-
ated improvement in performance and the presence of efficacy assessment that may
abrogate a further traditional phase II trial. Phase I-II trials are an opportunity to op-
timise the delivery of a new agent. In the Matchpoint scenario, unfortunately, higher
recruitment was simply not feasible because of the rarity of BP-CML.
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We also investigated the impact of using pE = pT = 0.1. The chances of stop-
ping in scenario 5 are improved by 30%. As expected, the reciprocal effect is that
the design stops slightly more frequently in scenarios like 3 where an optimal dose
exists.
As well as their propensity to make the correct decision, we also discriminate
designs on how they allocate doses to patients. A design that always makes the
correct decision but treats every patient at an over dose would not desirable, or
indeed ethical. Table 2.8 gives the mean number of patients allocated to each dose
in the scenarios presented in Table 2.6.
Of the three designs presented, our chosen design uses the fewest patients in
scenarios 5 and 6, where the correct decision is to stop the trial. On the four re-
maining scenarios, our chosen design allocates the most patients on average to the
optimal dose in two scenarios. We see this as further reason to prefer the design with
ESS=1.3.
In summary, we have shown by simulation that our selected EffTox parameter-
isation performs well in six scenarios. We have demonstrated that it stops reliably
in situations where all doses are too toxic or inefficacious. We have also shown it to
perform well in a scenario that broadly matches our prior, and in scenarios that de-
part from our prior. Lastly, we have demonstrated that our chosen parameterisation
with effective sample size set to 1.3 is superior to alternatives with ESS set to 0.5 and
1.5, in terms of probability of making the correct decision, and in the allocation of
patients to favourable doses.
2.4 Discussion
Finalising an EffTox design is generally an iterative process. The inferences from
analysing dose transition pathways and simulations will naturally lead to re-parameterisation
and further testing.
It is our general preference to first hone the dose transitions. For the reasons
described, we pay particular attention to the earliest circumstances under which
the trial would stop. The investigators should agree that these circumstances are
dire enough to warrant closing the trial. We also look for any sign that the design
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TABLE 2.8: Mean numbers of patients allocated to each dose, and in
total, in the six scenarios and three EffTox variants presented in Table
2.6. Sum 6= 30 when the trial stops early. Patients allocated to the
optimal dose are given in bold and admissible doses underlined.
Scenario Dose 1 Dose 2 Dose 3 Dose 4 Sum
1
Pr(Eff) 0.20 0.30 0.50 0.60
Pr(Tox) 0.03 0.05 0.10 0.30
Utility -0.33 -0.17 0.16 0.22
ESS=0.5 0.7 0.6 12.1 16.4 29.8
ESS=1.3 0.2 0.2 9.8 19.6 29.8
ESS=1.5 0.1 0.1 9.5 20.1 29.8
2
Pr(Eff) 0.40 0.60 0.75 0.79
Pr(Tox) 0.10 0.25 0.55 0.60
Utility -0.01 0.25 0.12 0.08
ESS=0.5 1.5 11.5 16.0 0.4 29.4
ESS=1.3 0.8 11.6 16.9 0.6 29.9
ESS=1.5 0.7 10.3 18.2 0.7 29.9
3
Pr(Eff) 0.25 0.40 0.60 0.60
Pr(Tox) 0.10 0.20 0.38 0.42
Utility -0.26 0.04 0.15 0.12
ESS=0.5 1.1 2.8 21.8 3.7 29.4
ESS=1.3 0.5 2.5 22.2 4.4 29.6
ESS=1.5 0.4 2.0 22.1 5.2 29.7
4
Pr(Eff) 0.50 0.60 0.70 0.80
Pr(Tox) 0.20 0.20 0.20 0.20
Utility 0.12 0.28 0.43 0.57
ESS=0.5 0.5 1.0 19.3 9.2 30.0
ESS=1.3 0.1 0.7 15.9 13.3 30.0
ESS=1.5 0.1 0.3 15.9 13.7 30.0
5
Pr(Eff) 0.05 0.08 0.20 0.25
Pr(Tox) 0.05 0.08 0.12 0.14
Utility -0.58 -0.54 -0.34 -0.26
ESS=0.5 2.4 2.4 4.7 14.1 23.6
ESS=1.3 1.5 1.9 4.7 15.3 23.4
ESS=1.5 1.4 1.7 4.5 16.0 23.6
6
Pr(Eff) 0.05 0.08 0.12 0.25
Pr(Tox) 0.60 0.65 0.70 0.80
Utility -0.78 -0.78 -0.76 -0.67
ESS=0.5 2.6 3.0 4.0 0.9 10.5
ESS=1.3 1.1 2.8 5.2 0.8 9.9
ESS=1.5 1.0 2.8 5.3 0.9 10.0
seems reluctant to select a dose. This could suggest unsuitable priors or inappro-
priate parameter choices. It should be stressed, however, that EffTox exists to guide
our sequential selection of doses based on patient outcomes. The trialists should
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not stipulate every conceivable dose path and select parameters that replicate their
choices. This approach would preclude the use of a model at all. Rather, in our
opinion, the parameters should be selected for generally acceptable behaviour, with
particular consideration given to the extremes.
Once an acceptable parameterisation has been proposed, the performance of the
design should be assessed by simulation under a broad range of scenarios. The de-
sign should stop sufficiently early and reliably when all doses are too toxic. In sce-
narios where optimal and/or acceptable doses exist, the design should select those
with acceptable probability. Refinements to the parameterisation here will likely re-
quire the trial designer to consider how they affect the behaviour of the design in
dose transition, and thus the circularity of the challenge is illustrated.
We have considered even steeper contours, as stressed by Thall et al.[94] and
Yuan et al.[111]. They did not lead to superior performance in the particular sce-
narios we have chosen. This is likely due to the fact that our contours are steep for
efficacy probabilities as high as 70%, which we consider to be the clinically plausible
scenario in BP-CML. However, the point remains that trade-off contours should be
steep to motivate the design to accept higher probabilities of efficacy for acceptably
higher probabilities of toxicity.
EffTox is a powerful yet underused statistical design for seamless phase I/II
dose-finding clinical trials. Model-based designs are becoming more important as
trialists and funders move away from so-called “up-and-down” designs[59] like 3+3.
This trend will be further driven as investigators research treatments for which the
maximum-tolerated dose is unlikely to coincide with the most effective dose. We have
described our approach to overcoming some of the obstacles we faced in implement-
ing EffTox in Matchpoint.
We were able to choose EffTox because our co-primary outcomes efficacy and
toxicity were assessed over a similar time-frame. EffTox and other dose-finding de-
signs with co-primary outcomes would not have been suitable if one had required a
longer assessment period.
A key reason for selecting EffTox was the readily available, free software pro-
vided by the MD Anderson Cancer Center for performing dose calculations and sim-
ulations of trial operating characteristics. With the many time pressures that come
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with working in an academic clinical trials unit, it was a tremendous advantage to
have reliable software with which to design and run this trial. One of the drawbacks
of using compiled software was our inability to alter or add certain behaviours. For
instance, we might have suppressed the no-skipping in de-escalation rule, had that
been possible. The desire to routinely calculate dose-transition pathways led us
to developing an open-source implementations of EffTox in clintrials[15] and
trialr[16].
2.5 Conclusion
Joint phase I/II clinical trials will likely become more common in coming years as
we investigate non-cytotoxic treatments and streamline the drug approval process.
EffTox is an important trial design because it addresses both of these goals. The
Matchpoint trial will yield data on the efficacy and toxicity of the optimum dose
of ponatinib to be given with FLAG-IDA chemotherapy. It will allow the research
community to decide whether there is sufficient promise to warrant a pivotal trial,
effectively shortening the pathway to approval by removing the need for a separate
phase II trial. This efficiency is important in a relatively rare disease like BP-CML.
However, EffTox presents its challenges. It requires parameterisation and pre-
liminary calculation. Choices for parameters can potentially have undesirable con-
sequences, and without care the efficiency gains can be eroded. The process of final-
ising an EffTox design is inherently iterative. We have described our experiences in
the hope that it helps trialists implement this design successfully.
We have discussed the parameters we chose and how we selected them. We have
stressed the need to look at the dose transition pathways, particularly in the early
stages when few outcomes are observed, and at the circumstances that would lead
to the trial’s termination. We have highlighted the problem of dose ambivalence,
illustrated graphically, and suggested a pragmatic solution. We have described the
problem of outcome ambiguity, and how dose-transition pathways can mitigate the
problem in the short term, allowing the dose-finding trial to proceed whilst clinical
evaluation is ongoing. Finally, we have advised on the simulation scenarios that
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should be considered. We hope this paper will help other investigators implement
this important dose-finding clinical trial design.
We used version 4.0.12 of the official EffTox software, available from the MD





Development of an Adaptive
Dose-Finding Design
Background: Wages and Tait introduced a method for phase I/II dose-finding
as an alternative to established designs like EffTox, described in the previous
chapter. Their method uses a simpler probability model than EffTox, and adap-
tive randomisation to preferably allocate patients to doses estimated to be tol-
erable and effective. Adaptive randomisation potentially brings an operational
cost to clinical trials units if the randomisation probabilities must be indepen-
dently validated before use. With frequent analyses, as in a dose-finding trial,
this administrative burden threatens to impact efficient trial progress.
Notable methods in this chapter: We introduce a hybrid trial design that bor-
rows Wages and Tait’s probability model, whilst abrogating the need for ran-
domisation by implementing the utility contours used in EffTox. We compare
nine variants of the three designs in a simulation study, seven of which do
not use randomisation, comparing them using a novel measure borrowed from
quantitative finance.
The implications on efficiency: A version of Wages & Tait’s design that does
not use randomisation showed superior statistical performance. This design
achieved our operational efficiency objective without compromising statistical
efficiency. Our hybrid design achieved the same operational objective but of-
fered slightly inferior statistical performance and greater heterogeneity, whilst
allocating marginally fewer patients at attractive doses.
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3.1 Symbols used
Table 3.1 contains a list of the symbols used in this chapter.
3.2 Introduction
This chapter builds on the last by considering alternative designs for phase I/II dose-
finding trials. The clinical motivations for conjoining phases I and II were discussed
in Chapter 2. For decades, chemotherapy has been one of the cornerstones of can-
cer treatment and the dose-finding objective has typically been to identify the MTD.
However, modern therapies increasingly challenge the validity of the cytotoxic as-
sumption. An immunotherapy example is developed in this thesis at length in Chap-
ter 5. A very brief review of phase I/II methodologies was presented in Chapter 2
and we elaborate on that now.
An early design in this area came from O’Quigley et al.[68] conducting dose-
finding studies in HIV retroviral therapies, extending the Continual Reassessment
Method (CRM)[69] by using relatively simple functions to model the probabilities of
efficacy and toxicity at discrete doses. They use a trinomial outcome with categories
Toxicity, No Response and Response, and consider situations where efficacy is not,
in general, monotonically increasing in dose.
Braun[12] introduced a bivariate generalisation of CRM (bCRM) with competing
outcomes for toxicity and response. In their setting, the ‘dose’ being studied is the
amount of time after a stem-cell transplant (SCT) to wait before tapering immuno-
suppressive (IS) therapy and beginning donor leukocyte infusions (DLI) intended to
incite a graft-versus-leukaemia (GVL) effect. If IS therapy is tapered too soon, there
is a risk of acute graft-versus-host disease (aGVHD), a common and potentially fatal
complication with SCTs. In contrast, if DLI are given too late, there is a risk of dis-
ease progression. Treating occurrence of aGVHD as the toxicity event and absence
of disease progression as the efficacy event, it is clear that a trade-off between the
two events must be sought to provide the best outcome for patients. They model




di for i = 1, ..., n a dose, e.g. 10 might represent 10mg
g(β) prior distribution for β
h(θ) prior distribution for θ
n the number of doses under investigation
i index of doses
j index of patients
k index of efficacy skeletons
k∗ index of efficacy skeleton with greatest posterior probability
pi prior probability of toxicity at dose i
pE , pT certainties required that efficacy / toxicity rate is acceptable
qik prior probability of efficacy at dose i under skeleton k
u(πE , πT ) utility function
w(k,Dj) posterior probability of efficacy skeleton k in WT and WATU
xj dose allocated to patient j
yj toxicity variable for patient j, 1 meaning tox; 0 meaning no tox
zj efficacy variable for patient j, 1 meaning eff; 0 meaning no eff
D the set of doses, di
Dj trial data up to and including patient j
ET EffTox
F (d, β) toxicity link function in WT and WATU
Gk(d, θ) efficacy link function using efficacy skeleton k in WT and WATU
Xj random variable for dose allocated to patient j
Yj random variable for toxicity presence in patient j
Zj random variable for efficacy presence in patient j
WT Wages and Tait
WATU Wages and Tait with Utility
αE significance for deficient efficacy at optimal dose in WT
αT significance for excess toxicity at lowest dose in WT
β toxicity curve parameter in WT and WATU
β̂j posterior estimate of β using data for j patients
βE,1 slope term for dose in EffTox efficacy logit
βE,2 slope term for dose-squared in EffTox efficacy logit
βT slope term in EffTox toxicity logit
δi for i = 1, ..., n transformed dose, used in EffTox
δ vector of transformed doses in EffTox, δi
θ vector of parameters in EffTox model
θ efficacy curve parameter in WT and WATU
θ̂jk posterior estimate of θ using efficacy skeleton k and data for j patients
λ curvature parameter in efficacy-toxicity contours
µT intercept term in EffTox toxicity logit
πE , πT probability functions for efficacy and toxicity
π̂E , π̂T posterior probabilities of efficacy / toxicity in WT and WATU
π∗1,E , π
∗
1,T , etc probabilities of efficacy / toxicity at notable points
πE lower threshold for efficacy rate
πT upper threshold for toxicity rate
τ(k) weight assigned to efficacy skeleton k
ψ association parameter in EffTox model
ω random draw from a normal distribution
TABLE 3.1: Symbols used in this chapter, in alphabetical order.
outcomes are then combined into a joint likelihood model with an association pa-
rameter to handle the tendency for events to co-occur.
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Thall and Cook[92] introduced EffTox in 2004. We covered this design in great
detail in the previous chapter so no further elaboration is warranted here.
Yin et al.[110] introduce another dose-finding method for co-primary efficacy and
toxicity. Unlike EffTox, they do not specify any functional form for the dose-response
curve. Instead, they use a novel class of priors to impose a monotonic constraint on
the probabilities of toxicity at increasing doses. The efficacy curve is free from con-
straint and they choose amongst doses by trading-off the efficacy-to-toxicity odds
ratios at the investigated doses.
Wang & Day[99] introduce another Bayesian approach for co-primary efficacy
and toxicity dose-finding. They model the patient-level thresholds at which events
occur using bivariate log-normal distributions and, like EffTox, select amongst doses
for individuals using utility functions. This allows patients and clinicians to poten-
tially influence the delivered dose by reflecting the extent to which toxicity will be
risked in pursuit of efficacy.
Zhang et al.[112]. introduced a model-based trivariate CRM (TriCRM) design.
It uses a continuation ratio logit models to partition the bivariate efficacy and tox-
icity outcome space into three exclusive and exhaustive outcomes: response with
no toxicity; no response and no toxicity; and toxicity (irrespective response). Wang
& Day[99] are critical of this approach, pointing out that toxicity with response is
clearly preferable to toxicity with no response and that this should be reflected in
the model.
Recently, Shimamura et al.[82] introduced a two-stage approach for combina-
tions of two agents in phase I/II trials. Their first stage is for identifying the ‘most
admissible toxicity zone’ by varying doses of treatments in the combination. In their
second stage, they use adaptive randomisation to collect outcomes under the admis-
sible combinations.
Further, Ananthakrishnan et al.[3] extended the modified Toxicity Probability
Interval (mTPI) design of Ji & Wang[49] and Toxicity Equivalence Range design
(TEQR) of Blanchard & Longmate[9] to include a binary efficacy outcome. They
apply isotonic regression to the observed toxicity and efficacy outcomes considering
a range dose-response curves to determine the optimal dose.
One of the focuses of this chapter is the method introduced by Wages and Tait[98]
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(that we will refer to as WT) for seamless phase I/II dose-finding trials. Their design
uses a latent CRM to continually model the probabilities of toxicity. To model the
rates of efficacy, they choose amongst pre-specified efficacy skeletons, simple sparse
efficacy curves that reflect the plausible shapes of the general dose-efficacy curve.
They choose the skeleton that best fits the observed efficacy curve using Bayes fac-
tors. The method of choosing amongst these skeletons is described in Section 3.3.
The vertical location of the dose-efficacy curve is allowed to vary using a single
parameter, much like the common empiric CRM model[24]. Overall, their method
requires two parameters, a prior estimate of the dose-toxicity curve and the specifi-
cation of the efficacy skeletons. They provide guidance in their paper for specifying
the recommended (2n− 1) skeletons in a trial that investigates n doses.
WT conducts a dose-finding study in two stages. In the first stage, patients
are adaptively randomised amongst the doses believed to be tolerable, with prob-
abilities proportional to the estimated chances of efficacy. Adaptive randomisation
creates potential friction within a trials unit where standard operating procedures
likely require that randomisation probabilities must be independently validated be-
fore use. Conducted infrequently, this is not a great hindrance. However, when a
model is updated after each small cohort, as is common in a dose-finding trial, the
validation requirement stands to become arduous. If the model is updated after ev-
ery patient, as Wages & Tait themselves investigated, the validation burden could
become prohibitive.
Our pre-occupation in this thesis is an examination of methods that promote
trial efficiency. WT is attractive because its probability model is relatively simple,
building upon methods used in CRM that are now well understood and widely
implemented in software[16, 24, 86]. However, its operational efficiency could be di-
minished by the use of adaptive randomisation. In this chapter, we propose a fusion
of WT and Thall & Cook’s EffTox (ET) that removes the randomisation requirement.
In Section 3.3, we describe the statistical aspects of WT and our motivation for com-
bining this design with ET. We introduce the hybrid method that we call Wages And
Tait with Utility (WATU) in Section 3.4. In Section 3.5, we compare the performance
of the three methods in a simulation study. Finally in Section 3.6, we close with a
discussion.
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3.3 Wages & Tait
The EffTox model was detailed in Chapter 2. In this section we introduce the WT
design, after establishing some notation.
We are studying seamless phase I/II dose-finding clinical trials with joint binary
efficacy and toxicity outcomes. We denote D = {d1, ..., dn} to be the set of n doses
under investigation. Each patient will be treated at exactly one dose level and will
yield binary outcomes for efficacy and toxicity. Let Xj be the random variable rep-
resenting the dose allocated to patient j, taking values xj ∈ D . Let Yj and Zj be the
random variables representing binary toxicity and efficacy events respectively for
patient j, taking values yj , zj ∈ {0, 1}, where 1 denotes the event occurred and 0 that
it did not.
Wages and Tait’s[98] method estimates the toxicity curve by delegating to the
univariate Bayesian variant of the Continual Reassessment Method (CRM)[69]. Let p
represent the trialists’ prior beliefs on the rate of toxicity at each dose. In a monotonic
dose-toxicity scenario, we have 0 < p1 < ... < pn < 1. We will denote the single
parameter in the toxicity model β and assume it has prior distribution g(β). Wages &
Tait choose the same β ∼ N(0, 1.34) prior used by O’Quigley & Shen[70]. Using trial
data for the first j patients Dj = {(x1, y1, z1), ..., (xj , yj , zj)} and toxicity probability




{F (xl, β)}yl {1− F (xl, β)}(1−yl) , (3.1)










1Note that in contrast to more common usage, the hat symbol here denotes the posterior mean and
not the maximum likelihood estimate.
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For instance, using the empiric link function F (di, β) = p
exp (β)
i , the posterior
estimate of the dose-toxicity curve is
π̂T (di) = F (di, β̂j) = p
exp (β̂j)
i (3.4)
The authors use the values of π̂T (di) to define an acceptable set of doses, an object
analogous to the admissible set in ET. Henceforth, we will use the term admissible
throughout for consistency. A dose is admissible in WT if the estimated rate of toxic-
ity is less than the maximum acceptable rate. More formally, the admissible set after
evaluation of patient j is:
Aj = {di : π̂T (di) < πT ; i = 1, ..., n} (3.5)
where πT is the maximum acceptable toxicity rate.
To model the efficacy probabilities, they use order restricted inference and Bayesian
model selection by specifying a set of working models, or skeletons, that describe
the plausible shapes of the dose-efficacy curve and iteratively choosing the skeleton
that best fits the observed efficacy data. The authors describe a general method for
identifying 2n − 1 skeletons when the dose-efficacy curve might be monotonically
increasing, unimodal (i.e. initially increasing and then decreasing) or plateaued.
Naturally, if the situation demands it, more or fewer skeletons could be consid-
ered. A monotonically increasing efficacy curve would have πE(d1) < ... < πE(dn).
In contrast, an efficacy curve that plateaus at the penultimate dose would have
πE(d1) < ... < πE(dn−1) = πE(dn).
Let K denote the number of efficacy skeletons under consideration in a trial.
For skeleton k, let the probabilities of efficacy at the n doses be (q1k, ..., qnk) for k =
1, ...,K. Under skeleton k, the authors model πE(di) = Pr(Zj = 1|di) ≈ Gk(di, θ) =
q
exp (θ)
ik . Once again, the empiric link function is used.
The parameter θ controls the vertical location of the efficacy curve. Let θ have
prior distribution h(θ). After j patients have been treated and assessed on the study,
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{Gk(xl, θ)}zl {1−Gk(xl, θ)}(1−zl) , (3.6)










At each dose-update decision, the authors select the skeleton with the highest
posterior probability. Their method allows investigators to express their prior be-
liefs on which skeletons are more likely via a weight function τ(k), scaled so that∑K
k=1 τ(k) = 1. If the investigators believe the skeletons to be equally likely, they set









and the skeleton chosen to model the dose-efficacy curve at the dose-update deci-
sion, k∗, is that with greatest posterior model probability, i.e.
k∗ = arg max
k
w(k,Dj) (3.10)
for k = 1, ...,K. As the authors note, “the more the data support model k, the greater
its posterior probability will be”. Having selected the best skeleton, the posterior
probabilities of efficacy are estimated as
π̂E(di) = Gk∗(di, θ̂jk∗) (3.11)
Wages & Tait propose two stages to their design and these differ in the way the
next dose is selected for the next patient or cohort.
During the first stage, the so-called randomisation stage, the next dose is randomly
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selected from the admissible set with probability proportional to π̂E(di) so that doses
with the high estimated efficacy are preferably selected. The adaptive randomisation





During the second stage, the admissible dose with maximal π̂E(di) is selected.
This is called the maximisation stage. At each stage, dose transition may be restricted
to avoid skipping untried doses in escalation and/or de-escalation. If at either stage
the admissible set is empty, the trial proposes no dose and the trial stops.
The trialists can set the size of the stages, or even choose to only use one partic-
ular stage by setting the size of the other to 0, an option we explore below. Wages &
Tait investigate different mixes and show that a 50:50 split works quite well.
As with ET, there are stopping rules in WT. The safety stopping rule is applied
at each dose update decision. The exact binomial quantile is calculated for the ob-
served rate of toxicity at the lowest dose, d1 using significance αT . If the lower bound
exceeds the maximum acceptable toxicity rate, πT , the treatment is understood to be
too toxic at all doses and the trial is stopped. If the lowest dose has not been given,
the lower bound for the confidence interval is effectively 0 and the safety rule does
not fire. Wages & Tait advocate using αT = 0.05.
There is also a futility stopping rule to stop investigators pursuing a treatment un-
duly when the observed efficacy rate is too low. This rule is applied at dose update
decisions only in the maximisation stage. It is not invoked during the randomisation
stage. This rule uses a similar method, calculating the exact binomial confidence in-
terval for the observed rate of efficacy at the proposed dose using significance αE . If
the upper bound is less than the minimum acceptable efficacy rate, πE , the treatment
is understood to be inefficacious at all doses and the trial is stopped. Wages & Tait
use αE = 0.05.
3.3.1 The Rationale for Combining WT and ET
EffTox is a powerful yet complicated trial design. It requires the specification of
many parameters and a degree of familiarity to ensure that those parameters work
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harmoniously to yield an effective trial design. We demonstrated this in Chapter 2.
The Bayesian update integral is six-dimensional, a not-inconsiderable challenge
that must be resolved at each dose decision. MD Anderson provides software for
conducting and simulating EffTox[45] trials but not source-code. Naturally, some
desirable features may be missing. We wrote an implementation of EffTox to pro-
duce dose-transition pathways for future cohorts. This was instrumental in our in-
vestigation into dose-ambivalence. To our knowledge, we have published the only
open-source EffTox implementations, in the Python package clintrials[15] and the R
package trialr[16].
Wages & Tait’s design is simpler and has several benefits. It delegates to a well-
known design in CRM to perform a key trial role. The method for modelling efficacy
is intuitive and tractable. At dose decisions, the method requires only that one-
dimensional integrals be solved. It is not particularly onerous to implement the
design in a new programming language.
In our opinion, WT has potential drawbacks too. The design randomises be-
tween doses in the first stage. This requires that the trialists be willing to give any
dose selected. Wages & Tait recommend that the design be constrained to avoid
skipping untested doses in escalation. In a similar vein, the design could select a
low dose that the trialists believe to be sub-therapeutic. To combat this, it would
be relatively simple to prevent skipping in de-escalation too. However, whilst it is
the job of clinical trials to provide objective evidence that may confirm or refute tri-
alists’ beliefs, we feel that in some scenarios, investigators might prefer a method
that changes doses deterministically rather than randomly. It is possible in WT to
skip the randomisation mechanism by moving straight to the maximisation stage.
We investigate this option in the simulation study.
Our main motivation to alter WT however is to remove the adaptive randomi-
sation component. Under the present operating procedures of our trials unit, ran-
domisation methods must be validated by the trial statistician. If the randomisation
mechanism changes, it has to be validated again. In the case of WT, this would at
least necessitate that each set of randomisation probabilities is independently repli-
cated. We believe this requirement would be present under the standard procedures
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of many trials units. Small but frequent hurdles such as this will reduce the opera-
tional efficiency of the method and could make it less attractive.
We feel that WT has many advantages that should be available to trialists in all
dose-finding scenarios that require the joint consideration of efficacy and toxicity,
particularly ease of use. In this spirit, we seek to adapt Wages & Tait’s design to
transition dose using the ET principle of utility maximisation, rather than adaptive
randomisation.
All seamless phase I/II methods can be considered efficient because they per-
form two trial functions at once. The efficiency of a dose-finding method could be
inferred from its performance. A design that identifies the optimum dose to a given
threshold reliability using fewer patients can be considered more efficient. To these
ends, we investigate the performance of WT, ET and their hybrid with a simulation
study.
3.4 WATU - A Hybrid Model
We introduce in this section a hybrid of Wages & Tait’s design and EffTox, named
Wages And Tait with Utility (WATU)2 The following design was conceived by Christina
Yap (CY) and Kristian Brock (KB) on a train journey, returning home from an early
phase trials workshop.
Our starting point is to mimic the probability models for both efficacy and tox-
icity in Wages & Tait. We advocate using a Bayesian CRM model to continually es-
timate the dose-toxicity curve. This requires the trialists’ prior beliefs on the rate of
toxicity at each dose, pi for i = 1, ..., n in a study of n doses. Using a one-parameter
CRM model with empiric link function, the posterior probabilities of toxicity are
given by (3.4). Other parameterisations and link functions are possible[24].
We also use Wages & Tait’s method of choosing amongst efficacy skeletons to
estimate the dose-efficacy curve. The posterior probabilities of efficacy are given by
(3.11).
2According to Wiktionary, watu is a Quechua word, meaning clothesline or spell. It seems appro-
priate to this author that a dose-finding trial design would be named at the intersection of support
structure and incantation.
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At this juncture, we depart from Wages & Tait. For calculating the admissible set
of doses, we mirror EffTox in equations (2.6) and (2.7) by admitting doses that are
threshold efficacious and tolerable according to their posterior distributions. A dose
d is admissible in WATU after observing trial data Dj if
Pr {πE(d) > πE |Dj} > pE (3.13)
and
Pr {πT (d) < πT |Dj} > pT (3.14)




β2P (β|Dj)dβ − β̂2j (3.15)
and the posterior distribution for β after j patients have been observed will be ap-
proximately N(β̂j ,var(βj)). It is simpler to sample from this specification of the
posterior distribution than from (3.2). We can estimate Pr {πT (d) < πT |Dj} and thus
resolve (3.14), for example, by randomly sampling ω1, ..., ωM from the normal distri-
bution N(β̂j ,var(βj)) for suitably large M , and calculating





I(F (di, ωm) < πT ) (3.16)
for each dose. Here I(A) is the indicator function taking value 1 when event A is
true, else 0. We infer that dose di is tolerable if the quantity on the right-hand side of
(3.16) is greater than pT . We can perform a similar calculation to resolve (3.13).
As with ET, the investigators must provide values for πE , πT , pE and pT . If no
dose is admissible, the trial stops. The admissible set is recalculated at the end of
each cohort.
A further departure from WT comes in the way the next dose is selected. We
explained our preference for a similar design to WT that does not randomly assign
doses. Having reappropriated in WATU the probability models from WT to estimate
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the posterior probabilities of efficacy and toxicity, we can mimic Thall & Cook’s ap-
proach in EffTox of selecting the admissible dose with the greatest utility. The equa-
tion for calculating dose utility is given in (2.5). The process of identifying an Lp
norm is the same as that described in Section 2.2 and Thall et al[93]. CY had the idea
of porting EffTox’s utility contours to abrogate the need for randomisation in WT.
A dose di is admissible if it satisfies (3.13) and (3.14). Additionally, the trialists
may choose to refine the admissible set by preventing the design from skipping un-
tried doses in escalation and/or de-escalation. Given our preference for determinis-
tic dose-transition and the nature of dose-finding under the competing moderators
efficacy and toxicity, we believe it is preferable to avoid skipping untried doses in
both escalation and de-escalation. At the dose update decision, WATU will select
the most attractive dose from the admissible set. What determines ‘most attractive’
changes in WATU according to the stage of the trial.
3.4.1 Trial Conduct - Stage One
The aim of the first stage is to gather information on which doses are safe. We en-
visage starting at a low dose, albeit not necessarily the lowest dose, and escalating
though the doses in a sequential fashion, all the while mindful to not allocate a dose
that is believed to be too toxic. To achieve these ends, we propose that dose be
guided by the underlying CRM model in the first stage. CRM is calibrated with a
target rate of toxicity and iteratively recommends the dose that it believes to have
associated toxicity rate closest to the target. The design forecasts the rate of toxicity
at each dose by combining observed trial outcomes with prior information. The tox-
icity target will be set as the clinical situation dictates but will naturally be less than
πT . For instance, in the Matchpoint setting (introduced below), we believe a priori
that efficacy will initially increase with dose (and toxicity) but then begin to level off.
Hence, we use a toxicity target slightly below πT when we use WATU in Matchpoint
scenarios.
The following pseudo-code describes the dose-update decision in the first trial
stage:
1. Select each dose in turn, ordered from estimated closest to
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furthest from toxicity target:
2. If the dose is admissible:
3. If the dose does not violate a no-skipping rule:
4. Select this as the recommended dose
5. Exit
6. If no dose is selected, stop the trial.
3.4.2 Trial Conduct - Stage Two
Stage two seeks to allocate to the optimal dose by trading the probability of toxic-
ity against the probability of efficacy. Each dose is allocated an attractiveness score
using the method of Thall & Cook[92], as described. Doses with high attractiveness
scores will offer a relatively high rate of efficacy for the rate of toxicity that must be
endured.
The following pseudo-code describes the dose-update logic in the second trial
stage:
1. Select each dose in turn, from highest to lowest utility:
2. If the dose is admissible:
3. If the dose does not violate a no-skipping rule:
4. Select this as the recommended dose
5. Exit
6. If no dose is selected, stop the trial.
3.4.3 Sizes of Stage One & Two
Trialists can set the sizes of the stages as they see fit. Stage one allows the design
to step through doses and collect efficacy and toxicity information when trial data
is very limited and safety is paramount. Naturally, the size of stage one could be
set to zero to suppress the CRM-only allocation stage. Stage one need not even be
of fixed size. Trialists might prefer stage one to end when some pre-defined event
happens, like the moment the first (or nth) efficacy event is observed, for instance.
We investigate different sizes for stage one below.
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3.5 Comparing the Designs by Simulation
In this section we compare the performance of ET, WT and WATU in simulations
motivated by the Matchpoint scenario, described in Chapter 2. The trial uses an
ET design although it could feasibly have used another joint phase I/II design like
WT or WATU. Once again, we codify the doses under investigation as 7.5mg, 15mg,
30mg and 45mg each day. The trial and hence our simulations will recruit up to 30
patients in cohorts of three. We will start each iteration of each design at dose-level
3, as we did in the actual study. The doses under investigation and our prior beliefs
on efficacy and toxicity are given in Table 2.2.
3.5.1 Designs Under Investigation
The main objective of the simulation study is to compare the general performance of
the three competing designs, ET, WT and WATU in a real trial situation. However,
it is important to consider that each of the designs may be configured in different
ways to promote or inhibit certain behaviour. There is no uniquely correct parame-
terisation in any case. Trialists will naturally use all available levers to get the most
desirable behaviour from their design. It is likely that a design could be configured
is such a way as to replicate the desirable behaviour of another. For instance, WT
provides a mechanism for suppressing adaptive randomisation by simply setting the
size of the randomisation stage to 0. As such, a secondary objective of the simulation
study is to compare the performance of variations of the designs.
Naturally, it is infeasible to analyse all design variants. Specifically, we are in-
terested in how reliably the designs pick the optimum dose. Further to this, we
will investigate how the designs perform in monotonic scenarios, where the dose-
efficacy curve broadly concurs with our prior beliefs. Additionally, we will analyse
performance in non-monotonic efficacy scenarios, where the prior beliefs must be
overruled by the designs to accurately model the prevailing clinical scenario. To
these ends, we propose to investigate two instances of EffTox (ET1, ET2), three in-
stances of Wages & Tait (WT1, WT2, and WT3) and three instances of Wages And Tait
with Utility (WATU1, WATU2 and WATU3), as described in the following sections.
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3.5.2 Parameterising the Designs
Each of the designs under study requires parameters. These determine the be-
haviour of the methods and will naturally be selected by the trialists to reflect their
expectations and objectives in the clinical trial. We discuss how our expectations on
efficacy and toxicity inform the parameterisation below.
In a phase I/II dose-finding setting, trial designs may either select a dose for fur-
ther study or recommend that the trial stop early with no dose being selected. A trial
may be stopped for lack of efficacy or excess toxicity. Highly divergent propensities
to stop hinder the comparison of designs. For instance, the performance of a design
that never stops will look artificially superior in scenarios where the correct decision
is to not stop. The indecision on whether to stop is a burden that must be carried
by all designs. ET, WT and WATU use different methods to infer dose admissibility.
After discussing efficacy and toxicity parameterisation below, we describe a system-
atic method for parameterising designs so that they stop with approximately equal
probability in a given benchmark scenario. Neutralising this important source of
variation aids comparison of the designs in general scenarios.
Our prior estimates for the rates of efficacy and toxicity at the four doses are
given in Table 2.2 in the previous chapter. The CRM models in WT and WATU
both use these prior toxicity probabilities. Each uses the empiric link function and a
N(0, 1.34) prior for β.
ET requires normal priors on the six elements of θ. In ET1, we use an effective
sample size of 1.3 to match the choice we made in the real Matchpoint trial. The
EffTox software produces the normal priors shown in Table 3.2. Under parameteri-
sation ET2 we have inflated the standard deviation hyperparameter for βE,2 fivefold
to 1.0, whilst leaving the other elements unchanged, to facilitate non-linearity and
turning points in the dose-efficacy curve.
To give validity to the choice of 1.0 as a suitable value for the standard deviation
of βE,2, consider the following example. In Matchpoint, the unimodal efficacy curve
(0.17, 0.44, 0.50, 0.40) is fitted by the parameter values µE = 0, βE,1 = 0.5 and
βE,2 = −1.2. Under the ET1 priors, this value of βE,2 is 6 prior standard deviations
away from the prior mean. Under the ET2 priors, however, this value is only 1.2
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TABLE 3.2: Normal priors for the elements of the EffTox parameter
vector θ in the Matchpoint setting. Priors in ET1 are calculated using
the MD Anderson EffTox software with ESS = 1.3.
ET1 ET2
Parameter Mean St Dev Mean St Dev
µT -5.4317 2.7643 -5.4317 2.7643
βT 3.1761 2.7703 3.1761 2.7703
µE -0.8442 1.9786 0.8442 1.9786
βE,1 1.9857 1.9820 1.9857 1.9820
βE,2 0 0.2 0 1
ψ 0 1 0 1
prior standard deviations away. This change increases the probability that ET2 will
fit unimodal efficacy curves. Unfortunately, the EffTox software does not reveal the
effect of inflating the prior standard deviation of βE,2 on ESS.
To create the efficacy skeletons in WT and WATU, we permuted the prior efficacy
rates, as demonstrated in Table 3.3. It does not matter that skeleton 7, for example,
plateaus at a high efficacy probability that we do not necessarily expect to manifest
because the θ parameter adjusts the average height of the curve to best fit the ob-
served efficacy rates. Rather, the ordering of the nodes is important. The efficacy
models in WT and WATU use a N(0, 1.34) prior for θ.
TABLE 3.3: Efficacy skeletons for WT and WATU in the Matchpoint
trial setting. We consider monotonic, unimodal and plateau skele-
tons.
k q1k q2k q3k q4k
1 0.6 0.5 0.3 0.2
2 0.5 0.6 0.5 0.3
3 0.3 0.5 0.6 0.5
4 0.2 0.3 0.5 0.6
5 0.3 0.5 0.6 0.6
6 0.5 0.6 0.6 0.6
7 0.6 0.6 0.6 0.6
In WT1, we allocate 15 patients to the randomisation stage, and 15 to the maximi-
sation stage, to give the design equal opportunity to explore the doses and identify
the optimal dose. Furthermore, in WT1 we equally weight the efficacy skeletons
with τ(k) = 1/7 for k = 1, .., 7 so that each efficacy scenario is equally likely, a priori.
We parameterise WT2 the same as WT1, with the exception that efficacy skeleton
4 is weighted twice as likely as the other skeletons, to reflect the anticipation of a
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monotonic dose-efficacy curve, i.e.
τ(k) =

1/4, for k = 4
1/8, for k = 1, 2, 3, 5, 6, 7
(3.17)
We parameterise WT3 the same as WT2 with the exception that the randomisation
stage size is set to 0, i.e. WT3 is inclined towards the monotonically-increasing
efficacy skeleton and proceeds immediately with the maximisation stage of dose-
allocation without randomisation, keeping maximum sample size fixed at 30.
In WATU1, we allocate 15 patients to the first stage and 15 patients to the second
stage, as described in Sections 3.4.1 and 3.4.2. In this configuration, the design has
equal opportunity to escalate through the doses safely and identify the optimal dose.
We also uniformly weight the efficacy skeletons, as with WT1.
In WATU2, we bias the model to prefer the monotonically increasing efficacy
skeleton using (3.17), as in WT2. In every other regard, WATU2 matches WATU1.
Lastly, we parameterise WATU3 the same as WATU2, with the exception that the size
of stage one is set to zero so that the design proceeds immediately with identifying
the optimal dose, without the initial CRM-driven safety stage,
We require utility measures for the ET and WATU designs. Following the ex-
ample in Thall et al[92, 93], we selected neutral utility points (π∗1,E , 0) = (0.4, 0),




3,T ) = (0.5, 0.4), yielding a family of utility curves
with p = 2.07. We calculate the utility of doses using (2.5). These match the utility
curves we used in Matchpoint.
The design parameterisations we consider in our simulation study are summarised
in Table 3.4.
3.5.3 Simulation method
To compare the general performance of the designs in Table 3.4, we conducted a
simulation study using a wide range of scenarios. Patient outcomes were randomly
sampled according to assumed true efficacy and toxicity probabilities, with the events
assumed to be independent. In each scenario, we simulate 10,000 trial outcomes us-
ing up to 30 patients in each iteration with doses being given in cohorts of three. For
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TABLE 3.4: Parameterisations of all designs under study. Only the pa-
rameters that vary are shown. Common parameters are given in the
text. The efficacy skeleton that is upweighted in WT2, WT3, WATU2
and WATU3 is the one representing a monotonic dose-efficacy curve.
Design Parameterisation
ET1 βE,2 ∼ N(0, 0.2)
pE = 0.15
pT = 0.16
ET2 βE,2 ∼ N(0, 1.0)
pE = 0.16
pT = 0.16
WT1 First stage (randomisation) size = 15
efficacy skeleton weights = (1,1,1,1,1,1,1)
αE = 0.3
αT = 0.3
WT2 First stage (randomisation) size = 15
efficacy skeleton weights = (1,1,1,2,1,1,1)
αE = 0.3
αT = 0.3
WT3 First stage (randomisation) size = 0
efficacy skeleton weights = (1,1,1,2,1,1,1)
αE = 0.32
αT = 0.32
WATU1 First stage (CRM) size = 15
efficacy skeleton weights = (1,1,1,1,1,1,1)
pE = 0.2
pT = 0.2
WATU2 First stage (CRM) size = 15
efficacy skeleton weights = (1,1,1,2,1,1,1)
pE = 0.2
pT = 0.2
WATU3 First stage (CRM) size = 0
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each design in each iteration, dose decisions were made at the end of each simulated
cohort of three and the next cohort treated at the recommended dose, or the trial
stopped, as the design advised. ET, WT and WATU were constrained from skip-
ping doses in escalation and de-escalation, as described for each design above. All
simulated trials started at dose-level 3, as Matchpoint did.
3.5.4 Parameters for Dose Admissibility
We have discussed the concept of dose admissibility and how this is handled in the
different designs. An inadmissible dose is not considered for allocation to a cohort
of patients. The sets of admissible and inadmissible doses will change as the trial
progresses and outcomes are collected. Designs will stop the trial when no dose is
admissible.
ET, WT and WATU use different methods to infer admissibility and this will
affect performance because a decision to stop is simultaneously a decision to recom-
mend no dose. For instance, a design that stops one third of the time and recom-
mends the correct optimal dose two thirds of the time will look inferior to another
design that never stops, selects the optimal dose 70% of the time and a sub-optimal
dose 30% of the time. However, if the stopping probability is calibrated in the first
design, it is likely that superior performance will be attained. Although this illus-
trative example is contrived, our early attempts at conducting simulation studies
to compare the designs using the original authors’ recommended stopping parame-
ters yielded such disparate stopping probabilities that performance was essentially
non-comparable. Calibration was necessary.
The aim of this section is to describe a systematic method of parameterising the
admissibility components of the designs so that each stops with similar probability
in a particular baseline scenario. The choice of baseline scenario will be important
and it is expository to consider the process of arriving at a recommendation to stop.
ET, WT and WATU use different statistical methods to model the dose-efficacy
and dose-toxicity curves, as described in Sections 2.2, 3.3 and 3.4. As with every sta-
tistical model, each is subject to estimation error and this is pertinent to the decision
to stop. For instance, when a design recommends stopping, it could have correctly
identified a scenario where all doses truly are too toxic. Alternatively, it could have
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misclassified a scenario where at least some doses are tolerable. In this instance,
the misclassification will stem from imperfect estimation of the dose-toxicity curve.
Generally in phase I/II trials, estimates of the efficacy and toxicity curves will have
bearing on the decision to stop. When calibrating designs to stop with similar prob-
ability, we remove this source of uncertainty using the following simple method.
In the baseline stopping scenario, we assume the toxicity and efficacy curves are
flat by setting the probability of efficacy and toxicity to be the same at every dose.
This removes the variation stemming from their imperfect estimation of the event
curves because any dose selected yields the same event probabilities. The partic-
ular dose selected does not affect the decision to stop. Rather, the act of choosing
any dose forgoes the opportunity to stop. The decision to stop is focussed as much
as possible on the mechanism explicitly introduced to govern stopping and not on
imprecise estimation of the dose-toxicity or dose-efficacy curves. We tweak the stop-
ping parameters in the designs until each stops with a pre-determined probability
in the baseline scenario.
In Matchpoint, we seek a dose with at least 45% efficacy and at most 40% toxicity
thus we set πE = 0.45 and πT = 0.4 in each design. These values are chosen for their
clinical relevance. WATU requires a toxicity target in the first stage. We set this to be
0.35, slightly below the toxicity limit. WT does not use a toxicity target in its CRM
component.
In our baseline stopping scenario we set the true efficacy to 45% throughout so
that each dose is borderline sufficiently efficacious. In contrast, we set toxicity to
50% at each dose. At this 10% margin over the maximum allowable toxicity rate,
we require that each design stop with 60% probability. Achieving an exact stopping
probability is not a realistic goal. At a practical level, we sought a parameterisation
that yielded a stopping probability between 60% and 62% in each design. Where
this was not possible, the parameterisation giving stopping probability closest to
60% was retained. Using the metric described in the previous section, the utility of
the point (πE , πT ) = (0.45, 0.5) is -0.15. In summary, in our four dose trial setting,
the baseline stopping scenario has true efficacy curve (0.45, 0.45, 0.45, 0.45) and true
toxicity curve (0.5, 0.5, 0.5, 0.5).
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Having fixed the threshold values for the acceptable maximum toxicity and min-
imum efficacy, stopping is governed in ET by the parameters pE and pT . We adjust
these until the requisite stopping probability is achieved in the baseline scenario.
Our preference is to have similar values for pE and pT because we have no particular
motivation to prioritise one source of error. In ET1, a modest amount of trial-and-
error lead to pE = 0.15 and pT = 0.16, yielding a design that stops 60%3 of the time
in 10,000 iterations. Likewise, the values pE = 0.16 and pT = 0.16 lead to stopping
in 61% of iterations in ET2. We must stress at this juncture that the values we have
derived are greater than: i) those used by the original authors; and ii) those used in
the Matchpoint trial described in Chapter 2. Thall & Cook use in their example[92]
the slightly lower values pE = pT = 0.1. Compared to their parameterisation and
our Matchpoint design, our ET1 and ET2 will less readily find a dose admissible and
thus will stop more often.
The stopping mechanism in WATU is similar to ET and requires values for the
same two parameters. The pair pE = 0.2 and pT = 0.2 lead to a stopping probability
of 61.3% in WATU1 using 10,000 iterations. Despite the similarity in the stopping
rules between ET and WATU, the specific values for pE and pT are different, hinting
at the role played by the methods of modelling the dose-event curves. In WATU2,
the same pair pE = 0.2 and pT = 0.2 lead to stopping 60.2% of the time. In WATU3,
pE = 0.22 and pT = 0.22 lead to stopping 60.9% of the time.
The probability of WT stopping can be modified via the αE and αT parameters
in the safety and futility stopping rules. Greater significance values will lead to
narrower confidence intervals and a greater chance of stopping. In WT1, αE = 0.3
and αT = 0.3 gives a stopping probability of 61.5% in 10,000 simulations of the
baseline scenario. In WT2, the same pairingαE = 0.3 andαT = 0.3 stops 60.8% of the
time. In WT3, the pair αE = 0.32 and αT = 0.32 stops 58.8% of the time. Although
fractionally less than 60%, this pair was chosen over αE = 0.33 and αT = 0.33, which
stopped 63.2% of the time.
Once again, we note that αE = 0.3 and αT = 0.3 in WT are far from the values
proposed by Wages & Tait[98]. This reflects that we have asked the designs to be
3The EffTox software published by the MD Anderson Centre gives stopping and dose selection
probabilities rounded the nearest whole percent
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Pr(Tox) ET1 ET2 WT1 WT2 WT3 WATU1 WATU2 WATU3
0.1 0.21 0.23 0.032 0.033 0.118 0.127 0.122 0.151
0.2 0.23 0.24 0.051 0.059 0.131 0.136 0.123 0.163
0.3 0.29 0.31 0.131 0.141 0.183 0.181 0.171 0.196
0.4 0.42 0.44 0.314 0.314 0.323 0.328 0.317 0.327
0.5 0.60 0.61 0.615 0.608 0.588 0.613 0.602 0.609
0.6 0.79 0.79 0.885 0.876 0.859 0.871 0.873 0.858
0.7 0.91 0.91 0.987 0.986 0.980 0.982 0.982 0.977
TABLE 3.5: Stopping probabilities under increasing, flat toxicity rates.
In each case, the probability of efficacy is 45% at each dose. The
probability of toxicity is 10% at each dose in the first row, increas-
ing in further rows. The baseline stopping scenario, where all design
should stop with probability approximately 60%, is shown in bold.
The EffTox software reports outcomes to the nearest whole percent.
quite willing to stop when toxicity is a fairly modest 10% greater than the threshold
value. We will see how this affects the performance of the designs in non-toxic sce-
narios in subsequent sections. Despite choosing values different to those proposed
by their authors, we do not expect a priori that this exercise favours any particular
design because the methods have been calibrated to behave similarly in a neutral
scenario.
The stopping parameterisations are summarised in Table 3.4.
3.5.5 Horizon Stopping Probabilities
Having calibrated the designs to stop with common probability at (πE , πT ) = (0.45, 0.5),
we examined how the designs varied in their stopping probabilities in similar sce-
narios with flat efficacy and toxicity curves.
In Table 3.5, we kept the probability of efficacy at dose i equal to 0.45 for i =
1, .., 4. We then analysed the stopping probabilities of all designs in scenarios with
increasing levels of uniform toxicity. For example, in the first row, we set the prob-
ability of toxicity equal to 0.1 at all doses and analysed how reliably the designs
advocated stopping. We did this for toxicity probabilities 0.1, ..., 0.7. It is preferable
that the designs do not stop when the toxicity rate is less than the upper threshold
of 0.4 and they should show an increasing propensity to stop as the toxicity rate
increases above 0.4.
WT is the design least likely to stop when the toxicity rate is 40% and below. At
toxicity rates 50% and above, however, WT is the most likely to stop. ET is much
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Pr(Eff) ET1 ET2 WT1 WT2 WT3 WATU1 WATU2 WATU3
0.15 0.98 0.97 0.972 0.963 0.981 0.993 0.989 0.995
0.25 0.90 0.91 0.790 0.797 0.852 0.888 0.867 0.888
0.35 0.70 0.71 0.515 0.517 0.577 0.605 0.578 0.607
0.45 0.42 0.43 0.314 0.312 0.323 0.328 0.317 0.327
0.55 0.20 0.22 0.227 0.218 0.190 0.198 0.187 0.182
0.65 0.10 0.10 0.213 0.192 0.149 0.152 0.152 0.120
0.75 0.06 0.06 0.207 0.194 0.136 0.147 0.141 0.113
TABLE 3.6: Stopping probabilities under increasing, flat efficacy rates.
In each case, the probability of toxicity is 40% at each dose. The prob-
ability of efficacy is 15% at each dose in the first, increasing in further
rows. The EffTox software reports outcomes to the nearest whole per-
cent.
more likely to stop than the other designs when toxicity is as low as 10%. Generally,
WATU stops with probability between that of ET and WT. Looking within model,
the different ET variations do not stop materially differently. In WT and WATU,
suppressing the first stage in each model (WT3 and WATU3) increases the chances
of stopping when toxicity is low, notably so in WT. The first stage exists to explore
doses and learn about the dose-event probabilities. It is intuitive that removing it
increases the probability of stopping even when treatment is tolerable and effective.
We perform a similar exercise in Table 3.6 to analyse stopping over a horizon of
efficacy probabilities. In this analysis, the probability of toxicity is held constant at
0.4 at dose i for i = 1, ..., 4 in every scenario, being the threshold maximum that
we would accept. In the first row of Table 3.6, the probability of efficacy is 0.15 at
each dose. We look at efficacy probabilities 0.15, 0.25, ..., 0.75, being increments of
0.1 from the minimum efficacy threshold, 0.45. Once again, the efficacy and toxicity
curves in each scenario are flat. Here, the designs should stop when the efficacy rate
is less than 45% but they should show a decreasing propensity to stop as the efficacy
rate increases above 45%.
All designs stop quite reliably when efficacy is very low, at 15%. ET is the design
most likely to stop with modest efficacy at 25% and 35%. WT is the least likely to
stop at low efficacy. A pertinent aspect of the WT design is that it only stops for
low efficacy in its second stage, the maximisation stage. WT3 has a larger second
stage than WT1 and WT2, so it follows that it stops more frequently for low efficacy.
Once again, WATU sits between ET and WT, in the main. At high efficacy, ET is least
likely to stop. The stopping probability in WT barely changes as efficacy increases
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from 55% to 75%, and only falls modestly in WATU.
In summary, the described method has yielded parameterisations that stop with
60% probability in the baseline stopping scenario. Tables 3.5 and 3.6 show that the
designs stop with broadly similar probabilities over efficacy and toxicity horizons.
However, despite this systematic calibration, some heterogeneity persists.
3.5.6 General Simulation Study
The simulations presented above were about calibration. In this section, we investi-
gate by simulation the performance of the designs in scenarios that are more likely
to manifest in a trial situation, with efficacy and toxicity rates that vary by dose.
The scenarios under consideration are given in Table 3.7. Scenarios 1 to 5 have
monotonically increasing efficacy and toxicity curves. The optimal dose differs in
scenarios 1 to 3. In Scenario 4, efficacy escalates rapidly up to the highest dose. In
Scenario 5, toxicity escalates rapidly up to the highest dose. Scenarios 6 and 7 show
plateau efficacy curves. Scenarios 8 and 9 show unimodal efficacy curves. In sce-
nario 10, all doses are inefficacious. Finally, in scenario 11, all doses are excessively
toxic.
The selection probabilities of each of the designs are also given in Table 3.7. An
admissible dose is one that has associated probability of efficacy greater than 45%
and probability of toxicity less than 40%. Each scenario has exactly one optimal
decision, be it to select the best admissible dose or to stop the trial where no dose
is admissible. Where there are several admissible doses, the optimal dose is the one
with the highest utility score, as determined by 2.5. Where there is no admissible
dose, the optimal and admissible decisions are to stop the trial. In each row, the
optimal decision is in bold text and the admissible decisions are underlined.
3.5.6.1 Results
Scenario 1 is evidently one where it is easy to select an admissible dose but relatively
difficult to select the optimal dose. Testament to this is that seven of the eight designs
pick the true optimum dose less than half of the time. The efficacy curve is mono-
tonically increasing and performance in WT and WATU is convincingly improved
by tilting the models towards the monotonic efficacy skeleton. In contrast, ET2 loses
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TABLE 3.7: Simulated selection probabilities. The probabilities of ef-
ficacy and toxicity are given at each dose, and utilities determined by
(2.5). The optimal dose is shown in bold and acceptable doses are
underlined. The EffTox software gives selection probabilities to the
nearest whole percent.
Scenario Dose 1 Dose 2 Dose 3 Dose 4 Stop
1
Pr(Eff) 0.21 0.46 0.58 0.69
Pr(Tox) 0.11 0.16 0.24 0.30
Utility -0.32 0.07 0.23 0.34
ET1 0.00 0.02 0.50 0.44 0.04
ET2 0.00 0.02 0.52 0.41 0.05
WT1 0.029 0.212 0.545 0.174 0.040
WT2 0.013 0.122 0.445 0.392 0.028
WT3 0.003 0.060 0.336 0.565 0.037
WATU1 0.005 0.078 0.579 0.249 0.089
WATU2 0.003 0.031 0.500 0.383 0.082
WATU3 0.001 0.024 0.515 0.372 0.088
2
Pr(Eff) 0.21 0.49 0.55 0.61
Pr(Tox) 0.05 0.32 0.53 0.69
Utility -0.32 0.04 -0.05 -0.17
ET1 0.02 0.36 0.23 0.00 0.39
ET2 0.02 0.36 0.22 0.00 0.40
WT1 0.041 0.521 0.294 0.002 0.142
WT2 0.029 0.488 0.344 0.003 0.136
WT3 0.046 0.544 0.216 0.000 0.194
WATU1 0.026 0.336 0.348 0.001 0.289
WATU2 0.028 0.248 0.392 0.002 0.332
WATU3 0.033 0.223 0.338 0.001 0.404
3
Pr(Eff) 0.21 0.52 0.64 0.77
Pr(Tox) 0.08 0.17 0.32 0.53
Utility -0.32 0.17 0.25 0.16
ET1 0.00 0.08 0.81 0.05 0.06
ET2 0.00 0.08 0.81 0.06 0.06
WT1 0.017 0.225 0.675 0.059 0.025
WT2 0.009 0.136 0.691 0.144 0.021
WT3 0.007 0.122 0.729 0.106 0.037
WATU1 0.006 0.127 0.792 0.018 0.058
WATU2 0.005 0.047 0.865 0.024 0.059
WATU3 0.002 0.031 0.870 0.026 0.070
4
Pr(Eff) 0.04 0.15 0.32 0.63
Pr(Tox) 0.07 0.12 0.19 0.31
Utility -0.60 -0.43 -0.16 0.25
ET1 0.00 0.00 0.08 0.73 0.19
ET2 0.00 0.00 0.08 0.71 0.20
WT1 0.001 0.013 0.162 0.442 0.382
WT2 0.001 0.007 0.118 0.581 0.293
WT3 0.000 0.003 0.092 0.648 0.257
WATU1 0.003 0.005 0.082 0.433 0.476
WATU2 0.002 0.002 0.069 0.533 0.395
WATU3 0.003 0.001 0.070 0.534 0.391
5
Pr(Eff) 0.21 0.37 0.51 0.58
Pr(Tox) 0.07 0.16 0.28 0.52
Utility -0.32 -0.07 0.10 -0.01
ET1 0.00 0.02 0.66 0.12 0.20
ET2 0.00 0.02 0.65 0.12 0.21
WT1 0.045 0.194 0.566 0.083 0.112
WT2 0.026 0.121 0.590 0.174 0.088
WT3 0.009 0.085 0.638 0.140 0.129
WATU1 0.017 0.084 0.586 0.112 0.201
WATU2 0.016 0.045 0.583 0.179 0.177
WATU3 0.014 0.039 0.571 0.174 0.201
Scenario Dose 1 Dose 2 Dose 3 Dose 4 Stop
6
Pr(Eff) 0.37 0.51 0.51 0.51
Pr(Tox) 0.04 0.11 0.28 0.38
Utility -0.05 0.17 0.10 0.03
ET1 0.02 0.04 0.51 0.26 0.17
ET2 0.00 0.06 0.53 0.23 0.17
WT1 0.175 0.408 0.339 0.053 0.025
WT2 0.118 0.304 0.375 0.177 0.027
WT3 0.046 0.192 0.442 0.250 0.070
WATU1 0.070 0.247 0.443 0.137 0.103
WATU2 0.063 0.156 0.385 0.297 0.099
WATU3 0.056 0.119 0.389 0.298 0.138
7
Pr(Eff) 0.22 0.37 0.51 0.51
Pr(Tox) 0.04 0.11 0.28 0.38
Utility -0.30 -0.06 0.10 0.03
ET1 0.01 0.01 0.42 0.42 0.15
ET2 0.00 0.02 0.46 0.37 0.15
WT1 0.052 0.194 0.534 0.118 0.103
WT2 0.030 0.131 0.509 0.261 0.070
WT3 0.011 0.085 0.518 0.275 0.111
WATU1 0.018 0.097 0.514 0.164 0.206
WATU2 0.015 0.062 0.421 0.319 0.183
WATU3 0.014 0.052 0.404 0.309 0.222
8
Pr(Eff) 0.37 0.51 0.4 0.27
Pr(Tox) 0.04 0.11 0.28 0.38
Utility -0.05 0.17 -0.07 -0.32
ET1 0.08 0.04 0.25 0.07 0.55
ET2 0.02 0.09 0.26 0.06 0.57
WT1 0.220 0.521 0.192 0.013 0.055
WT2 0.181 0.467 0.233 0.043 0.077
WT3 0.101 0.350 0.236 0.054 0.259
WATU1 0.150 0.396 0.190 0.022 0.242
WATU2 0.152 0.351 0.169 0.066 0.261
WATU3 0.133 0.323 0.140 0.066 0.337
9
Pr(Eff) 0.22 0.51 0.59 0.33
Pr(Tox) 0.04 0.11 0.20 0.35
Utility -0.30 0.17 0.26 -0.21
ET1 0.04 0.05 0.53 0.14 0.25
ET2 0.00 0.09 0.62 0.08 0.21
WT1 0.028 0.293 0.621 0.036 0.023
WT2 0.022 0.275 0.564 0.117 0.022
WT3 0.010 0.315 0.460 0.120 0.095
WATU1 0.014 0.332 0.523 0.033 0.098
WATU2 0.018 0.319 0.403 0.126 0.134
WATU3 0.015 0.286 0.384 0.125 0.190
10
Pr(Eff) 0.04 0.15 0.24 0.32
Pr(Tox) 0.04 0.11 0.20 0.35
Utility -0.60 -0.42 -0.29 -0.23
ET1 0.00 0.01 0.02 0.19 0.77
ET2 0.00 0.02 0.03 0.17 0.79
WT1 0.003 0.021 0.125 0.154 0.697
WT2 0.003 0.024 0.098 0.222 0.654
WT3 0.002 0.008 0.071 0.173 0.746
WATU1 0.021 0.006 0.037 0.070 0.866
WATU2 0.024 0.006 0.020 0.120 0.829
WATU3 0.017 0.006 0.012 0.108 0.857
11
Pr(Eff) 0.21 0.37 0.51 0.58
Pr(Tox) 0.47 0.55 0.62 0.69
Utility -0.47 -0.30 -0.19 -0.20
ET1 0.02 0.12 0.06 0.00 0.80
ET2 0.03 0.11 0.06 0.00 0.80
WT1 0.045 0.028 0.003 0.000 0.924
WT2 0.047 0.026 0.005 0.000 0.921
WT3 0.052 0.030 0.007 0.000 0.912
WATU1 0.020 0.060 0.033 0.000 0.886
WATU2 0.022 0.052 0.038 0.000 0.888
WATU3 0.027 0.044 0.036 0.000 0.894
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relatively little using a much vaguer prior on βE,2 to facilitate an efficacy curve that
initially increases and then decreases as dose is increased. WT1 and WATU1 per-
form quite poorly compared to ET1 and ET2, however, WT3 performs the best in
this scenario. The chances of choosing the optimum dose with WT and WATU in
this scenario seem to be sensitive to choosing the right parameterisation, a feat that
is very difficult prior to experimentation. Notably, no design is likely to do anything
highly undesirable like stopping or selecting the lowest dose. Each dose selects an
admissible dose with probability at least 90%.
The challenge with scenario 2 is that dose 2 is the only admissible dose. Gener-
ally, WT performs much better than ET and WATU. All designs show a predilection
for dose 3, allowing a little too much toxicity when looking for superior efficacy.
Scenario 2 demonstrates the increased risk of stopping when only one dose is ad-
missible, especially in ET and WATU here. Surprisingly, the performances of WT2
and WATU2 have been hindered by biasing the models towards the monotonic (i.e.
correct) efficacy skeleton.
In scenario 3, toxicity ramps up at the highest dose. All designs perform well,
correctly picking dose 3 as optimal with high probability. The performance of WT
slightly lags that of ET and WATU. All designs avoid doses 1 (for inactivity) and 4
(for excess toxicity) very well.
In scenario 4, efficacy escalates rapidly at the highest dose, with the first three
doses being inefficacious. ET most reliably identifies dose 4 as the optimum. WT
and WATU only identify the correct dose in the majority of cases once they have been
inclined towards the monotonic efficacy scenario. All designs stop quite frequently.
In scenario 5, efficacy is high at the top two doses but toxicity is also high at dose
4. Dose 3 is the optimum dose and the only admissible dose. All designs are 56%-
66% likely to correctly recommend dose 3. Once again, ET outperforms WT and
WATU.
Scenario 6 is the first of two scenarios where the efficacy curve plateaus, in this
instance at dose 2. Doses 2, 3 and 4 are all admissible but dose 2 is optimal. ET
identifies the true optimal dose less than 10% of the time, opting for the admissible
but inferior doses 3 & 4 more frequently. ET2 performs similarly poorly, suggesting
that the obstacle in this scenario is not surmounted by tweaking the prior for βE,2
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alone. WT1 performs relatively well and is the only method more likely to choose
dose 2 than 3. As might be imagined, WATU has performance between that of ET
and WT. Performance in WT and WATU diminishes understandably as the models
are biased towards the monotonic efficacy prior. It diminishes further still as the first
stage is suppressed, suggesting that both methods benefit from their exploratory
stages when biased towards an incorrect efficacy skeleton.
Efficacy plateaus again in Scenario 7, with dose 3 being the optimal and doses 3
& 4 admissible. WT is slightly superior to ET and WATU here. As with the previous
scenario, WATU is harmed by inclining towards the monotonic efficacy skeleton.
Interestingly, WT scarcely is.
Scenario 8 is the first of two unimodal efficacy curves. Dose 2 is the single admis-
sible dose, and thus the optimal dose. Once again, WT is the superior design and
WT1 shows the best performance. ET is very unlikely to select the best dose. The
performance of ET, and to a lesser extent, WATU, is compromised by a propensity
to stop too often. This suggests that idiosyncrasies in stopping behaviour persist,
despite the calibration exercise.
Scenario 9 is another unimodal example. The optimal dose is dose 3 but dose
2 is also admissible. Once again, WT1 is the best performing design. ET performs
much better in this scenario than in scenario 8, however, it still retains a tendency to
stop too often. This is the first example where the vague prior for βE,2 in ET2 has
materially improved model performance. Consistent with this, WT2 and WATU2
both suffer from the inclination towards the monotonic efficacy skeleton.
Scenarios 10 and 11 both call for stopping and selecting no dose. Overall, all
designs do this quite reliably, with overall better performance from WATU. Despite
the exercise to calibrate stopping probabilities, there is reasonable heterogeneity in
scenario 10, with the lowest probability (WT2) more than 20% less than the greatest
probability (WATU1). WT designs are the least likely to stop here. This is slightly
surprising given the extent to which we promoted stopping by choosing parame-
ters such as αE = αT = 0.3 rather than the αE = αT = 0.05 proposed by Wages &
Tait[98]. In contrast, WT designs are most likely to stop in scenario 11. This ques-
tions the success of our stopping calibration exercise and highlights the difficulty in
parameterising stopping mechanisms.
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TABLE 3.8: Probabilities of each design making optimal and admissi-
ble selections in the scenarios listed in Table 3.7, plus summary statis-
tics. Information ratio (IR) is calculated as Mean / StDev. In each
column, the best score is bolded.
Pr(Optimal) All Scenarios Scenarios 1-9
1 2 3 4 5 6 7 8 9 10 11 Mean StDev IR Mean StDev IR
ET1 0.44 0.36 0.81 0.73 0.66 0.04 0.42 0.04 0.53 0.77 0.80 0.509 0.281 1.8 0.448 0.275 1.6
ET2 0.41 0.36 0.81 0.71 0.65 0.06 0.46 0.09 0.62 0.79 0.80 0.524 0.271 1.9 0.463 0.264 1.8
WT1 0.174 0.521 0.674 0.442 0.566 0.408 0.534 0.521 0.621 0.697 0.924 0.553 0.189 2.9 0.496 0.146 3.4
WT2 0.392 0.488 0.691 0.581 0.590 0.304 0.509 0.467 0.564 0.654 0.921 0.560 0.164 3.4 0.509 0.115 4.4
WT3 0.565 0.544 0.729 0.648 0.638 0.192 0.518 0.350 0.460 0.746 0.912 0.573 0.198 2.9 0.516 0.164 3.1
WATU1 0.249 0.336 0.792 0.433 0.586 0.247 0.514 0.396 0.523 0.866 0.887 0.530 0.232 2.3 0.453 0.174 2.6
WATU2 0.383 0.248 0.865 0.533 0.583 0.156 0.421 0.351 0.403 0.829 0.888 0.514 0.251 2.0 0.438 0.206 2.1
WATU3 0.372 0.223 0.870 0.534 0.571 0.119 0.404 0.323 0.384 0.857 0.894 0.505 0.268 1.9 0.422 0.218 1.9
Pr(Admissible) All Scenarios Scenarios 1-9
1 2 3 4 5 6 7 8 9 10 11 Mean StDev IR Mean StDev IR
ET1 0.96 0.36 0.89 0.73 0.66 0.81 0.84 0.04 0.58 0.77 0.80 0.676 0.267 2.5 0.652 0.292 2.2
ET2 0.95 0.36 0.89 0.71 0.65 0.82 0.83 0.09 0.71 0.79 0.80 0.691 0.252 2.7 0.668 0.276 2.4
WT1 0.931 0.521 0.899 0.442 0.566 0.800 0.652 0.521 0.913 0.697 0.924 0.715 0.186 3.8 0.694 0.193 3.6
WT2 0.958 0.488 0.827 0.581 0.590 0.856 0.770 0.467 0.839 0.654 0.921 0.723 0.174 4.2 0.708 0.179 4.0
WT3 0.961 0.544 0.851 0.648 0.638 0.885 0.793 0.350 0.775 0.746 0.912 0.737 0.180 4.1 0.716 0.190 3.8
WATU1 0.906 0.336 0.919 0.433 0.586 0.827 0.679 0.396 0.855 0.866 0.887 0.699 0.224 3.1 0.660 0.231 2.9
WATU2 0.915 0.248 0.912 0.533 0.583 0.838 0.740 0.351 0.722 0.829 0.888 0.687 0.230 3.0 0.649 0.239 2.7
WATU3 0.911 0.223 0.901 0.534 0.571 0.806 0.712 0.323 0.670 0.857 0.894 0.673 0.238 2.8 0.628 0.241 2.6
In a real trial situation, we pick one design that we trust will perform well in
all (or most) scenarios. That trust is motivated by analysing performance over an
indicative range of scenarios, as we have done here. The probabilities of each design
selecting the optimal and admissible doses are shown in Table 3.8 for each scenario.
We can crudely estimate broad model performance across the range of scenarios
by taking the mean probability of each design selecting the optimal or admissible
dose. Likewise, we can estimate the variability of performance by calculating the
standard deviation. A smaller standard deviation reflects greater homogeneity in
performance. Means and standard deviations are included in Table 3.8. We have
also calculated the information ratio (IR) for each design. In finance, IR is a metric
used to appraise the risk-adjusted performance of a security or fund, defined as the
expected value of a set of returns (potentially less some risk-free or benchmark rate)
divided by the standard deviation of those returns, defined in equation 3.18.
IR (x1, ..., xn) =
Mean (x1, ..., xn)
SD (x1, ..., xn)
(3.18)
A high IR is better, signifying high average value for relatively low variability.
We have used the measure here to compare dose selection strategies across the sce-
narios, defined as the mean probability of selection divided by standard deviation
of those probabilities. We seek a design that performs well on average in many sce-
narios with relatively little variability, and IR scores allow us to measure this. For
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instance, a design that selects the best dose 50% of the time in scenarios A and B is
preferable to one that selects the best dose with probability 100% in A and 0% in B.
In this contrived example, the two strategies have the same selection probability but
the first strategy has better risk-adjusted performance and greater IR.
The designs in the WT family offer the highest average selection percentages, the
lowest standard deviations and naturally, the greatest IRs. Table 3.8 shows that WT
does this when all scenarios are grouped, and when scenarios 1-9, the non-stopping
scenarios, are considered. The IRs are smallest in this particular study for the ET de-
signs. The WATU designs sit in between WT and ET. This is perhaps to be expected,
given the fact that WATU combines elements from WT and ET.
Table 3.9 shows the average number of patients allocated by each design to each
dose.
WT uses more patients in scenarios 10 & 11 where the correct decision is to stop.
WT1 and WT2 use considerably more in scenario 10 where the doses are ineffective
but tolerable. This is partly because WT designs do not stop for futility in the ran-
domisation stage. WT3 sets the randomisation stage size to 0 and is able to stop for
toxicity or futility at each dose decision. As such, it uses fewer patients than WT1
and WT2. In non-stopping scenarios, there is considerable heterogeneity in alloca-
tions.
Table 3.10 summarises the allocations to optimal and admissible doses. In sce-
narios 10 and 11, the desired action is to stop without allocating many patients so
in these two scenarios we have instead provided the number of patients left unal-
located, i.e. 30 minus the numbers allocated to doses 1, ...., 4. The IR statistics are
again provided as a measure of risk-adjusted performance.
ET treats the greatest number of patients at optimal and admissible doses, on
average. However, ET also has the greatest variability in allocation. Notably, in sce-
nario 8 it allocates only a single patient on average to the single admissible dose. WT
generally provides the lowest average allocation to attractive doses. This is under-
standable given its use of randomised allocation in the first half of the trial. Note for
example that WT3, the variant with no randomisation, has allocation figures that are
more comparable to the other designs. As we might expect by now, WATU provides
performance between the two.
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TABLE 3.9: Mean numbers of patients allocated to each dose. Figures
for the optimal dose is shown in bold and acceptable doses are un-
derlined. For stopping scenarios, the total is bolded and underlined.
Scenario Dose 1 Dose 2 Dose 3 Dose 4 Total
1
Pr(Eff) 0.21 0.46 0.58 0.69
Pr(Tox) 0.11 0.16 0.24 0.30
Utility -0.32 0.07 0.23 0.34
ET1 0.1 0.6 16.5 11.9 29.1
ET2 0.0 0.6 16.9 11.3 28.8
WT1 4.9 8.6 13.2 2.9 29.6
WT2 4.1 7.0 12.9 5.8 29.8
WT3 0.9 2.4 11.8 14.4 29.5
WATU1 0.9 2.6 15.1 9.7 28.3
WATU2 0.7 1.5 13.7 12.5 28.4
WATU3 0.6 0.9 16.0 10.8 28.2
2
Pr(Eff) 0.21 0.49 0.55 0.61
Pr(Tox) 0.05 0.32 0.53 0.69
Utility -0.32 0.04 -0.05 -0.17
ET1 0.4 7.2 13.9 0.9 22.4
ET2 0.4 7.1 13.7 0.9 22.1
WT1 7.0 12.2 9.6 0.2 29.0
WT2 6.6 11.6 10.5 0.3 29.0
WT3 4.4 12.1 10.9 0.8 28.2
WATU1 3.4 8.2 13.5 0.9 25.9
WATU2 3.1 6.1 15.1 1.0 25.3
WATU3 2.7 4.8 15.5 1.2 24.1
3
Pr(Eff) 0.21 0.52 0.64 0.77
Pr(Tox) 0.08 0.17 0.32 0.53
Utility -0.32 0.17 0.25 0.16
ET1 0.1 2.1 23.0 3.7 28.9
ET2 0.0 1.9 23.1 3.6 28.6
WT1 5.1 9.0 14.2 1.5 29.8
WT2 4.6 7.7 14.5 3.0 29.8
WT3 1.5 4.2 18.1 5.7 29.5
WATU1 1.1 4.4 19.0 4.4 28.9
WATU2 0.9 2.6 20.5 4.9 28.9
WATU3 0.6 1.2 23.6 3.2 28.7
4
Pr(Eff) 0.04 0.15 0.32 0.63
Pr(Tox) 0.07 0.12 0.19 0.31
Utility -0.60 -0.43 -0.16 0.25
ET1 0.0 0.1 7.4 18.8 26.3
ET2 0.0 0.1 7.4 18.8 26.3
WT1 3.7 6.2 10.6 6.4 26.9
WT2 2.6 4.9 10.9 9.1 27.5
WT3 0.5 0.9 8.0 18.0 26.4
WATU1 1.7 1.4 7.6 10.0 20.6
WATU2 1.4 0.4 6.5 13.2 21.5
WATU3 1.3 0.3 6.5 13.4 21.5
5
Pr(Eff) 0.21 0.37 0.51 0.58
Pr(Tox) 0.07 0.16 0.28 0.52
Utility -0.32 -0.07 0.10 -0.01
ET1 0.1 0.7 19.3 6.1 26.2
ET2 0.0 0.7 19.4 6.0 26.1
WT1 5.4 8.5 13.3 2.0 29.2
WT2 4.3 7.2 14.1 3.8 29.4
WT3 1.3 3.5 16.8 6.8 28.4
WATU1 1.7 3.5 16.0 5.6 26.8
WATU2 1.4 2.1 15.9 7.6 26.9
WATU3 1.3 1.3 16.9 7.0 26.6
Scenario Dose 1 Dose 2 Dose 3 Dose 4 Total
6
Pr(Eff) 0.37 0.51 0.51 0.51
Pr(Tox) 0.04 0.11 0.28 0.38
Utility -0.05 0.17 0.10 0.03
ET1 0.4 1.0 16.4 8.8 26.6
ET2 0.1 1.2 17.1 8.0 26.4
WT1 7.2 10.4 10.7 1.5 29.8
WT2 5.6 8.6 11.8 3.8 29.8
WT3 2.0 4.9 13.6 8.7 29.2
WATU1 2.7 5.7 13.8 6.2 28.4
WATU2 2.2 3.7 12.8 9.6 28.4
WATU3 2.4 2.6 13.8 9.0 27.8
7
Pr(Eff) 0.22 0.37 0.51 0.51
Pr(Tox) 0.04 0.11 0.28 0.38
Utility -0.30 -0.06 0.10 0.03
ET1 0.3 0.4 14.1 12.4 27.2
ET2 0.0 0.5 15.1 11.3 26.9
WT1 5.3 8.4 13.0 2.5 29.2
WT2 4.2 7.1 13.4 4.8 29.5
WT3 1.2 3.6 14.8 9.0 28.6
WATU1 1.7 3.9 14.6 6.6 26.8
WATU2 1.4 2.6 13.1 9.8 26.9
WATU3 1.5 1.8 13.8 9.3 26.4
8
Pr(Eff) 0.37 0.51 0.4 0.27
Pr(Tox) 0.04 0.11 0.28 0.38
Utility -0.05 0.17 -0.07 -0.32
ET1 1.4 1.0 11.5 5.6 19.5
ET2 0.4 1.5 12.1 5.0 19.0
WT1 8.3 11.5 8.9 0.9 29.6
WT2 6.7 10.1 10.3 2.3 29.4
WT3 3.4 7.7 10.6 5.0 26.7
WATU1 5.0 7.9 10.5 3.2 26.7
WATU2 4.8 6.5 9.7 5.4 26.4
WATU3 5.4 6.3 8.2 5.4 25.3
9
Pr(Eff) 0.22 0.51 0.59 0.33
Pr(Tox) 0.04 0.11 0.20 0.35
Utility -0.30 0.17 0.26 -0.21
ET1 1.2 1.3 15.9 7.4 25.8
ET2 0.1 1.8 18.3 5.8 26.0
WT1 4.6 9.4 13.9 2.0 29.9
WT2 3.8 8.5 13.3 4.3 29.9
WT3 0.8 8.0 12.6 7.5 28.9
WATU1 1.0 7.6 13.4 6.4 28.4
WATU2 1.1 6.8 11.4 8.9 28.1
WATU3 1.4 6.6 12.3 7.2 27.4
10
Pr(Eff) 0.04 0.15 0.24 0.32
Pr(Tox) 0.04 0.11 0.20 0.35
Utility -0.60 -0.42 -0.29 -0.23
ET1 0.1 0.3 5.4 9.8 15.6
ET2 0.0 0.3 5.7 9.1 15.1
WT1 4.0 6.8 10.0 4.0 24.8
WT2 2.8 5.4 10.5 6.5 25.2
WT3 0.9 2.4 7.9 9.6 20.8
WATU1 2.9 2.0 6.1 4.0 15.1
WATU2 2.7 1.2 5.1 6.2 15.3
WATU3 2.8 1.2 4.2 6.4 14.6
11
Pr(Eff) 0.21 0.37 0.51 0.58
Pr(Tox) 0.47 0.55 0.62 0.69
Utility -0.47 -0.30 -0.19 -0.20
ET1 0.7 4.6 9.2 0.6 15.1
ET2 0.8 4.4 9.2 0.5 14.9
WT1 11.7 2.7 3.7 0.1 18.2
WT2 11.7 2.7 4.0 0.1 18.5
WT3 8.5 2.5 4.9 0.4 16.3
WATU1 4.6 4.4 5.9 0.4 15.3
WATU2 4.2 3.5 6.9 0.4 15.1
WATU3 3.6 2.5 8.4 0.7 15.3
We further discuss model performance and mitigating factors in the next section.
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TABLE 3.10: Mean number of patients that each design allocates to
optimal and admissible doses, plus summary statistics. Information
ratio (IR) is calculated as Mean / StDev. Scenarios 10 & 11 show mean
patients left unallocated. The best score in each column is bolded.
Full data is listed in Table 3.9.
Mean treated at optimal dose
1 2 3 4 5 6 7 8 9 10 11 Mean StDev IR
ET1 11.9 7.2 23.0 18.8 19.3 1.0 14.1 1.0 15.9 14.4 14.9 12.9 7.1 1.8
ET2 11.3 7.1 23.1 18.8 19.4 1.2 15.1 1.5 18.3 14.9 15.1 13.3 7.2 1.8
WT1 2.9 12.2 14.2 6.4 13.3 10.4 13.0 11.5 13.9 5.2 11.8 10.4 3.8 2.7
WT2 5.8 11.6 14.5 9.1 14.1 8.6 13.4 10.1 13.3 4.8 11.5 10.6 3.3 3.2
WT3 14.4 12.1 18.1 17.0 16.8 4.9 14.8 7.7 12.6 9.2 13.7 12.8 4.1 3.1
WATU1 9.7 8.2 19.0 10.0 16.0 5.7 14.6 7.9 13.4 15.0 14.7 12.2 4.1 3.0
WATU2 12.5 6.1 20.5 13.2 15.9 3.7 13.1 6.5 11.4 14.8 15.0 12.1 4.9 2.5
WATU3 10.8 4.8 23.6 13.4 16.9 2.6 13.8 6.3 12.3 15.4 14.8 12.2 6.0 2.1
Mean treated at admissible dose
1 2 3 4 5 6 7 8 9 10 11 Mean StDev IR
ET1 29.0 7.2 25.1 18.8 19.3 26.2 26.5 1.0 17.2 14.4 14.9 18.1 8.6 2.1
ET2 28.8 7.1 25.0 18.8 19.4 26.3 26.4 1.5 20.1 14.9 15.1 18.5 8.5 2.2
WT1 24.7 12.2 23.3 6.4 13.3 22.6 15.5 11.5 23.3 5.2 11.8 15.4 7.0 2.2
WT2 25.7 11.6 22.2 9.1 14.1 24.2 18.2 10.1 21.8 4.8 11.5 15.8 7.0 2.3
WT3 28.6 12.1 22.3 17.0 16.8 27.2 23.8 7.7 20.6 9.2 13.7 18.1 7.0 2.6
WATU1 27.4 8.2 23.4 10.0 16.0 25.7 21.2 7.9 21.0 15.0 14.7 17.3 6.9 2.5
WATU2 27.7 6.1 23.1 13.2 15.9 26.1 22.9 6.5 18.2 14.8 15.0 17.2 7.2 2.4
WATU3 27.7 4.8 24.8 13.4 16.9 25.4 23.1 6.3 18.9 15.4 14.8 17.4 7.5 2.3
3.6 Discussion
We proposed a fusion of the EffTox and Wages & Tait methods to create a new seam-
less phase I/II trial design that we call WATU. Our primary motivation was to re-
move the need for adaptive randomisation in WT for situations where frequent ad-
justments to a randomisation algorithm could lead to operational inefficiency. We
also examined by way of comparison a WT variant that also abrogates randomisa-
tion. We described a systematic method of calibrating designs to control for dis-
parate stopping probabilities and used this method to calibrate eight phase I/II de-
signs with a common stopping probability in a baseline case. We then conducted a
broad simulation study, inspired by a real trial that used an EffTox design, to anal-
yse performance of these designs. We used a novel approach to compare designs,
borrowing a measure from finance to identify the design that provided the best risk-
adjusted performance. In summary, we generally found that WT has superior per-
formance in this setting in terms of determining the optimal doses, but not in terms
of optimal allocation to doses. We found that on average, WATU performs similarly
to ET.
Despite our exercise to calibrate stopping across the designs, we noted material
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heterogeneity. For instance, Table 3.7 shows that the WT designs are on average
much less likely to stop than ET and WATU in scenarios 1-10. This naturally makes
us question the value of calibration exercise and ponder whether we are truly com-
paring like-for-like. Calibration could have been conducted differently. Instead of
setting the prevailing efficacy equal to the threshold rate 45% at all doses, we could
have chosen 100% to completely remove the estimation of efficacy as a source of
variability in stopping.
Of our 11 simulation scenarios, two required stopping, five had an optimal dose
in a monotonic efficacy curve, two used a plateau efficacy curve, and two an uni-
modal curve. Instead of taking the uniformly-weighted mean of selection probabil-
ities, as we have in Table 3.8, we might have weighted the performance numbers
by the scenario importance or prior likelihood. However, our counts of stopping,
monotonic, plateau and unimodal scenarios broadly match our prior beliefs on the
shape of the dose-efficacy curve. Thus, the scenarios have already been implicitly
weighted in our situation.
Our simulation study investigates only a small number of the practically infinite
possible scenarios. Different scenarios might have provided different conclusions.
The scenarios we have chosen are motivated by a genuine clinical trial situation.
They do not cover all eventualities but reflect those that are plausible and pertinent
in this setting.
When randomly sampling efficacy and toxicity outcomes in simulations, we have
assumed that the two events are independent. In a real trial, it is natural to consider
that efficacy and toxicity might be dependent. For instance, a patient that ceases
treatment early because of toxicity has less opportunity to receive the therapeu-
tic benefit of treatment and is, presumably, less likely to achieve an efficacy event.
The EffTox software offers the ability to sample dependent efficacy and toxicity out-
comes, as does Wages’ implementation of the WT design. It remains an exercise
for further study to verify whether the conclusions we have made from this work
persist in scenarios where efficacy and toxicity occurrences are associated.
It should be stressed that WT does not maximise utility so it may (legitimately)
favour a different dose to ET and WATU. Trialists will appraise designs on their abil-
ity to select a dose with attractive qualities. In trial settings that explicitly quantify
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utility using a metric, this can sensibly be interpreted as the dose with the highest
utility or any dose with positive utility. In a setting that does not quantify util-
ity, however, any dose satisfying efficacy and toxicity criteria may be attractive. As
such, comparing the probability of selecting the optimal dose is not necessarily fair
because ‘optimal’ is not uniquely defined. It is arguably fairer to compare the prob-
ability of designs selecting an admissible dose. Nevertheless, WT outperformed the
two utility-maximising designs so the putative hindrance has not comparatively im-
paired the design in this study.
Our motivation for analysing different parameterisations of the three designs
was to assess the extent to which performance might vary in our trial setting. For
instance, ET2 has a much vaguer prior than ET1 on the coefficient of the squared-
term in the efficacy logit model. In the monotonic efficacy scenarios (1-5), this vague
prior reduces performance by 1-3%. In the plateau scenarios (6-7), performance im-
proves marginally, and in the unimodal scenarios (8-9), performance improves 5-9%.
IRs improve from 1.8 to 1.9 and 2.5 to 2.7, suggesting a slight model improvement
overall in this setting. Naturally, if there was strong prior evidence to suspect a non-
monotonic dose-efficacy curve, different efficacy priors would be used. We reiterate
that the prior for βE,2 is fixed by default to be N(0, 0.2) in the MD Anderson EffTox
implementation[45] but can be changed to suit.
The extent of variation within the WT family of designs is more noteworthy. In
the monotonic scenarios, there are material improvements in the chances of picking
the optimal dose in scenarios 1 and 4 for WT2 compared to WT1. With WT3, there
is further benefit, between 3 and 18 percentage points, to suppressing the adaptive
randomisation stage. On average, WT3 is 14.9% better than WT1 at selecting the op-
timal dose in the monotonic scenarios. In the non-monotonic scenarios, comparing
WT2 to WT1 and WT3 to WT2, the probability of selecting the optimum falls with
each model change. In scenarios 6-9, WT3 is 14.1% on average less likely to pick the
optimum dose than WT1. Although we have only considered a modest number of
scenarios, it appears that WT2 and WT3 are better than WT1 in monotonic scenarios
and worse in non-monotonic scenarios, as expected. Naturally, the model used will
be parameterised to match the investigators’ prior beliefs on efficacy and toxicity.
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This, however, suggests that it is difficult to improve on WT1 without prior informa-
tion on the prevailing efficacy and toxicity scenarios, which is unlikely to be known
with confidence in a situation where a dose-finding clinical trial was deemed neces-
sary. Similar, albeit less pronounced, effects can be observed in the WATU family of
designs.
We sought to remove randomisation from WT in pursuit of operational efficiency.
Over the scenarios presented, the mean performance penalty to using WATU1 over
WT1 in selecting the optimal dose is approximately 2.3%. This can be interpreted
as the expected cost of using WATU1 over WT1. Notional operational efficiency
might have been achieved but statistical efficiency, in this situation the probability of
making the correct decision with a given set of resources, has marginally diminished.
Whether the trade-off is acceptable depends on the prevailing trial situation.
Part of the performance difference will stem from removing randomisation. Ran-
domisation in WT provides a facility to assess outcomes at different doses. This in-
formation is useful in estimating the dose-event curves. If randomisation is to be
removed, as may or may not be desirable, the challenge is to remove it in the way
with least loss. There will be trial scenarios when a modest performance penalty
is an acceptable price to pay. However, in this study, it would have been supe-
rior to simply implement WT3, another design that avoids randomisation. WT3 has
higher average performance and lower variability than each of the WATU designs
we studied. Comparisons between WT3 and WATU2 or WATU3 are natural because
each is biased towards the monotonic efficacy skeleton and avoids randomisation.
WT3 outperforms WATU2 in making the optimal choice by 5.8 percentage points
on average and performs better in eight of eleven scenarios. We did not consider a
non-randomising variant of WT with uniform values for τ(k).
The conclusion from our simulation study is that WT3 abrogates the need for ran-
domisation, thus achieving our operational efficiency objective, whilst offering supe-
rior performance, thus maintaining statistical efficiency. Our hybrid design WATU
achieves the same operational objective but offers slightly inferior mean statistical
performance, has greater heterogeneity in performance, and allocates marginally
fewer patients at attractive doses.
In completing this research, we have gained a lot of experience working with
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ET and WT. If designing a phase I/II trial from fresh, speaking purely in a per-
sonal capacity, the author would start with the WT design. The underlying proba-
bility models are simpler so it is easier to select parameters and to calculate the next
dose. Our simulation study has suggested that WT has superior performance in non-
monotonic efficacy scenarios. This would presumably be important where a phase
I/II trial design was deemed preferable. If adaptive randomisation is operationally
tolerable, we would use half of the patients in the first stage, as recommended by
Wages & Tait.
These phase I/II trial designs are so-called because they perform tasks typical of
phase I and II clinical trials. They are considered efficient because they potentially
reduce the number of trials required to approve a treatment. However, they do not
repeal the potential need for randomised phase II studies, where an experimental
treatment is compared to a control to assess whether a likely large and expensive
phase III trial is warranted. Retaining randomisation in WT’s design actually offers
an opportunity to further increase efficiency in the clinical trial pathway by addition-
ally achieving the objective of these randomised phase II trials. In situations where
a treatment can be ethically compared to a placebo, or can be offered adjunctly with
a standard of care, it is possible to include the comparator in WT as a zero-dose con-
trol arm. This effectively prepends d0 onto the list of ordered doses d1, ..., dn under
investigation. Patients can be randomised to d0 or one of the admissible non-zero-
doses and the randomisation probabilities would need to be adjusted to incorporate
the new arm and provide a reasonable allocation of control patients throughout the
trial. Depending on the clinical scenario, the stopping criteria would scrutinise tox-
icity at d1 rather than d0, the ‘lowest’ dose. As before, if there are no admissible
non-zero doses, the trial would end with no dose being selected. At the culmina-
tion of the trial, the efficacy outcomes yielded by the optimal dose level could be
compared to those yielded by d0, achieving the goal of a randomised phase II trial.
This complex design has the alluring potential to provide a genuine single-trial so-
lution before phase III, achieving toxicity- and efficacy-oriented dose-finding and a
randomised comparison with a legitimate control arm. A trial designed by the au-
thor is currently in set-up at the Cancer Research UK Clinical Trials Unit that seeks
to implement this design.
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Chapter 4
Design of a practice-changing
clinical trial in an ultra-rare
condition
Background: Wolfram syndrome is an ultra-rare neurological condition in chil-
dren and young adults. One of the symptoms is progressive loss of visual acuity.
Many clinical trials that analyse visual acuity as a primary outcome have taken
place but none in Wolfram syndrome.
Notable methods in this chapter: We use mixed effects models, simulation,
and consider several patterns of data-missingness to prospectively estimate the
power of a clinical trial of sodium valproate. Our motivation to consider this
level of detail is the severely constrained feasible sample size in this rare dis-
ease. Our literature review shows that this approach is novel in clinical trials of
visual acuity.
The implications on efficiency: We demonstrate that clinical trials in ultra-rare
diseases that achieve conventional error rates are feasible. Key to achieving
this in our situation was using a repeated measures analysis to make use of
all outcome information. Furthermore, using simulation allowed us to verify
that randomisation favouring the experimental treatment could be used whilst
maintaining a defensible design.
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4.1 Introduction
The previous chapters were concerned with dose-finding clinical trials. In this chap-
ter, we focus on a randomised efficacy study in a rare disease.
4.1.1 Wolfram Syndrome
Wolfram Syndrome (WS) is an ultra-rare, neurodegenerative disorder of children
and young adults. It was first described in 1938 by Wolfram & Wagener[107], who
reported on a family of nine siblings. Four of the siblings were affected with child-
hood onset diabetes mellitus, progressive optic atrophy leading to blindness, sen-
sorineural deafness, and diabetes insipidus.
Wolfram Syndrome is caused by homozygous or compound heterozygous mu-
tation of the WFS1 gene that encodes wolframin. It is registered in the Online
Mendelian Inheritance in Man (OMIM) database with identifier 222300. The syn-
drome is also known as DIDMOAD, for Diabetes Insipidus, Diabetes Mellitus, Op-
tic Atrophy and Deafness. The natural history typically involves diabetes mellitus
in the first decade of life together with progressive optic atrophy. Deafness, neu-
ropathic bladder and cranial diabetes insipidus appear in the second decade. The
minimum criteria for diagnosis are diabetes mellitus and optic atrophy in an indi-
vidual under 16 years of age.
The diagnosis of Wolfram syndrome is devastating for the affected person and
their family or carers, as it virtually guarantees progressive sensory, motor, auto-
nomic and mental faculty loss, and reduced life expectancy. The median age of
death in patients is around 30 years and usually arises from respiratory failure as
a result of brain stem atrophy[7]. Thankfully, Wolfram Syndrome is very rare, hav-
ing a prevalence of approximately 1 in 770,000[8]. Using a population size of 64
million, being the estimated UK population in 2013 by the World Bank, this suggests
there are approximately 83 affected patients in the UK.
There is no pharmaceutical treatment for Wolfram Syndrome. Instead, current
therapies focus on the clinical management of symptoms. Being a multisystemic
syndrome, different treatments exist to manage the different elements.
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Treatments for diabetes mellitus aim to control metabolism by maintaining gly-
caemic targets. Interventions may include insulin injections, blood glucose and ke-
tone testing, exercise, nutrition and smoking avoidance, and management of dia-
betic ketoacidosis (DKA) and hypoglycaemia. After the onset of diabetes insipidus,
patients may receive desmopressin to treat bed-wetting. Vision loss may lead to
cataract surgery or correction of refractive error, as appropriate. Hearing loss may
lead to the use of hearing aids or cochlear implants. Neuropathic bladder may re-
quire clean intermittent self-catheterisation.
Reduction in the amount or activity of wolframin is associated with the death
of neurons. At present, there are no known methods to prevent the neurodegener-
ation observed in Wolfram syndrome. Nagy et al.[67] showed that the re-entry of
neurons into the cell cycle may be a step on the pathway to apoptosis in neurode-
generation. They also showed that p21cip1 acts as an anti-apoptotic molecule. Sig-
nificant down-regulation of p21cip1 was seen in wolframin-depleted cells compared
with controls. Those cells that retained p21cip1 expression had much lower levels of
apoptosis compared to those cells without. This led to the hypothesis that increased
p21cip1 expression may prevent neuronal death even in Wolframin-depleted cells.
4.1.2 Sodium Valproate
Nagy and colleagues at the University of Birmingham conducted a screen of 1,040
US Food and Drug Administration-approved drugs and short-listed 22 drugs that:
• are known to increase expression of p21cip1;
• would likely be tolerable in children for chronic administration.
Five drugs were identified that showed clear evidence for protecting nerve cells
from death in a Wolfram syndrome disease model. Sodium valproate, the sodium
salt of valproic acid, was one of these drugs. It is classed as an anticonvulsant and
currently approved in the treatment of epilepsy and bipolar disorder. It is known
to cross the blood-brain barrier. Sodium valproate was selected for further study
in Wolfram syndrome because it has been used for decades in children as an ap-
proved medicinal product and thus has an established safety profile. In patients
with Wolfram syndrome, we expect sodium valproate to increase p21cip1 expression
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levels, increase wolframin expression, and ultimately to diminish neurodegenera-
tion. There have been no clinical trials of sodium valproate in Wolfram syndrome to
date.
4.1.3 The TreatWolfram Trial
We propose a randomised clinical trial to test the hypothesis that sodium valproate
reduces the rate of neurodegeneration in patients with Wolfram syndrome. An early
version of this trial was proposed by Lucinda Billingham and the lead clinical inves-
tigator, Timothy Barrett (TB). After feedback from the regulator advising against the
use of Bayesian statistics, the trial underwent a complete redesign by Kristian Brock
(KB) and TB. From this point, all aspects of a statistical nature were led by KB.
The treatment will be considered successful with respect to an outcome if it is
associated with a significant, clinically relevant reduction in the rate of degradation.
Naturally, improvements in symptoms would be very welcome but we do not nec-
essarily expect this. There are many symptoms mentioned in the previous section
that generally degrade over time. Knowing that the sample size of our trial would be
severely constrained by the rarity of the syndrome, it would be important to identify
the outcomes that are most conducive to study. Notwithstanding the fundamental
requirement that outcomes are relevant and important to patients, we specifically
seek outcomes with maximal information content. That is, we would like to identify
outcomes associated with disease progression that typically see large changes over
time with relatively low variability. To these ends, we were incredibly appreciative
that Professor Tamara Hershey of the Wolfram Syndrome Research Clinic, Wash-
ington University in St Louis, USA, provided longitudinal data on 26 patients with
Wolfram syndrome from her clinical cohort, collected under grant NIH HD070855,
“Tracking Neurodegeneration in Early Wolfram Syndrome".
The remainder of this chapter proceeds as follows. In Section 4.2, we elaborate
in detail on the St Louis dataset. We systematically search for a primary outcome
measure that will promote an efficient analysis, conduct some preliminary regres-
sion modelling of the candidate outcome variable, and calculate sample sizes for
hypothesis-testing trials, appraising these in light of the severely constrained feasi-
ble size of accrual. In Section 4.3, we apply the inferences from the St Louis dataset to
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describe an experimental design for the TreatWolfram trial and a proposed method
of analysis. We investigate the efficiency of our efforts through a simulation study,
including considerations for missing data. In Section 4.4, we demonstrate by de-
tailed literature review the novelty of our simulation-based approach incorporating
different schemes for missing data to study a visual acuity outcome. In Section 4.5
we provide some discussion and in Appendix B, we appraise our efforts using the
recently-published framework on randomised trials in small populations by Parmar
et al.[72]. Finally, we conclude in Section 4.6.
4.2 The St Louis Cohort
The St Louis dataset contains observations over a period of six years on 26 patients
with Wolfram syndrome of the Washington University Wolfram Syndrome Research
Clinic. These patients would be candidates for the TreatWolfram trial because many
meet the inclusion criteria. Data were assessed approximately annually. Figure 4.1
shows the frequency of the assessment times, relative to the first visit for each pa-
tient. We see that there is less long-term data than short-term data. The study re-
cruited 11 patients in its first year and added between three and seven new patients
each year in its second to fifth years. There has been very little drop-out. The de-
creasing number of observations in Figure 4.1 is consistent with the staggered re-
cruitment times and patients passing through the follow-up schedule. Most obser-
vations times fall close to the anniversary of the initial visit, but there are a small
number of assessment times that occur part way through the year.
The dataset contains up to six measurements per patient for each of the variables
listed in Table 4.1. We will give sodium valproate to Wolfram patients under the
expectation that it will diminish the rate of progression, rather than reverse their
symptoms. The patients on trial will be children and young adults, with potentially
very different baseline values. Furthermore, WS is a lifelong condition characterised
by chronic deterioration of performance. Our primary interest in this dataset will
be to characterise the typical rate of change in the clinical symptoms associated with
WS. In Table 4.1 under n, we have listed the number of year-on-year change values.
Much more data is provided for visual acuity than balance, for instance. We have
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FIGURE 4.1: Assessment times of patients in the St Louis cohort.
There are a small number of observations not near an anniversary
of the initial visit.
Variable NumObs NumPats StdEff
Visual acuity 68 24 0.6
Colour vision 59 23 0.5
Ventral pons volume 61 21 0.4
Brainstem volume 61 21 0.4
Balance 22 13 0.3
Upsit (smell) 66 24 0.2
RNFL 62 22 0.2
Humphrey visual field, mean defect 41 17 < 0.1
Humphrey visual field, pattern standard deviation 41 17 < 0.1
TABLE 4.1: Volume of information for variables in the St Louis
dataset. NumObs is the number of observed year-on-year differences.
NumPats is the number of patients that contributed at least one year-
on-year difference, i.e. two consecutive values. StdEff is the absolute
value of the mean of the year-on-year differences, divided by their
standard deviation.
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also presented the absolute value of the standardised effect size, being the mean
year-on-year difference divided by the standard deviation of the differences. We use
the absolute value because the direction of change is not pertinent to quantifying the
volume of information.
Variables with higher standardised effect sizes are more conducive to study be-
cause the variability of the change is small relative to the mean. This makes it easier
to observe a trend amidst the noise. By this measure, the variables most conducive
to study are visual acuity, colour vision, ventral pons volume, and brainstem vol-
ume. These variables broadly cluster as measures of vision and brain size. Primary
outcomes in clinical trials should be important to patients and conducive to study.
Visual acuity is the most important of these variables to patients and their carers
so it is extremely fortuitous that it ranks highest by our information measure. Any
treatment that ameliorates the loss of vision will be welcome, for obvious reasons.
Colour vision is understandably regarded as less important. Based on this, we in-
vestigate visual acuity as the potential primary outcome of our clinical trial. In the
next section, we provide a detailed examination of this variable.
4.2.1 Visual Acuity
Visual acuity (VA) is measured on the LogMAR scale in clinics using Early Treatment
Diabetic Retinopathy Study (ETDRS) charts. Patients read letters from a set distance
and the scores reflect the number of letters correctly identified. In best corrected
VA, patients wear glasses to correct for refraction disorders. Values are taken for
each eye and generally range from 0, which represents perfect vision, to +2.0, which
represents near blindness. Thus, increases in LogMAR represent deterioration. A
LogMAR score of 0 is also referred to as “20/20”, reflecting that a person can at 20
feet read letters that most humans will also be able to read at 20 feet. On this scale,
LogMar 2.0 is expressed as 20/2000, to reflect that the person can read at 20 feet
what most others could read at 2000 feet, making quite tangible the paucity of visual
acuity in a patient with LogMAR 2.0. Values less than 0 are also possible, reflecting
that the patient can read at distances greater than 20 feet what most others could
read at 20 feet.
81
Chapter 4. Practice-changing RCT in an ultra-rare condition
FIGURE 4.2: Visual acuity in 26 patients with Wolfram syndrome in
the St Louis cohort.
Figure 4.2 shows VA of the 26 patients in the St Louis dataset. We took VA to be
the average of the LogMAR scores in the left eye and right eye in 95 complete pairs
of data. We use the simple mean because it is preferable to maintain vision in each
eye and neither takes precedence over the other. For analysis, the mean of scores is
an equivalent statistic to their sum in binocular patients and can be interpreted as a
measure of the overall quality of vision. In the discussion, we consider a model that
analyses eyes separately.
Figure 4.3 shows a scatter plot and locally estimated scatterplot smoothing (loess)
line of the concurrent left-eye and right-eye assessments. Loess is an example of
local regression, fitting simple regression models to small localised subsets of the
data. The fits from these local models are combined to produce a smooth non-linear
overall model.
Differences of up to 0.4 are observed between eyes but the average relationship
showed by the blue line follows the line y = x for x ∈ (0, 1.5). There are two obser-
vations with very large VA values where this relationship breaks down. These relate
to a single individual that experienced rapid progression in symptoms.
At one assessment, this same patient yielded a VA measurement in one eye only.
Figure 4.4 shows two methods we considered for imputing an average value on this
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FIGURE 4.3: Left-eye vs right-eye visual acuity in the St Louis cohort.
(A) Assume same score (B) Assume same year-on-year change
FIGURE 4.4: Two methods for dealing with a missing VA value in one
eye to create combined VA score.
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occasion. There are values for the right eye at all periods but no observation for the
left eye at Time = 4. In both methods, the combined values at Time = 0-3 are the
simple arithmetic means. In Figure 4.4a, the combined value at Time = 4 is taken to
be the single value provided in the right eye, effectively assuming the same score
in each eye. We see that this is inappropriate because it artificially suggests that the
patient experienced an overall improvement. In truth, the patient’s vision had de-
teriorated over each period in each eye. In Figure 4.4b, the combined value at Time
= 4 is created by imputing that the left eye deteriorated at the same rate as the right
eye, and then taking the arithmetic mean. We used this method to impute the sin-
gle missing value because it conveys deterioration at all periods and pragmatically
makes use of all available data.
Including the imputed value, we have 96 observations for VA in total, an average
of 3.7 observations per patient. The ages of patients at time 0 ranged from 5.4 to 25.8
years. The mean VA score at time 0 was 0.59 LogMAR units (range, 0.0 to 1.3).
Figure 4.2 demonstrates many noteworthy characteristics. We see that VA gen-
erally increases over time but is subject to a reasonable amount of natural variation.
Patients appear to progress at a similar rate, irrespective of age and VA level. There
is a stark outlier series that we have already identified. The patient with a LogMAR
score of approximately 1.1 at age 13 progresses more rapidly than the rest of the pa-
tients, albeit from a high starting value. This demonstrates the types of progression
that can occur, perhaps in a relative minority of cases. We will address the implica-
tions of this series with respect to modelling and hypothesis testing in later sections.
4.2.1.1 Classical sample size calculations
Let us briefly consider conducting a standard parallel-groups randomised controlled
trial (RCT), where patients are assigned to receive either sodium valproate or placebo.
Let our primary outcome be change in VA. In a so-called analysis of change scores,
VA would be assessed in all patients at baseline, again after a period of treatment,
and changes calculated as the latter minus the former. The mean changes in each
group would be compared using a two-sample t-test (for approximately normally-
distributed data) or Mann-Whitney-U test (for non-normal data) to assess whether
the rate of progression significantly differed. A persistent therapeutic benefit is
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sought. Let us assume for elucidation that a 0.04 LogMAR units reduction in the rate
of progression per annum is a meaningful treatment effect. Below we demonstrate
using hierarchical regression models that the annual average progression in VA is
approximately 0.08 units LogMAR. Thus, an annual difference between groups of
0.04 units would represent a treatment effect that halved natural progression. Here,
we power tests to detect a difference of 0.04 in mean annual change in VA. We revisit
effect sizes later in this chapter.
To estimate required sample sizes, we require estimates of the mean and vari-
ability of changes in VA. There are 68 one-year changes in VA in the St Louis dataset,
with mean 0.067 and standard deviation 0.110 units LogMAR. We assume that the
standard deviation of one-year changes is 0.110 in each arm. To achieve 80% power
at a 5% significance level using a one-tailed t-test to detect a difference of 0.04 re-
quires 95 patients per arm, thus a total sample size of 190. We perform this calcu-
lation using the software provided with the book by Machin & Campbell[61]. The
required sample size vastly exceeds the number of patients in the UK. The sample
size for a two-tailed test would be larger still. Greater efficiency is needed.
VA scores are not perfectly correlated so the standard deviation of two-year
changes is less than twice the standard deviation of one-year changes. Perhaps in-
creasing the assessment period will lead to a feasible sample size. There are 46 two-
year changes in VA, with mean 0.157 and standard deviation 0.164 units LogMAR.
To detect a 0.08 difference in the average two-year change with 80% power at a 5%
significance level using a one-tailed t-test requires 53 patients per arm, or a total of
106. This too, is infeasible.
There are 28 three-year changes in VA, with mean 0.240 and standard deviation
0.224 units LogMAR. To detect a 0.12 difference in the mean three-year change with
80% power at a 5% significance level using a one-tailed t-test requires 44 patients
per arm, or 88 in total. For this sample size to be feasible, we would have to recruit
every patient in the UK. This is unrealistic.
The above power calculations are based on two-sample t-tests. This requires
the changes to be approximately normally distributed. Non-parametric tests would
require further increases in sample size to achieve the same power. We have estab-
lished that an RCT using an analysis of change scores requires an infeasibly high
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sample size. To achieve defensible power with a feasible sample size, it will require
a more efficient approach to suit this particular situation. The series in Figure 4.2
seem amenable to repeated measures analysis. To these ends, we investigate mod-
elling VA using mixed-effects regression models.
4.2.1.2 Characterising VA through time
We note that the majority of the series in Figure 4.2 appear to progress at a similar
rate over multi-year periods. There are instances where VA increases and decreases
in consecutive years. This may be a manifestation of measurement error or reversion
to the mean. This supports the use of longitudinal analysis to distinguish the multi-
year trend from the short-term noise.
We also note the presence of outliers. For the purpose of assessing the treatment
in a controlled experiment, we seek to estimate the average rate of change and out-
liers present a challenge. A single period analysis that compares VA scores before
and after treatment in different groups would generally be more at risk of being af-
fected by outliers than a longitudinal analysis, which has the opportunity to smooth
out outliers if regression to the mean is subsequently observed.
We seek to characterise the dynamics of VA in Wolfram patients using linear
mixed effects models. This hierarchical approach lets us reflect that repeated mea-
sures are nested within individuals through time.
There is evidently a population-level effect in time, because VA deteriorates as
practically all patients age. We can immediately see from Figure 4.2 that patient-level
intercepts are warranted because the series start at different values, irrespective of
age.
Figure 4.5 shows the relationship of one-year forward changes in VA with A)
age; and B) VA at the start of the period. For example, VA = 0.4 in an 11-year old at
t = 0, increasing to VA = 0.6 one year later in the same individual would appear in
plot 4.5a as the point (11, 0.2) and in plot 4.5b as (0.4, 0.2). Figure 4.5a provides no
reason to believe that changes in VA systematically vary by age.
Figure 4.5b suggests that changes in VA can reasonably be assumed to be in-
dependent of the level of VA for VA < 1.5. However, there is a suggestion that
outcomes increase more rapidly at higher values. This remains just a suspicion,
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(A) Age (B) VA
FIGURE 4.5: Forward one-year change in VA vs age and VA at the
start of the period. The blue lines shows the loess mean and the grey
shaded regions the 95% uncertainty interval of the mean. The dashed
orange lines show the mean one-year change in VA.
however, because both VA values greater than 1.5 in this dataset are yielded by the
single aforementioned individual. Symptoms could deteriorate more rapidly when
disease and symptoms are already well-developed. The World Health Organisation
defines blindness to be best-corrected VA worse (i.e. scores greater) than 1.3 Log-
MAR[96]. It is plausible that the accuracy of visual acuity measurements decreases
as blindness becomes more comprehensive. Alternatively, rapid progression might
be a characteristic of this particular individual. The St Louis dataset does not allow
us to distinguish amongst these scenarios because only one patient is seen at such
levels. Patients with baseline LogMAR less than or equal to 1.6 are eligible for the
TreatWolfram trial, so we may encounter patients with high values and thus strongly
prefer a model that will handle outcome heterogeneity. As much as possible, we re-
sist the temptation to remove this patient from the modelling.
Let τij be the age in years of patient i at VA observation j, for i = 1, ..., 26 and
j = 0, ..., 5. Let tij = τij − τi0 so that tij is the time after baseline of observation j
for patient i. The tij are continuous values, not integers or factors. This is desirable
because, as Figure 4.1 demonstrates, assessments are not always conducted on an-
niversaries of the first visit. We see that ti0 = 0 ∀ i. Let yij be the VA observation
for patient i at time tij .
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We consider the hierarchical model
yij = α+ ai + βtij + eij eij ∼ N(0, σ2), ai ∼ N(0, σ2a) (4.1)
Here, α is the fixed-effect intercept, interpretable as the average baseline VA score;
ai is the random intercept adjustment for patient i, assumed normally distributed
with mean 0; and β is the fixed effect for mean change in VA per annum, assumed
constant in time and uniform across patients. We call this the random intercepts
model.
Using the nlme[74] package in R[76], the estimated parameters are α = 0.567
(s.e. 0.080) and β = 0.082 (s.e. 0.010), both with p < 0.001. In this cohort, this model
estimates the mean annual increase in VA to be 0.082 LogMAR units per annum.
This estimate differs from the simple mean period-on-period change of 0.067 given
in Section 4.2.1.1 for two reasons: (i) the regression model has adjusted for some
sources of variability to produce a better estimate of the change in VA attributable
to the passage of time; and (ii) some of the period-on-period changes did not strictly
cover periods of one-year, as demonstrated by Figure 4.1. The estimates of the stan-
dard deviations are σ = 0.125 (95% CI, 0.106 - 0.147) and σa = 0.382 (95% CI, 0.287
- 0.508). We have reported standard errors for coefficients but confidence intervals
for standard deviations to reflect the summary statistics provided by the nlme pack-
age. The model was fit using general positive-definite structure for the variance-
covariance matrix.
This model yields the fitted values shown in Figure 4.6a. Overall, we see that
the fitted values are close to those observed for VA scores up to approximately 1.75.
There are two values observed greater than 2 that are not fit particularly well. These
values relate to the same individual noted above with rapid progression at high VA
scores, suggesting the benefit in accounting for heterogeneity in gradients. First,
however, we consider further population-level terms.
Seeking to improve the model fit, particularly at high VA values, we consider
non-linear functions of time. We investigate alternative models that use the square
of tij
yij = α+ ai + βtij + γt
2
ij + eij eij ∼ N(0, σ2), ai ∼ N(0, σ2a) (4.2)
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(A) Random intercepts (B) Random gradients
FIGURE 4.6: Fitted and observed VA values under the two models.
Each was fit using the nlme package using REML.
and the square-root of tij
yij = α+ ai + βtij + ζ
√
tij + eij eij ∼ N(0, σ2), ai ∼ N(0, σ2a) (4.3)
as additional fixed effects. The incremental benefit of each of these models is as-
sessed by testing the nested models via likelihood ratio test using the anova.lme
function in nlme[74]. As recommended by Pinheiro & Bates[73], these models and
the comparator (4.1) were fit using maximum likelihood (ML) because testing nested
models with different fixed effects structures is invalid under restricted maximum like-
lihood (REML). The p values are 0.45 and 0.25 respectively. The case for including the
extra variables is not particularly strong. More importantly, neither rectifies the poor
model fit at high VA values. We seek improvements elsewhere.
Our difficulties with the outlier patient have been largely driven by their hetero-
geneous rapid rate of progression. This suggests we extend (4.1) by considering the
following model with patient-specific gradients with respect to time:
yij = α+ ai + (β + bi)tij + eij , (4.4)
eij ∼ N(0, σ2), ai ∼ N(0, σ2a), bi ∼ N(0, σ2b )
We call this the random gradients model. It reflects that individuals will commence
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(A) Random intercepts (B) Random gradients
FIGURE 4.7: Observed (dark grey) VA series and those estimated by
the two mixed effects models (red).
our study under different levels of visual acuity and that through repeated measures
in time, each will experience their own rate of progression. It yields the fitted values
shown in Figure 4.6b. We see that allowing heterogeneity in gradients improves
model fit at high VA values. A likelihood ratio test of the nested random intercepts
and random gradients models yields p < 0.001, confirming that this model is very
likely superior for modelling the St Louis data. For this test, models (4.4) and (4.1)
were fit by REML. As described in Pinheiro & Bates[73], tests of nested models fit by
REML that differ only in random effects are valid. Furthermore, the ML method of
fitting mixed models has an undesirable tendency to underestimate the size of the
variance components, a flaw rectified by fitting by REML.
The plots in Figure 4.7 clearly demonstrate how including random gradients im-
proves model fit. They show the fitted (red) series superimposed on the observed
(dark grey) VA series for each patients using the random intercepts (left) and ran-
dom gradients (right) models. The random intercepts model is surprisingly good for
the majority of patients. However, it does not model at all well those that progress
quickly. These patients still progress approximately linearly, albeit at a much faster
rate. The random gradients model facilitates this.
The random gradients model yields estimates α = 0.571 (s.e. 0.072), β = 0.070
(s.e. 0.017), σ = 0.074 (95% CI, 0.061 - 0.090), σa = 0.356 (95% CI, 0.266 - 0.477) and
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FIGURE 4.8: Raw residuals of the random gradients model. The solid
black line shows a Gaussian kernel smoother to estimate the distribu-
tion.
σb = 0.071 (95% CI, 0.049 - 0.103). The estimated mean annual progression is 0.012
LogMAR units lower when we allow heterogeneity in gradients. This reflects the
reduced influence of the patient with rapid progression.
Figure 4.8 shows the distribution of the “raw” residuals, i.e. the observed values
less the fitted values, of the random gradients model. We see that they are approxi-
mately normal, as required.
Figure 4.9 shows the distributions of the random parameters, both also assumed
normal in (4.4). Figure 4.9a shows that the random intercepts are indeed approxi-
mately normal. In contrast, Figure 4.9b also shows clear central tendency, but also
shows a large positive outlier in the random gradients. Perhaps unsurprisingly, the
outlier is the patient with very large VA values. The result is that the estimate above
for σ2b is possibly inflated by the data for this single patient. All else being equal, this
would overestimate the variability of outcomes and dictate an inflated sample size
for a given power. We return to this in following sections.
Figure 4.10 shows two further diagnostic plots. Figure 4.10a shows that residu-
als are centred at zero for each assessment point, and that their variance is approxi-
mately constant through time. Finally, we consider the autocorrelation of residuals.
Figure 4.10b shows the auto-correlation function for the residuals, produced using
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(A) intercepts (B) gradients
FIGURE 4.9: Distributions of the patient-specific parameters from the
random gradients model, assumed normal. The solid black lines
show Gaussian kernel smoothers.
(A) Skedasticity of residuals (blue crosses).
Loess smoother demonstrates the mean.
(B) Auto-correlation function, with 1% signif-
icance bounds.
FIGURE 4.10: Further diagnostic plots of residuals from the random
gradients model.
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the ACF command in nlme[74]. Mirroring Pinheiro & Bates[73, p. 241], we add sig-
nificance bounds (blue lines) at the 1% level. Assuming the observations are taken
at points equally-spaced through time, which Figure 4.1 demonstrates to be over-
whelmingly the case, we see from Figure 4.10b that the residuals at lags 1 and 2
years do not show significant autocorrelation. In contrast, the residuals are appar-
ently significantly autocorrelated at lags 3 and 5 years. Two factors motivate us to
cautiously interpret this finding as chance. The first is the lack of material autocor-
relation at lower lags. If the residual process retained information from previous
observations, for instance via an auto-regressive moving average (ARMA) process,
we would expect to see significant autocorrelation at short lags too. Secondly, there
are very few pairs of observations at these long lags.
Of our two candidate models for fitting VA in the St Louis data, the random-
gradients model is clearly superior. We consider further embellishments to this
model by testing two other population-level effects. We have demonstrated that
VA is related to age. Time is already included as a population-level effect and is per-
fectly correlated with age, so age at each assessment point is not a sensible covariate
to add. However, age at baseline could add marginal information. Testing the addi-
tion of this covariate via nested models estimated by ML yields p = 0.77. The data
are largely consistent with the additional effect associated with this variable being
zero. This is perhaps not surprising because the information contained in baseline
VA is already reflected in the model by the patient-level intercepts, ai.
Lastly, we consider a population-level effect with respect to sex. Again, a test via
nested models yields p = 0.46 and no strong case for inclusion.
We have demonstrated in figures above that the fit of our random gradients
model is good and that errors are reasonably independent. The model has valid-
ity because it maps to the research question we seek to answer and incorporates
effects that are intuitive and biologically plausible. The assumption of additive ef-
fects is reasonable given the small number of terms that combine to essentially yield
patient-specific straight lines. The one modelling assumption that is questionable
is normality of the random terms. Gelman & Hill[38] identify this as the least im-
portant of the modelling assumptions. Nevertheless, it is a topic we repeatedly visit
in subsequent sections when we use the random gradients model to simulate and
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analyse VA paths.
4.3 TreatWolfram Statistical Design
We present our design for an international, double-masked, randomised, placebo-
controlled trial of sodium valproate versus control in patients with Wolfram syn-
drome. This design was conceived and developed by KB. There is currently no phar-
maceutical treatment for Wolfram syndrome so the control arm will be a placebo,
manufactured to match the appearance of sodium valproate.
A severe constraint in designing a pivotal clinical trial in an ultra-rare disease is
the limited sample size. We have already noted above that a conventional experi-
mental design requires infeasibly high accrual. A more efficient analysis is required
to achieve conventional error rates with our restricted sample size.
In this chronic disease setting, we are able to measure the outcome variable many
times. In fact, the treatment is only likely to materially improve the lives of patients
if it demonstrates prolonged efficacy. In the following sections, we calculate the re-
quired sample size for the TreatWolfram trial assuming a repeated measures analysis
of the candidate primary outcome, VA. The sample size analysis will be informed by
the St Louis cohort.
A key component of a repeated measures is the frequency with which the out-
comes are measured. All else held constant, more frequent assessments yield more
information and a more powerful analysis.
VA is measured in clinics using standardised charts. The assessment is not costly
nor invasive and the frequency of assessment is constrained only by how often it is
reasonable to expect patients to attend clinic. We propose to measure this outcome
at baseline and every six months for three years, giving the seven assessment times
tVA = (0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0).
We are keen to maximise the chances that each patient will experience therapeu-
tic benefit on the trial. Given the absence of a standard treatment, we will investi-
gate the feasibility of randomisation that favours the experimental arm. However,
the most efficient allocation is equal-sized groups. We will tolerate modest deterio-
ration in efficiency arising from non-equal randomisation if it achieves the patients’
94
4.3. TreatWolfram Statistical Design
stated preference to increase the chances of receiving the experimental drug. We
investigate this via simulation.
As with any clinical trial, we expect to collect less than complete outcomes as
some assessments may not be performed as planned, or some patients may drop out
of the study. Less than complete data collection reduces the efficiency of analysis.
Furthermore, the pattern in which data is missing is potentially pertinent in longitu-
dinal analyses. We present three methods for simulating missing data and analyse
their effects on statistical efficiency.
4.3.1 Sample size for longitudinal analysis
We propose a longitudinal analysis because it will use more information and be
more efficient than a single post-baseline comparison. We showed in section 4.2.1.2
that VA series are amenable to analysis by mixed effects models. We investigate in
this section whether we can achieve conventional clinical trial error rates using our
limited sample size.
We follow the example of Diggle et al.[31, p. 30] to calculate the required sample
size for a test by repeated measures model of a continuous outcome. Using equal-
sized arms, for a two-tailed test with power P and significance α, Diggle gives the







where Q = 1 − P ; zα and zQ are quantiles from the unit normal distribution; σ2 is
residual variance discussed below; ρ = Corr(yij , yik) for all j 6= k; d is the difference
in slope coefficients to be detected; s2t =
∑
j(tj − t̄)2/n is the within-subject variance
of the explanatory variables, t; and n is the number of assessments times in t. For a
two-arm trial, the total sample size is 2N .
Diggle et al. estimate the variability of residuals, σ2, using an ordinary least
squares regression model
yij = α+ βtij + eij eij ∼ N(0, σ2) (4.6)
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TABLE 4.2: Serial correlations of VA in the St Louis dataset, at baseline
(VA0) and years 1-3.
VA0 VA1 VA2 VA3
VA0 1
VA1 0.949 1
VA2 0.923 0.978 1
VA3 0.867 0.970 0.980 1
for i = 1, ..., 2N and j = 1, ..., n. This model is used only to estimate σ2. It is not
the proposed analysis model. Model (4.6) fit to the St Louis data yields the estimate
σ2 = 0.164.
We will initially investigate α = 0.05 and power ≥ 80% to comply with con-
ventional clinical trial error rates. Where possible, we prefer to increase power. We
estimate the required parameters using the St Louis dataset. The correlation param-
eter in (4.5) is assumed to be the same at all lags. Smaller values for ρ demand larger
sample sizes because previous response values contain less information about future
values. Thus, to avoid the risk of under-powering the study, we seek to estimate the
lower bound of ρ.
The serial correlations in VA at baseline and years 1-3 years, chosen to match the
time-frame over which we will analyse this outcome in TreatWolfram, are shown in
Table 4.2. We see that the serial correlation values are at least 0.867. For conservative
sample size estimation and the reasons explained above, we assume ρ = 0.867.
With assessment times tVA (defined above), we have s2tV A = 1.0 and n = 7. As
before, we power to detect a reduction of 0.04 LogMAR units in the rate of increase
in VA per annum. Using these values, by (4.5) we require N = 25 patients per
arm to achieve 80% power to detect the specified difference at a 5% significance
level. Similarly, we require N = 29 to achieve 85% power and N = 34 to achieve
90% power. These represent marked improvements over the sample sizes in Section
4.2.1.1 and ably demonstrate the boost to efficiency that comes from using a repeated
measures analysis.
Paradoxically, one of the distinct benefits of designing a clinical trial in a con-
dition as rare as Wolfram syndrome is that many feasible patients can be identified
before the trial has commenced. Many countries, including the United Kingdom,
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have registries of patients and/or patient and carer support groups. Patients at-
tend routine clinics for monitoring and management of symptoms. Patient groups
and clinical leads have been consulted in several European countries to estimate
the likely number of patients that can be recruited. Thus, in a disease where trial
recruitment will be highly constrained, we can say with reasonable confidence the
exact number of patients that are feasible to recruit. In the UK, the lead investigator
predicts they can recruit 48 patients. Sites in France, Spain and Poland indicate that
they will be able to recruit 11, 6 and 5 patients respectively, leading to a maximum
feasible sample size of 70 patients. Further recruitment would require many centres
with low potential recruitment and this would contribute materially to the trial cost.
In the proceeding sections, we treat 70 patients as the maximum feasible accrual.
We have shown above that power up to 90% can be expected to detect an annual
difference in progression of 0.04 LogMAR units if all data is collected. We investigate
the sensitivity of efficiency to this last assumption in coming sections.
4.3.2 Measuring statistical performance using simulation
The sample sizes in the previous section are feasible given the expected number
of patients in the UK and our European neighbour countries. Those sample sizes
assume 1:1 randomisation. Given the dearth of pharmaceutical treatments for Wol-
fram syndrome, the fact that it afflicts children, and the fact that symptoms generally
progress continuously, we and our funders are highly motivated to use randomisa-
tion that allocates more patients to the experimental treatment. Equation (4.5) above
assumes equal-sized arms. Diggle et al.[31] do not give a version for general ran-
domisation ratios, and we could not find one in the literature. We use simulation
to investigate the feasibility of unequal arms by estimating statistical power at var-
ious allocation ratios in favour of sodium valproate. Furthermore, it is inevitable
in a longitudinal analysis that some data will be missing. Simulation allows us to
easily incorporate various patterns for data loss and assess their impact on statistical
efficiency.
We describe in the next section our methods for sampling patient outcomes. In
Section 4.3.2.2, we describe three schemes for simulating missing data. In Sections
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4.3.3 and 4.3.4, we investigate the power of two proposed models, including sce-
narios with missing data. Finally, we summarise the benefits of using simulation in
Section 4.3.5.
4.3.2.1 Methods for simulating VA paths
To make inference by simulation, we require a method of randomly sampling patient
VA paths. We desire that these paths mirror the statistical characteristics of those
observed in the St Louis dataset under the belief that the patients we recruit will be
similar. We achieve this using two methods of path generation, each inspired by the
random gradients model described in Section 4.2.1.2. We will refer to these as the
parametric method and the parametric bootstrap method.
In both methods, we sample VA path starting values to be uniformly distributed
on (0.0, 1.6), to reflect the patients we will recruit on trial. Patients with VA greater
than 1.6 are ineligible.
The rate of increase in VA per annum is assumed to have a fixed component,
common to all patients, and a patient-specific component. In each method, the fixed
component for patients allocated to the control treatment is 0.07 LogMAR units, to
match β, the estimated fixed effect with respect to time in (4.4). In the parametric
method, the patient-specific gradient components, bi, are randomly drawn from a
N(0, σ2b ) distribution, with σb = 0.071 to match the estimates yielded by the random
gradients model.
Figure 4.10a shows the skedasticity of the residuals from the REML random gra-
dients model derived in Section 4.2.1.2. The raw residuals are shown as blue crosses
and a loess smoother with confidence intervals is overlaid. The residuals are dis-
tributed about zero with some modest outliers. They could reasonably be described
as homoskedastic for t ∈ (0, 4) where the width of the confidence interval is approx-
imately constant. The variability in year 5 appears to be slightly larger, but there
are very few observations at this point. As such, random errors εij for each VA as-
sessment are assumed time-invariant and sampled from a N(0, 0.0742) distribution.
Once again, these fixed values are chosen to match the result of fitting model (4.4) to
the St Louis data.
With each of these components, the paths are calculated using tV A and (4.4).
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(A) Parametric method (B) Bootstrap method
FIGURE 4.11: Three-hundred simulated VA series (grey lines) pro-
duced using the methods described. The overplotted black lines
show the actual 26 St Louis patients.
TABLE 4.3: Correlation matrix of 300 3-year VA paths simulated using
the parametric method.
VA0 VA0.5 VA1 VA1.5 VA2 VA2.5 VA3
VA0 1
VA0.5 0.96 1
VA1 0.95 0.96 1
VA1.5 0.93 0.94 0.96 1
VA2 0.91 0.92 0.95 0.96 1
VA2.5 0.87 0.89 0.93 0.95 0.96 1
VA3 0.86 0.87 0.91 0.94 0.96 0.97 1
Figure 4.11a shows 300 paths simulated using the parametric method. Overlaid
in black are the paths observed in the St Louis cohort. The rapidly progressing in-
dividual is simple to identify. We see that the parametric method yields paths that are
generally less extreme in high values than the St Louis paths. For instance, none of
them progresses as rapidly as the patient in the St Louis cohort. Table 4.3 shows the
serial correlation matrix for these paths. These broadly match the serial correlations
observed in the St Louis cohort in Table 4.2.
A reasonable theoretical flaw of the parametric method is that the random gra-
dients are not strictly normally distributed, as shown in Figure 4.9b. They are pos-
itively skewed by the single, rapidly-progressing individual. To investigate perfor-
mance under non-normal random progression, in the parametric bootstrap method of
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TABLE 4.4: Correlation matrix of 300 3-year VA paths simulated using
the parametric bootstrap method.
VA0 VA0.5 VA1 VA1.5 VA2 VA2.5 VA3
VA0 1
VA0.5 0.98 1
VA1 0.98 0.98 1
VA1.5 0.97 0.98 0.98 1
VA2 0.95 0.96 0.97 0.98 1
VA2.5 0.94 0.95 0.97 0.98 0.99 1
VA3 0.92 0.94 0.95 0.97 0.98 0.99 1
path generation, we sample with replacement random gradients from the 26 values
calculated on the St Louis dataset, depicted in Figure 4.9b. Likewise, we re-sample
errors εij from the model residuals in Figure 4.8. All other aspects remain the same
as the parametric method and the components are combined using (4.4).
Three hundred paths by this method are shown in Figure 4.11b. We see that the
simulations now yield paths as extreme as the St Louis cohort. Analysis of paths
generated by this method will provide a valuable measure of the sensitivity of our
statistical design to modest departures from the Gaussian assumptions. The serial
correlations of these paths are shown in Table 4.4. These paths have generally greater
serial correlation that those generated by the parametric method.
In both methods, paths for patients allocated to the experimental treatment are
simulated in a similar way. The single difference is that the fixed effect gradient β is
assumed to be 0.07 − λ, for some treatment effect λ. The random gradients are not
adjusted, nor are the starting values or the measurement errors.
We expect some data to be missing on trial. Having described our way of simu-
lating repeated measures data, in the next section we describe ways to obscure some
data to estimate the power of our statistical test when data coverage is less than
100%.
4.3.2.2 Missing data
Some data loss is practically unavoidable in TreatWolfram so it is conservative to
factor this into the power estimation, especially when sample size is so severely
constrained and the efficiency of the design is so critical. For n assessments of m
patients, the full dataset should contain mn data points.
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DefineRij to be a data presence indicator variable that takes the value 1 if the out-
come yij is observed, else 0 if it is missing. Data are said to be Missing Completely
At Random (MCAR) if P (Rij = 1) is constant over patients and time-horizons. This
is not likely in a multi-year longitudinal analysis where later observations are natu-
rally more likely to be missing for a variety of reasons, e.g. people move home. Data
are said to be Missing At Random (MAR) if P (Rij = 1) is a function of the value or
presence of previous observations or contemporaneous covariates. Critically, data-
missingness is independent of the current outcome, yij under MAR. If P (Rij = 1) is
a function of yij , the data are said to be Missing Not At Random (MNAR).
Mixed effects models assume that data is MAR. Analysing MCAR or MAR data
using mixed effects models does not result in bias but does lead to a loss of precision
compared to an analysis of the complete dataset. Notably, analysing MNAR data
using mixed effects models results in bias and a loss of precision. A distinct compli-
cation is that “distinguishing between MAR and MNAR is not trivial and relies on
fundamentally untestable assumptions”[30]. We revisit this in the Discussion.
We investigate three methods for simulating missing data, illustrated in Figure
4.12. In the method depicted in 4.12a (that we will refer to as missingness 1), a number
of series are assumed to be completely missing. All other series are fully observed.
This naturally leads to the interpretation that it is the patients, rather than the ob-
servations, that go missing. The percentage of missing patients is equal to the per-
centage of missing data points. This method maximises the number of completely
observed series.
Under missingness 2 in 4.12b, all data points are missing with equal probability,
unaffected by whether other data are available for that patient.
Under missingness 3 in 4.12c, patient discontinuation points are randomly sam-
pled iteratively until a threshold amount of missing information has been achieved.
Once discontinued, a patient yields no further data. Some patients provide full data
series, some provide no data, and some provide truncated series. To simulate this
method, we used the following algorithm:
While target level of data loss is not yet reached:
• Select a patient at random;
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(A) Whole series are missing
(B) Points are missing completely at random
(C) Discontinuation points are randomly sampled
FIGURE 4.12: Three methods of simulating missing outcome data.
The orange cells represent missing observations.
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• Select a time point t∗, at random;
• Remove all observations for that patient with t ≥ t∗;
• Loop.
Under missingness 2, responses are MCAR. Under missingness 1 and 3, responses
are MAR because missingness is dependent on the presence of the trailing obser-
vation: once an observation in a series is missing, no subsequent observations are
made.
4.3.3 Power of the random intercepts model
In the TreatWolfram setting with experimental and control treatment arms, the ran-
dom intercepts model generalises to
yij = α+ ai + (β + γzi)tij + eij eij ∼ N(0, σ2), ai ∼ N(0, σ2a) (4.7)
where zi = 1 if patient i is allocated to the experimental treatment, else 0. The param-
eter γ estimates the mean adjustment in annual progression in VA associated with
receiving the experimental drug compared to control. The presence of a treatment
effect is assessed by testing the null hypothesis H0 : γ = 0 against the alternative
HA : γ 6= 0. The other parameters maintain the roles previously described in Section
4.2.1.2.
Our test of H0 entails a test of a fixed effect. As advised by Pinheiro & Bates[73,
p. 87-90], we test the marginal significance of γ not by likelihood ratio test, which
is “sometimes quite badly anticonservative” but by the conditional t-test statistics
provided in the standard table of regression output. We use a significance level of
5% so that p-values < 0.05 lead to rejection of the null hypothesis. This test is two-
sided although only values of γ < 0 indicate efficacy, i.e. a reduction in progression.
In a randomised controlled trial, a difference would be interpreted as having been
caused by the difference in treatments.
The power of this analysis at various sample sizes with patients allocated equally
between the arms is shown in Figure 4.13. We see that 70 patients provides approx-
imately 88% power when no data is lost, and at least 80% power when up to 15%
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FIGURE 4.13: Power using the random intercepts model to detect a
0.04 unit decrease in the annual rate of increase in VA, with all data
observed and under the three methods for removing 15% of outcomes
described in Figure 4.12. 10,000 trial iterations were simulated in each
scenario. VA outcomes were sampled using the parametric method.
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TABLE 4.5: Total sample size required with equal sized arms to detect
a difference of 0.04 LogMAR units per annum. The Diggle et al. esti-
mates are derived in the text. The estimates for the random intercepts
model are interpolated from Figure 4.13.
(A) 1:1 randomisation (B) 2:1 randomisation
FIGURE 4.14: Power at various effect sizes using the random inter-
cepts model, with all data observed and under the three methods for
removing 15% of outcomes. 10,000 trial iterations were simulated
in each scenario. VA outcomes were sampled using the parametric
method.
of data is lost, irrespective the pattern of missingness. Table 4.5 shows that when no
data is lost, power estimated by the simulation method is close to that implied by
the calculations using Diggle et al.’s method in Section 4.3.1.
The overwhelming problem with this model is that the type I error is vastly in-
flated, as demonstrated in Figure 4.14. Even when the true treatment effect is zero,
there is approximately 33% probability of incorrectly approving the treatment. Ap-
proval probabilities are a few percent lower under 2:1 randomisation. This is because
the model misinterprets any chance imbalance in patient-specific gradients as treat-
ment effect. This is further demonstration that random gradients are necessary in
our analysis model.
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FIGURE 4.15: Power to detect with the random gradients model a 0.04
unit decrease in the annual rate of increase in VA, with all data ob-
served and under the three methods for removing 15% of outcomes.
10,000 trial iterations were simulated in each scenario. VA outcomes
were sampled using the parametric method.
4.3.4 Power of the random gradients model
We demonstrated that the random gradients mixed effects model fits the St Louis
data better than the random intercepts model. As before, with two treatment arms,
the model generalises to
yij = α+ ai + (β + bi + γzi)tij + eij (4.8)
where bi ∼ N(0, σ2b ) are the random gradients with respect to time and all other
parameters retain their previous definitions.
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(A) 1:1 randomisation (B) 2:1 randomisation
FIGURE 4.16: Power at various effect sizes using the random gradi-
ents model, and different values for σ2B . We assume that 15% of data
is lost under missingness method 3. 10,000 trial iterations were sim-
ulated in each scenario. VA outcomes were sampled using the para-
metric method (solid lines) and parametric bootstrap method (dotted
purple line).
The power of this proposed analysis using 1:1 randomisation is shown in Figure
4.15. The random gradients model requires much larger sample sizes to achieve the
same level of power as the random intercepts model. To achieve 80% power when
no data is lost, we would expect to require about 110 patients, a material increase on
the random intercepts model.
It is noteworthy that under the random gradients model, power is similar un-
der missingness methods 1 and 3. It is intuitive to think that a regression model
would be adept at dealing with data missing completely at random as in missing-
ness method 2 because the model simply interpolates using the points on either side.
Figure 4.15 shows that losing sequences of points is more detrimental to power in
this scenario.
Figure 4.16 shows that the type I error rate is under control, as required. It also
shows that 70 patients randomised 2:1 in favour of valproate yields roughly 80%
power to detect a 0.06 LogMAR unit treatment effect when 15% of data is missing
by method 3 and σb = 0.071. Under 1:1 randomisation, the same power would be
available to detect an effect size of approximately 0.056, showing a modest perfor-
mance penalty to using non-equal arms. Figure 4.16 also makes plain the sensitivity
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of power to σb. The red line shows estimated power when σb = 0.036. This is the
value estimated by the random gradients model fit to the St Louis data when the en-
tire series for the rapidly-progressing patient is removed, i.e. the standard deviation
approximately halves. We see that 80% power is now estimated to be achieved at a
treatment effect between 0.035 and 0.040 LogMAR units with 2:1 randomisation.
The green series in Figure 4.16 shows power when σb = 0.0535, being the value
halfway between the two extreme values. Notably (and unexpectedly), this series is
very close to the line depicting power estimated using the random gradients model
on outcomes simulated by the parametric bootstrap method (dotted purple line).
This makes plain the uncertainty surrounding power and the role played by the
variability of the patient-specific gradients. If rapid patient-specific progression is
relatively common, we could expect our true, notional power curve to resemble the
blue line with σb = 0.071. We highlighted when developing the random gradients
model the large positive outlier in the random gradients, and how this value over-
states σb. We have seen that the distribution of patient gradients is not normally
distributed with mean 0 and standard deviation of 0.071. Instead, it is more like a
combination of two distributions: a normal distribution with mean 0 and standard
deviation of 0.036; and a single heterogeneous case. Thus, we expect the simulations
using bootstrapped outcomes to be more indicative of what we may see on trial. The
best outcome we could reasonably expect is represented by the red line where there
is no rapid progression.
There is one additional qualitative explanatory factor that is exhibited by our
single rapidly progressing patient, and this variable will be used on trial to maintain
statistical efficiency. We expand on this in the Discussion.
4.3.5 Benefits of simulation
In previous sections, we described a method for simulating VA paths that statisti-
cally resemble those observed in the St Louis cohort. We also defined three methods
for simulating data missingness. We then used these methods with mixed effects
model analysis, and used computer simulation to infer statistical performance of our
clinical trial design. The resulting power estimates reflect the implications of reason-
ably punitive data loss. It was important for us to understand the effect of data loss
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and the various patterns of missingness that may manifest in our scenario where the
size of feasible recruitment cohort is so severely constrained. Similarly, it was impor-
tant for us to be able to measure the effect of non-equal randomisation. Simulation
afforded us the flexibility to measure the simultaneous effect of these different com-
plications. Furthermore, we learned from simulation that, whilst power under the
random intercepts model was close to that suggested by the Diggle method, power
under the random gradients model is lower because of the extra source of variabil-
ity. We conducted this with the eventual goal of testing the effect of a treatment on
a visual acuity outcome. A literature review follows in the next section of methods
for estimating required sample size in trials that assess visual acuity.
4.4 Literature Review
We seek to demonstrate the novelty of our method for prospectively calculating the
required sample size of a longitudinal analysis of visual acuity by simulation, in-
cluding the effect of various patterns of data missingness. For brevity, we will refer
to this as “our method” in the remainder of this section.
Appendix B.1 describes how a literature search of “visual acuity sample size
trial” yielded ninety manuscripts for review, summarised in Table 4.6.
Primarily, manuscripts concerned trials, but there were many pertaining to re-
views and cohort studies as well. Despite the search terms, it was relatively common
that studies did not identify visual acuity as an outcome.
Despite being a continuous outcome measure, it was quite common that sam-
ple size estimation was conducted using a dichotomisation, e.g. defining response
to be change from baseline of at least x. Testing differences by t-test was relatively
common, as were ANOVA and ANCOVA (or their repeated measures analogues).
Reporting of sample size methodology was frequently quite vague, making it impos-
sible to identify exactly what method was used. In seven instances, it was possible to
determine only that the researchers had not used simulation or repeated measures.
These have been enveloped under the category Other in Table 4.6.
Methods using simulation or repeated measures were relatively rare, with only
five manuscripts identifying either and only one manuscript identifying both.
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Simulation or repeated measures 5
Other 15
Not given 51
Adjust sample size for missingness
Yes 10
Linear inflation 10
No, or not applicable 80
Overall 90
TABLE 4.6: Summary of manuscripts examined in literature review
of the approach used in TreatWolfram to estimate statistical perfor-




Data missingness was also mentioned very infrequently. Only ten manuscripts
mentioned adjustment of the sample size to account for missing data. Each of these
appeared to use a basic method of linearly inflating the calculated sample size. None
gave evidence of having considered further how the data might be missing.
Of particular note were four manuscripts that described using mixed effects
models for analysis, or simulation for calculating a sample size. Lambertus et al.[56]
performed a retrospective cohort study in patients with Stargardt disease, a form of
macular degeneration. Instead of modelling the level of visual acuity as we seek to
do, they analysed the time to degeneration to a given threshold. Linear mixed mod-
els were used to analyse other variables. They used simulation to estimate sample
size for an outcome other than visual acuity. They did not include loss-to-follow-up
as a factor when estimating sample size.
Wiley et al.[106] present a randomised crossover trial of bevacizumab vs ranibizumab
in patients with diabetic macular oedema. They analyse mean changes in visual acu-
ity using linear mixed effects models. However, they did not model the manner in
which longitudinal observations may be missing.
Lam et al.[55] presented the natural history of patients with a type of hereditary
optic neuropathy to design a trial of gene therapy. They used mixed effects models
to analyse outcomes but calculated sample size for a non-controlled study. They do
not consider the effect of missing data.
Finally, Yeh et al.[109] present a study of the effects of acupressure and multi-
media on the visual health of school children in Taiwan. They used a longitudinal
method to calculate sample size using the “G Power” software, but no further de-
tails of the method are given. They apparently adjusted their sample size by 20% in
anticipation of drop-out, but further details are not given.
In summary, we found evidence that other researchers have used mixed effects
models to analyse visual outcomes, and have used simulation to calculate sample
size. We found little evidence of complexity in simulating data missingness. Over-
all, we found no evidence that any researchers have previously used simulation to
prospectively calculate a sample size for a longitudinal analysis of visual acuity
whilst incorporating assumed patterns of data missingness. The manuscripts that
came closest to our proposal are those of Wiley et al.[106] and Yeh et al.[109].
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The reasons for focusing on visual acuity are clear but we believe that this serves
as an example of methodologies typically used in studies with repeated numerical
measures as outcomes. The results of the review for visual acuity are likely to be
generalisable to other types of numerical outcome measured over time.
4.5 Discussion
Throughout this chapter, we have demonstrated statistical power to detect a treat-
ment effect using the threshold 0.04 units p.a. LogMAR. The misidentification of a
line of five letters on an ETDRS chart adds 0.1 to the LogMAR score, so that a score
of 0.04 equates to two letters. Under a treatment that reduces annual average pro-
gression by 0.04 units, we would expect a patient to be able to read an extra line and
an extra letter (i.e. six letters) after three years, compared to if they had not received
the treatment. This makes clear the value of 0.04 units as a treatment effect. Trials
that have used visual acuity as a primary outcome have sought larger differences
in diseases where greater sample sizes are possible. In this chronic setting where
sight progressively diminishes, any positive treatment effect would be of value be-
cause it lengthens the time a patient has vision. Clinical acceptability is generally a
trade-off between efficacy and toxicity. Sodium valproate is not without side effects
so we expect to see some adverse reactions in patients. We would potentially be in-
terested in the treatment if it was demonstrated to be associated with a mean annual
effect of 0.035 units that is statistically unlikely to have arisen by chance, and the
incidence of adverse reactions was low and events were generally manageable. We
anticipate that patients would too. A project supplementary to the trial will analyse
patient-reported outcomes with respect to efficacy and toxicity, and seek to clarify a
patient-oriented threshold. The difference of 0.04 units LogMAR does not constitute
a hard threshold for approving the drug.
The foundation of our simulation study has been the outcomes observed in the
St Louis cohort. Wolfram syndrome is a monogenic condition commonly observed
in siblings, as in the original description by Wolfram & Wagener[107]. Other unob-
served genetic or environmental traits could dictate that the outcomes we observe
in the European trial differ from those in the American cohort study. The possibility
112
4.5. Discussion
that European or British patients progress more slowly on average would be detri-
mental to our notional power. Nevertheless, the use of randomisation in the trial
will promote a fair comparison.
We have made frequent reference to the rapidly progressing patient in the St
Louis cohort and the difficulties that this introduced into the analysis. We have
resisted the temptation to simply remove the patient because we may observe pro-
gression of this ilk in TreatWolfram. There was 1-in-26 in the St Louis cohort so there
could be several in our larger cohort. Our model should be able to analyse outcomes
from patients like these and provide robust inference. Additional explanatory infor-
mation pertaining to rapid progressors exists, however.
The highest LogMAR value provided by EDTRS charts is 1.98, where only a sin-
gle letter is correctly identified. How then, do we have values greater than 2 in Fig-
ure 4.2? Ophthalmologists have developed methods to ascribe so-called “off-chart”
LogMAR scores to those who fail to read a single letter[57]. If a patient can correctly
count fingers held up by the ophthalmologist, they are given a LogMAR score of 2.0.
If they can correctly identify the presence of hand waving, they score 2.3. If they can
correctly perceive the presence of light, they score 2.6.
These methods were used by the ophthalmologist assessing the St Louis patients
and have been used in a published RCT e.g. [52, 53]. They provide pragmatic in-
formation on outcomes when patients can no longer be measured by the desired
tool. Simply removing these points would understate the average disease progres-
sion. However, using off-chart outcomes presents a challenge for analysis because
they introduce a discontinuity on an otherwise continuous scale. How do we know
that progression assessed by off-chart methods belongs in the same distribution as
that assessed on-chart? If we know which VA measures have been recorded us-
ing off-chart methods, we will be able to analyse progression under both on-chart
and off-chart regimes. For instance, if off-chart measurements become common-
place, a simple method could analyse the on-chart and off-chart subsets separately,
estimating the average progression whilst allowing for random patient-specific per-
turbations in intercepts and gradients in the manner we have demonstrated in this
chapter. However, separate models are unlikely to provide the most efficient analy-
sis. We did not do this when modelling the St Louis data because of the very small
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number of off-chart measurements. Leaving the patient with rapid progression in
the analysis set and allowing shrinkage of regression parameters by attaching prob-
ability distributions seemed the most conservative solution.
We investigated age and initial VA as prognostic variables and found that they
did not improve our multi-level models. However, in the trial dataset, those same
covariates could be predictive of treatment effect. That is, the age or initial VA value
of a patient may in part determine the efficacy of the treatment. We will consider
this when specifying the statistical analysis plan.
We used computer simulation to gauge the combined effect of non-equal ran-
domisation and missing data on statistical efficiency. Guo et al.[42] introduced soft-
ware to estimate required sample size in parallel groups studies with repeated mea-
sures. The method they present applies to complete cases. They acknowledge that
missing data is a distinct complication in repeated measures studies. Furthermore,
they describe how “validated power and sample size methods exist only for a lim-
ited class of mixed models...are based on approximations, and make simple assump-
tions about the study design”. They advocate computer simulations as a general
method to obtain reliable sample size estimates when formulae are not available.
More generally, Lu et al.[60] introduce a framework for estimating sample sizes in
repeated measures analyses with missing data. They assume “monotone” missing-
ness for simplicity, akin to our method in Figure 4.12c. In contrast, our missingness
method in Figure 4.12b contravenes their assumption that the number of data-points
at any given time never exceeds that at each earlier time. Nevertheless, their method
for estimating the inflation factors required to compensate for missing data is valu-
able for gaining insight into our scenario. Applying their method to the St Louis cor-
relations in Table 4.2 and the expected data presence at each time given 70 patients
and 15% missing data under the method shown in Figure 4.12c, yields inflation fac-
tor estimates of 1.05 when part-year correlations are linearly interpolated, and 1.07
when only year-end data are used. Thus, even though we expect 15% of data-points
to be missing, the sample size need be inflated by less than 15% to compensate and
regain power. This is driven by the high expected correlation values.
We have used mixed models but alternative analysis methodologies exist. If
assessment times were uniform across all patients, analysis by ANOVA would be
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possible. Even though we intend to collect outcome assessments at set times, we
would be foolish to expect that they never differ from schedule. The St Louis dataset
contains some assessments that were not conducted near an anniversary of the first
visit. We prefer a method that allows the time variable to be continuous rather than
categorical. This naturally suggests using ANCOVA. However, ANCOVA does not
allow the specification of random effects and these have demonstrably improved our
modelling of the St Louis outcomes. Furthermore, the multi-level model approach
allows the specification of generalised variance-covariance structures. Although we
have not needed to use those here, they could well become necessary in the proposal
below.
The experimental unit has hitherto been the individual: we have analysed the
mean of left and right eye visual acuities for each individual through time. We also
described an isolated incident where a measurement was only available in one eye
and the care we had to take when imputing the effective “mean” value. An ap-
proach to abrogate this complication, and potentially increase statistical efficiency,
is to analyse the eyes separately. This is possible in our setting because symptoms
affect both eyes. Here, the experimental unit would be eyes rather than individuals,
and we would have approximately double the number of series to analyse. How-
ever, care would have to be taken to handle the association between eyes. Figure
4.3 shows that contemporaneous left- and right-eye measurements are highly cor-
related. For this reason, double the number of experimental units would yield less
than double the effective sample size. Multilevel models are flexible enough to han-
dle this. Firstly, eyes are nested within individuals. For example, each patient may
take their own visual acuity intercept to reflect their general baseline quality of vi-
sion, and also eye-specific intercepts to reflect the chance baseline disparity between
the two eyes. A similar specification will be possible for random gradients. Multi-
level models can specify these types of nested effects: observations are nested within
eye through time, and eyes are nested within individuals, all subject to overarching
population-level effects. Furthermore, they facilitate covariance structures to model
heteroskedasticity and serial correlation in residuals, should they arise.
This potential lift to efficiency and power would be very welcome. It would
provide some insurance against a potential decrease in power that would arise if our
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repeated measures have a lower serial correlation than those in the St Louis dataset.
Analysing series within eye within patient would actually be expected to slightly
increase serial correlation as a source of variability, eyes within patient, would have
been removed.
A more prosaic option to increase the amount of information is to assess out-
comes every three months, for example, rather than every six months, effectively
increasing the size of tV A from 7 to 13. Primarily, this would help the model more
accurately estimate σ and increase power. However, variability across patients is
also important. In our random gradients model, more accurate estimation of σa and
σb requires more patients, not just more assessments of the patients.
In Section 4.3.2.2 we considered missing data. It is customary under some analy-
sis methods to impute missing values. Imputation unavoidably makes assumptions
about the distribution of unobserved values. Last Observation Carried Forward
(LOCF) is a popular method, where missing values are assumed to take the value
that was last observed for a patient. This would be highly inappropriate in Treat-
Wolfram because symptoms demonstrate a tendency to deteriorate through time, as
demonstrated by Figure 4.2. LOCF is sometimes justified as a conservative assump-
tion. However, assuming no change here assumes the symptom ceases to deteriorate
and this is clearly an optimistic assumption. An analysis using LOCF would show
bias in favour of the trial arm with the most drop-out.
Another method is multiple imputation (MI), where likely values for missing
observations are calculated from observed outcomes and covariates. However, this
requires a model for imputation and if the imputation model is the same as the anal-
ysis model, the inference of the analysis using MI will match the inference from
fitting a mixed effects model to just the observed data [104]. Thus to improve on our
scenario in TreatWolfram, we would need to incorporate auxiliary information like
treatment compliance or alternative outcomes. One of the considerable strengths of
mixed effects models is that they do not mandate imputation; the model is simply
fit to the available data. There is no requirement for us to impute, so we do not.
We cited the impossibility of distinguishing MAR from MNAR. An accepted
pragmatic solution is to use sensitivity analyses to distinguish how the inferences
of an analysis change if the assumption of MAR is violated [105]. We propose to
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do this. Furthermore, we will ask patients why outcomes are not reported. If, for
instance, patients stop attending visual acuity clinics because their vision has deteri-
orated to the extent that they do not feel comfortable travelling, then the assumption
of MAR would clearly be violated. In circumstances like this, we would analyse the
outcomes using a method that incorporates informative dropout like pattern mix-
ture models.
In Appendix B, we describe our search strategy for identifying papers concern-
ing clinical trials that use a visual acuity outcome and describe a method of calcu-
lating sample size. We also compare the methods we used to arrive at a feasible
randomised clinical trial design in this rare disease to the framework on designing
randomised trials in small populations by Parmar et al.[72]. They recommend steps
in three sequential categories: increase what is feasible; explore commonly-considered ap-
proaches to reducing sample size; and explore less common approaches to reducing sample
size. We found high fidelity with the steps we took and the recommendations in their
first two categories.
4.6 Conclusion
We have succeeded in specifying a defensible clinical trial design with conventional
statistical error rates in an ultra-rare disease. Instrumental to this was our ability to
select outcomes amenable to repeated measures analysis. We selected parameters
for hypothesis testing and simulated frequentist operating performance of our de-
sign using the St Louis dataset provided by Prof. Hershey. Using a standard pre-
and post-treatment analysis of two groups would have required a sample size ex-
ceeding the disease population in the UK. Analysing repeated measures solved this
problem. In our ultra-rare disease setting, this boost to efficiency was the critical fac-
tor that made the described trial feasible. Simulation allowed us to make informed
judgements on preferential allocation to the experimental arm that has proved so




A Phase II Stratified Medicine Trial
with Efficacy and Toxicity
Outcomes and Predictive Variables
Background: PePS2 is a phase II trial of the efficacy and safety of pembrolizumab
in performance status 2 non-small-cell lung cancer patients. Previous studies
have shown that the chances of clinical response are correlated with baseline
covariates, particularly the extent to which PD-L1 is expressed by the cells in a
tumour biopsy. There are few clinical trial designs that test co-primary efficacy
and toxicity outcomes in phase II, and fewer still that allow the incorporation of
stratifying baseline variables.
Notable methods in this chapter: The design of Thall, Nguyen and Estey is one
such design but it has been scarcely used in actual trials. Furthermore, their
model incorporates terms to conduct a dose-finding study. This aspect is not
required in PePS2 because an effective and safe dose has already been identi-
fied in a closely-related population. We introduce a novel simplification of their
design suitable for use in phase II that focuses on testing efficacy and toxicity at
a fixed dose whilst adjusting for baseline cohort effects.
The implications on efficiency: The method allows sharing of information
across cohorts. Using a total of 60 patients to test the treatment in six distinct
cohorts, we can expect error rates typical of those used in phase II trials. Our
simulations show it is far more efficient than a method that analyses cohorts
individually.
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5.1 Introduction
There is a relative dearth of phase II clinical trial designs that incorporate predictive
patient covariates to assess efficacy and toxicity. Thall et al.[89] introduced a family
of methods that perform dose-finding trials guided by binary efficacy and toxicity
outcomes whilst accounting for baseline patient covariates. This enables dose rec-
ommendations tailored to individual patients. Our motivation is PePS2, a phase II
trial of pembrolizumab in non-small cell lung cancer patients of performance status
2. PePS2 is not a dose-finding trial. Instead, it seeks to estimate the probabilities of
efficacy and toxicity at a dose of pembrolizumab previously demonstrated to be safe
and effective in performance status 0 and 1 patients. In this chapter we introduce a
novel implementation of a simplified version of Thall et al.’s method. We remove the
dose-finding components but retain aspects to study co-primary efficacy and toxic-
ity outcomes that are associated with baseline covariates. In Section 5.2, we describe
the trial setting and review existing clinical trial designs for analysing both efficacy
and toxicity. In Section 5.3, we present our proposed alteration to Thall et al.’s model.
In Section 5.4, we simulate performance in PePS2 and compare it to that of simple
Bayesian beta-binomial conjugate models. We discuss some limitations of the model
and potential further development in Section 5.5. Finally in Section 5.6 we finish
with some conclusions.
5.2 Background
5.2.1 The PePS2 Trial
PePS2 is a phase II trial of pembrolizumab in non-small cell lung cancer (NSCLC)
patients with Eastern Cooperative Oncology Group (ECOG) performance status 2
(PS2). A patient with PS2 is ambulatory and capable of taking care of themselves
but typically too ill to work. Critically, it is doubtful that a PS2 patient could tolerate
the toxic side effects of chemotherapy.
The joint primary outcomes of the trial are (i) toxicity, defined as the occurrence of
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a treatment-related dose delay or treatment discontinuation due to adverse event re-
lated to pembrolizumab; and (ii) efficacy, defined as the occurrence of a complete re-
sponse (CR), partial response (PR), or stable disease (SD), without prior progressive
disease (PD) as measured by RECIST v1.1[35], at or after the second scheduled CT
scan that is detailed in the protocol to occur at 18 weeks. For instance, if the second
scheduled scan is missed, potentially for reasons of illness, but a subsequent scan
confirms absence of progression with respect to baseline, then this will be treated as
efficacy. The primary objective of the trial is to learn if the treatment is associated
with sufficient efficacy with acceptably low toxicity to approve for further research
in performance status 2 patients.
Pembrolizumab inhibits the programmed cell death 1 (PD-1) receptor via the
programmed death-ligand 1 (PD-L1) protein. In a phase I study with 495 patients,
Garon et al.[37] showed pembrolizumab to be active and tolerable in performance
status 0 & 1 patients. Overall, 19.4% of patients had an objective response (OR),
defined as the occurrence of PR or CR, and 9.5% experienced an adverse event of
grade 3 or higher. The rate of toxicity compares favourably to those typically seen in
advanced NSCLC patients using chemotherapy [10, 79]. With few treatment options
available for PS2 patients, it seemed worthwhile to investigate if similar rates of
efficacy and toxicity could be achieved in a PS2 population and thus we hope to
show that pembrolizumab is a viable treatment in this specific patient population.
TABLE 5.1: Objective response rate (ORR), where OR = CR or PR, in
PD-L1 score cohorts for the 204 patients in the validation sample of
Garon, et al.[37] with evaluable PD-L1 status.
Pretreated PD-L1 Cohort PD-L1 Criteria n ORR%, (95% CI)
Yes Low PD-L1 < 1% 22 9.1 (1.1, 29.2)
Yes Medium 1% ≤ PD-L1 < 50% 77 15.6 (8.3, 25.6)
Yes High PD-L1 score ≥ 50% 57 43.9 (30.7, 57.6)
No Low PD-L1 score < 1% 6 16.7 (0.4, 64.7)
No Medium 1% ≤ PD-L1 score < 50% 26 19.2 (6.6, 39.4)
No High PD-L1 score ≥ 50% 16 50.0 (24.7, 75.3)
All Low PD-L1 score < 1% 28 10.7 (2.3, 28.2)
All Medium 1% ≥ PD-L1 score < 50% 103 16.5 (9.9, 25.1)
All High PD-L1 score ≥ 50% 73 45.2 (33.5, 57.3)
Garon et al. introduce the PD-L1 proportion score biomarker, defined as the per-
centage of neoplastic cells with staining for membranous PD-L1, hitherto referred
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to as PD-L1 score. In the nomenclature of Buyse et al.[20], they demonstrate PD-L1
to be a valid and predictive biomarker of pembrolizumab activity. They use the hold-
out method to identify subgroups based on PD-L1 thresholds, using distinct training
and validation subsets of their overall trial population. Efficacy outcomes for the
204 patients in their validation group are shown in Table 5.1. Objective responses
are observed in all cohorts and the probability of response generally increases with
PD-L1 score.
Based on this information, we expect PD-L1 score to be predictive of response
in our PS2 population. Additionally, we expect a mix of patients that have and
have not previously received treatment for their cancer. In the Garon trial, 24.8% of
treatment-naive (TN) patients achieved a response, whereas only 18.0% did in the
pre-treated (PT) patients. A chi-squared test of association between pretreatedness
and response yielded a p-value of 0.166. A patient with recently diagnosed disease
such that no therapy has yet been given could be quite different to a patient that
has received previous lines and progressed. Pretreatedness represents a potentially
small but important effect that should be considered when testing the treatment.
The PePS2 chief investigator, Gary Middleton (GM), and the lead biostatistician,
Lucinda Billingham (LB), proposed a single arm phase II trial that investigates drug
in the six cohorts formed by jointly stratifying by: the three Garon PD-L1 classifica-
tions; and the PT or TN statuses. Each patient in PePS2 will belong to one of these
six cohorts. The trial aims to recruit over one year.
Being a phase II trial, there is strong motivation to deliver findings quickly to
inform potential phase III research in a timely manner. It is felt that recruitment in
the region of 60 patients within one year would be feasible but that recruitment ma-
terially higher would be prohibitive. Given the relative dearth of treatments for PS2
patients and the prior evidence of activity and tolerability in all NSCLC subgroups,
GM felt it important to offer a trial aimed at all-comers and not limit the target pop-
ulation by our covariates. Pembrolizumab has not been investigated in PS2 patients
so the clinical scenario requires a trial design that tests efficacy and toxicity. Given
the evidence that PD-L1 score and previous treatment status are associated with the
likelihood of response to this drug in NSCLC patients, it is highly desirable to use a
clinical trial design that incorporates these potentially predictive variables to tailor
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the treatment approval decision in specific patient subgroups. In the next section,
we describe our search for a clinical trial design that achieves these objectives.
5.2.2 Review of Competing Trial Designs
The trial statistician, Kristian Brock (KB) sought a clinical trial design that admits
explanatory variables to study joint primary outcomes efficacy and toxicity at phase
II. The results of our search are summarised in Table 5.2.
Reference Design Co-primary Covariates Phase II
Braun[12] BCRM Yes No No
Ivanova[46] Yes No No
Zhang et al.[112] TriCRM Yes No No
Wang & Day[99] Yes No No
Thall et al.[27, 92, 93] EffTox Yes No No
Ghebretinsae et al.[40] Yes No Yes
Cook & Farewell [28] Yes No Yes
Brutti et al.[18] Yes No Yes
Bouckaert & Mouchart[11] Yes No Yes
Bryant & Day[19] Yes No Yes
Conaway & Petroni[25, 26] Yes No Yes
Thall, Simon & Estey[87, 90] Yes No Yes
Thall & Sung[91] Yes No Yes
Wathen et al.[103] No Yes Yes
Thall, Nguyen & Estey [89] TNE Yes Yes No
TABLE 5.2: Results of literature review seeking a design for PePS2.
Covariates reflects inclusion of baseline data without further adapta-
tion. Phase II reflects original intent.
Using PubMed, KB searched for publications under the MeSH major topic ‘clin-
ical trials’ that are categorised with the MeSH Terms ‘Drug-Related Side Effects and
Adverse Reactions’ and ‘Models, Statistical’. Efficacy was not made explicit in our
search because establishing efficacy is such a common motivation for trials. We ex-
pected the presence of a toxicity outcome to be a more effective discriminator. On
5-Aug-2015, this query returned 67 documents whose collective focus was primarily
statistical clinical trial methodology in scenarios where toxicity is a key outcome.
Forty-eight of the papers were discarded because they focused on a univariate
outcome: forty-four focused primarily on toxicity alone and a further four focused
on efficacy alone. Four papers were reviews or advisory in nature and did not con-
tain specific model proposals. One paper was discarded because it was in Danish
with no English translation.
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This left fourteen papers for further consideration. Naturally, given the subject
matter, these papers concerned a preponderance of dose-finding and early phase
trials. With cytotoxic treatments, dose-finding has typically sought to find the maxi-
mum tolerable dose under the assumption that efficacy and toxicity increase in lock
step as dose is increased. In so-called cytostatic treatments, disease may be con-
trolled without reducing the overall tumour burden and the probability of efficacy
may not be an increasing function of dose. As such, in cytostatic treatments, effi-
cacy and toxicity can be jointly scrutinised to find the optimal dose rather than just
the maximal dose. The growth of targeted therapies and immunotherapies is asso-
ciated with a growing focus on methods that jointly model efficacy and toxicity for
dose-finding purposes. These have been already reviewed in Chapters 2 and 3.
Eight of the papers in our search describe dose-finding methods for cytostatic
treatments. Although these works detail designs that address a different trial objec-
tive (i.e., finding a dose), they are pertinent to our problem because they potentially
use probability models that could be redeployed for our purposes. We consider
those briefly now.
Braun[12] introduced a bivariate extension of the Continual Reassessment Method
(CRM) to two competing outcomes, toxicity and disease progression, where the two
events are associated. CRM itself was originally published by O’Quigley et al.[69]
with the purpose of conducting dose-finding trials under the cytotoxic assump-
tion. Ivanova[46] presented a rule-based up-and-down design that seeks to max-
imise the number of subjects allocated in the neighbourhood of the optimal dose.
Zhang, Mandrekar and Sargent[63, 112] introduced TriCRM, another extension of
CRM that considers the ordinal trinary outcome: no response and no serious toxic-
ity; efficacy without serious toxicity; and toxicity so serious that it precludes efficacy.
Wang & Day[99] present a method where response and toxicity outcomes occur ac-
cording to bivariate log-normally distributed patient thresholds. They allocate the
next dose to maximise patient-oriented expected utility. Finally, Thall et al.[27, 92,
93] present EffTox, the Bayesian adaptive dose-finding design that is the focus of
Chapter 2. Generally in dose-finding models, as with EffTox, dose (or transformed
dose) is used as the sole explanatory variable that determines outcome probabilities.




Five papers present models for efficacy and toxicity in a non-dose-finding set-
ting. Ghebretinsae et al.[40] present a method for modelling non-gaussian contin-
uous outcomes from assay data. This is not applicable to our scenario because our
outcomes are not continuous. In the single arm setting, Cook & Farewell [28] present
a sequential design to analyse correlated bivariate efficacy and toxicity events, ac-
counting for multiple analyses over time. Jin[50] presents a two-stage method ac-
counting for the trade-off between efficacy and toxicity. Brutti et al.[18] present a
two-stage Bayesian method to compare the overall toxicity rate and the true efficacy-
and-safety rate to pre-specified target thresholds. None of these methods explicitly
include predictive variables, although that is not to say they could not be adapted to
use them.
In the two-arm setting, Bouckaert & Mouchart[11] present a model to analyse a
two arm randomised controlled trial from the view that trial outcomes can be at-
tributed to therapeutic effects and toxic effects. They also do not explicitly consider
predictive variables but their model uses binary variables to denote arm member-
ship so it is sensible to conclude that this specification could be generalised to in-
clude arbitrary explanatory variables.
Finally, our PubMed search returned Bryant & Day[19]. This is perhaps the
best known and widely used phase II trial design for studying efficacy and toxic-
ity. Theirs is a two-stage method that offers a chance to reject a treatment for being
inactive or excessively toxic at an interim stage. The design takes threshold values
for the probabilities of efficacy and toxicity that are acceptable and unacceptable and
returns the minimum number of efficacy events and maximum number of toxicity
events that should be observed to approve the treatment for further study. For given
levels of statistical significance and power, the threshold event counts define the op-
timal trial of the competing outcomes of efficacy and toxicity. Their method consid-
ers different levels of association between efficacy and toxicity events and chooses
an optimal design. The design implicitly assumes that the patient population is ho-
mogeneous thus it does not use predictive variables.
Using a Bryant & Day optimal design to contrast efficacy rates of 10% and 30%
and toxicity rates of 10% and 30%, with efficacy and toxicity significance of 10%
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and overall power of 80%, requires the final analysis to use 27 patients. If we were
to use this design in each PePS2 cohort, we would require 6 × 27 = 162 patients,
an infeasibly high number. Even if we were to ignore the potentially important
information in the pretreatment variable and analyse three PD-L1 cohorts, we would
still require 81 patients using parallel Bryant & Day designs. Analysing the cohorts
separately in this way is inefficient. At this juncture, our preference was for a model-
based design that could increase power by incorporating predictive information.
Not included in our PubMed search but frequently cited in similar work is Conaway
& Petroni[25, 26]. They present sequential designs for phase II trials with bivariate,
associated activity and toxicity outcomes. In each case, their emphasis is on the de-
velopment of stopping rules rather than the incorporation of predictive information.
To further supplement our search, we studied review articles of biomarker-guided
clinical trial designs. Table 2 in Buyse et al.[20] lists the targeted (or selection) design
(as used in the ToGA trial[6]) and Bayesian adaptive design (as used in the BATTLE
trial[51], amongst others) as potential designs for validated, predictive biomarkers
of an experimental treatment. These are multi-arm designs, randomly allocating
patients to treatments, conditional on biomarker status. Neither of these designs
analyse toxicity as a co-primary outcome, although naturally safety would be an
important secondary outcome in trials that use either. Freidlin & Korn[36] review
randomised designs that can be used to develop or validate biomarkers. Our set-
ting is non-randomised and concerns studying the treatment modification effect of
a biomarker that has already been validated in a closely related patient population.
More recently, Antoniou et al.[5] described in detail the adaptive biomarker-guided
clinical trial designs they encountered in a review that covered 171 papers and 14,436
candidate abstracts. None of the eight designs they describe explicitly incorporates
a co-primary outcome.
We were also aware of other pertinent publications through knowledge of the
field. Thall, Simon & Estey[87, 90] and Thall & Sung’s[91] work on monitoring mul-
tiple outcomes (commonly, efficacy and toxicity) using Dirichlet-multinomial mod-
els and stopping boundaries in single arm phase II trials. These methods do not use
predictive information. Wathen et al.[103] published a method that uses predictive




Finally, Thall, Nguyen & Estey (TNE)[89] introduce an extension of EffTox[92]
that adds baseline patient covariates to the analysis of co-primary efficacy and toxic-
ity outcomes at different doses. Theirs is a Bayesian design that uses uninformative
priors on dose-effects and informative priors justified by historic data on the co-
variate effects. The objective achieved by their design is to recommend a personal
dose of an experimental agent that is estimated to offer sufficient probability of effi-
cacy and acceptable probability of toxicity, after taking into consideration predictive
baseline covariates.
In an example demonstrating their design in AML, TNE use age as a continuous
covariate, and a three-level ordinal variable reflecting prognosis with respect to cy-
togenetic subtype. They conducted a search of previously untreated AML patients
aged less than 60 that were then treated with chemotherapy at MD Anderson Cancer
Center between January 2000 and December 2004. They found 693 patients treated
with three general classes of chemotherapy and tabulated the frequencies of efficacy
and toxicity using their covariates, age and cytogenetics. They demonstrated that
efficacy decreases and toxicity increases with age. Similarly, they demonstrated that
efficacy decreases and toxicity increases as cytogenetic category worsens from good,
to intermediate and ultimately poor. In the marginal efficacy and toxicity models they
used quadratic terms with respect to dose-level to handle non-linearity, and associ-
ated these using a Gaussian copula with probit link.
On 05-Dec-2017, we identified 16 manuscripts listed on PubMed that cite TNE[89].
Of these, 10 were further methodology papers, each concerned with dose-finding.
None of these works sought to adapt the design for use in the typical phase II
scenario of investigating efficacy and toxicity at a single dose. Three papers were
methodological reviews, citing TNE as a potential method. Another was a sys-
tematic review of thrombolysis for acute ischaemic stroke that cited TNE but made
no explicit reference to it in the main body. A manuscript by Konopleva et al.[54]
uses TNE in a dose-finding study of PR104 in relapsed or refractory AML and acute
lymphoblastic leukaemia (ALL). The final paper was an expert panel recommenda-
tion [32] on the diagnosis and management of AML. It referred to TNE simply as a
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method that incorporated covariates when dose-finding in contrast to standard de-
signs like 3+3. This literature search suggests that TNE’s method has only been used
in blood cancer and only for the purposes of dose-finding. We found no suggestion
that the method had been adapted for the non-dose-finding context.
The Konopleva study[54] identified above used TNE in a dose-finding study of
17 AML and ALL patients. This study investigated doses of the hypoxia-activated
prodrug PR104, ranging from 1.1 to 4 g/m2. A further 8 patients were then treated at
selected doses (i.e. not guided by the design), and a further 25 patients were used in
an expansion phase. The manuscript mentions that “3 prognostic covariates” were
used in the dose-finding study but does not explicitly define them. We sought to
identify the covariates. An online supplement is referred to in the manuscript but
was not available at the Haematologica website on 3-Apr-2018. We contacted the lead
author by email but received no response.
PePS2 is not a dose-finding trial. Previous studies of pembrolizumab using col-
lectively over 1,000 PS0/1 NSCLC patients[37, 44] showed that response and adverse
event outcomes are not materially affected by dose changes in the range 2 mg/kg to
10 mg/kg. For this reason, subsequent trials of pembrolizumab, including PePS2,
used a flat dose of 200mg not adjusted for weight.
We sought a design that: i) studied associated co-primary binary outcomes; ii)
and admitted explanatory covariates; iii) at a single common dose. We resolved to
remove the dose-finding elements of TNE and retain the model that uses covari-
ates to study correlated co-primary outcomes and tailor the trial decision to each
covariate-determined cohort. Of all the candidate designs that could be adapted to
achieve these ends, we selected TNE for two reasons. The first was our familiarity
with the underlying probability model having used EffTox in the Matchpoint trial,
as described in Chapter 2. The second motivation was that TNE offers more than
we require, and it is generally easier to simplify something by taking unnecessary
elements away than it is to extend something by adding extra complexity. This is the
focus of the next section.
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5.3 A Design for Co-Primary Efficacy and Toxicity Outcomes
and Covariates
In this section, we describe novel adaptations to the TNE design to arrive at a model
that studies associated, co-primary probabilities of efficacy and toxicity of an exper-
imental agent, adjusted for baseline predictive covariates. We refer to our phase
II version of the TNE design as P2TNE. In the following section, we describe the
probability model, retaining the elements to incorporate covariates but removing
the elements that perform dose-finding tasks.
5.3.1 Probability Model in P2TNE
TNE present the marginal probability models of an experimental treatment
logitπk(τ, x,θ) = fk(τ,αk) + βkx+ τγkx (5.1)
for k = E, T denoting efficacy and toxicity, respectively. Here, τ is the given
dose; x is a vector of covariates; θ is the vector of model parameters to be estimated;
the fk(τ,αk) characterise the dose effects; βk is the vector of covariate effects; and
γk is a vector of dose-covariate interactions. They also introduce analogous models
for the events under historical treatments where covariate effects are present.
As with EffTox[92], let Y = (YE , YT ) be indicators of binary efficacy and toxicity
events. Let πa,b(τ, x, θ) = Pr(YE = a, YT = b|τ, x, θ) for a, b ∈ {0, 1}. The authors
associate the marginal probabilities of efficacy and toxicity in a joint model with
association parameter ψ:
πa,b = πa,b(πE , πT , ψ) (5.2)
One possibility for this joint model is that used in EffTox (2.4), sometimes referred to
as the Gumbel model.
In P2TNE, we can simplify this if we have no motivation to investigate different
doses by removing the terms that pertain to dose-effects.
In our model description for P2TNE, let x denote the baseline covariate infor-
mation for a given patient. The marginal probabilities of efficacy and toxicity are
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estimated using the logit models:
logitπE(x,θ) = g(x,θ) (5.3)
and
logitπT (x,θ) = h(x,θ) (5.4)
where θ is the vector of all parameters in the model. The exact specifications of g and
h are left for the trialists to specify to reflect the perceived relationships of x with the
probabilities of efficacy and toxicity. Generally, as with all statistical models, g and
h should be both plausible and parsimonious. We present our choices for the PePS2
trial in the next section.
Let patient i have covariate vector xi, and let ai = 1 if they experience efficacy,
else 0; and bi = 1 if they experience toxicity, else 0. For trial data
X = {(x1, a1, b1), ..., (xn, an, bn)} (5.5)




πai,bi(πE(xi,θ), πT (xi,θ), ψ) (5.6)
where ψ is a member of θ. Let θ have prior distribution function f(θ). For patients
with predictive variable vector x, the posterior expectation of the probability of effi-














where I(A) is again the indicator function.
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and the posterior probability that the probability of toxicity is less than π∗T is




I(πT (x,θ) < π∗T )f(θ)L(θ|X)dθ∫
f(θ)L(θ|X)dθ
(5.10)
The posterior expectation of the parameter vector is





The number of dimensions in the integrals (5.7) to (5.11) is equal to the number
of elements in θ. The difficulty in solving such integrals increases with dimension,
although modern Markov chain Monte Carlo (MCMC) methods like Stan[22] make
it relatively simple to sample from the posterior distribution.
Further taking the lead from TNE[89] and Thall & Cook[92], we propose the
treatment be approved in patients with predictive variable vector xi when it is suffi-
ciently likely that the associated efficacy probability exceeds some minimum thresh-




Pr(πE(xi, θ) > π
∗
E |X) > pE
Pr(πT (xi, θ) < π
∗
T |X) > pT
(5.12)
where pE and pT are determined using clinician input and simulation. Naturally,
π∗E , π
∗
T , pE and pT can vary by patient cohort. We could, for example, set the efficacy
hurdle lower in PT patients if a dearth of feasible alternatives dictates that a lower
efficacy hurdle is nevertheless clinically relevant.
The tests in (5.12) can be invoked at any time during the trial with different values
for π∗E , π
∗
T , pE and pT , making it simple to incorporate interim analyses in a clinical
trial, exploiting the flexibility offered by Bayesian cumulative learning. We revisit
this in the Discussion.
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5.3.1.1 Practical Steps for Implementation
Trialists should assess the operating performance of a design like P2TNE in the-
oretical scenarios using computer simulation. At the very least, we conduct sim-
ulations to estimate the probability that a design will incorrectly approve a poor
treatment (similar to the notion of significance in frequentist trial designs) and cor-
rectly approve a good treatment (essentially, statistical power). Simulated trials are
conducted by randomly sampling outcomes for notional patients and invoking the
acceptance decision determined by (5.12) at the final (and potentially also interim)
stages. In general, prior to simulating performance, we:
1. Specify forms for the marginal efficacy and toxicity models (5.3) and (5.4).
2. Specify a form for the joint model.
3. Specify f(θ), the prior distribution for θ.
4. Specify efficacy and toxicity thresholds, π∗E , π
∗
T based on clinical rationale.
These may vary by cohort or they may be common, as the clinical scenario
dictates.
With this information, we simulate trial data sets, Xj for j = 1, ..., J and infer the
decision of the design on each. Values for pE and pT need not be specified before
simulations are run. Instead, it is more flexible to record the value of (5.8) and (5.10)
in simulated iterations for each distinct value of xi. Then, we adjust the performance
of the design by considering different values for pE and pT , inferring the operating
characteristics of the pair by invoking (5.12) on the simulated output.
In summary, the values for π∗E , π
∗
T are based on clinical rationale and set at run-
time. In contrast, the values of pE and pT need not be, so it is easier to tweak model
operating characteristics by varying pE and pT . We invoke this algorithm below.
5.3.2 P2TNE in PePS2
GM selected π∗E = 0.1 and π
∗
T = 0.3 for all cohorts because these represent the
thresholds beyond which the treatment would be considered not sufficiently active
or too toxic.
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We define the predictive variables used in PePS2. Let patient i have x1i = 1 if
they have been pretreated, else x1i = 0. For the primary analysis, we will allocate
patients to exactly one of the three PD-L1 groups presented in Table 5.1. Let patient
i have x2i = 1 and x3i = 0 if they belong to the Low PD-L1 cohort; x2i = 0 and
x3i = 1 if they belong to the Medium PD-L1 cohort; and x2i = 0 and x3i = 0 if they
belong to the High PD-L1 cohort. Thus, x2i and x3i are dummy variables that wholly
determine membership to the three groups Low, Medium and High PD-L1 1. The
cohorts and values for xi = (x1i, x2i, x3i) are shown in Table 5.3.
Cohort Treatment status PD-L1 category xi
1 Treatment naive Low (0,1,0)
2 Treatment naive Medium (0,0,1)
3 Treatment naive High (0,0,0)
4 Pretreated Low (1,1,0)
5 Pretreated Medium (1,0,1)
6 Pretreated High (1,0,0)
TABLE 5.3: Cohorts used in the PePS2 trial. xi shows the covariate
vector for each patient in that cohort.
Using these variables, we propose that the marginal probabilities of efficacy and
toxicity be described by logit-models so that, for a patient with predictive data xi:
logitπE(xi,θ) = α+ βx1i + γx2i + ζx3i
logitπT (xi,θ) = λ
(5.13)
and associate πE and πT using the Gumbel model (2.4 ). In the PePS2 protocol, the
toxicity outcome includes occurrence of adverse events that lead to treatment cessa-
tion. If patients discontinue treatment, it naturally hinders their ability to gain ther-
apeutic benefit from the treatment and makes response less likely. In contrast, those
patients that stay on treatment give themselves the best opportunity for response if
the treatment does have a therapeutic effect. As such, it is sensible to facilitate that
efficacy and toxicity would be associated. Including ψ to model the association, our
parameter vector θ = (α, β, γ, ζ, λ, ψ) has six elements.
Under (5.13), the expected probability of efficacy is different for each distinct ar-
rangement of xi. Furthermore, the log-odds of efficacy for TN patients in the three
PD-L1 categories are assumed to be a common linear shift of those for PT patients
1Using three dummy variables and an intercept would yield a singular design matrix
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in the same PD-L1 cohorts, determined by β. Figure 5.1 shows the log-odds of ob-
jective response with uncertainty bars by cohort for the validation subgroup of the
Garon study. The model we propose effectively assumes that the equivalent lines in
our study using our definition of efficacy will be piecewise parallel. We see that this
assumption is broadly supported by the small amount of data reported by Garon.
The assumption is perhaps modestly violated in the Low cohort, but the estimates
are fairly uncertain, particularly in the low PD-L1 groups. A more complicated al-
ternative specification could remove the parallelism assumption by incorporating
interaction terms for PD-L1 cohort and pretreatment status. This alternative model
would require two extra parameters to handle interactions between x1i and x2i, and
x1i and x3i, respectively, a topic we develop in the next chapter.
FIGURE 5.1: Log-odds of objective response and 95% uncertainty in-
terval, by cohort of the validation sample (n = 204) of the Garon et al.
study.
Figure 5.1 suggests that parallel lines is not an implausible working model. With
accrual anticipated to reach 60 patients, the prospect of using six parameters instead
of eight is attractive, so we proceed with the six-parameter model. Nevertheless,
with only three data-points per line, we remain mindful to not reach conclusions
unmerited by the limited data. In Section 5.4 we simulate performance in a scenario
where there is a modest interaction between PD-L1 and pretreatment status, similar
to that depicted in Figure 5.1.
In contrast, the probability of toxicity is assumed constant across all cohorts.
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Garon, et al.[37] do not report in the main paper or supplementary appendix any
difference in toxicity in the different PD-L1 or pretreatment groups. Furthermore,
no heterogeneity with respect to adverse events is reported by Herbst et al[44] in the
phase III study of pembrolizumab in NSCLC. However, another topic of the next
chapter is an embellishment of our P2TNE model that allows toxicity to vary by
PD-L1 and pre-treatedness.
5.3.3 Priors in PePS2
We specify normal priors for the elements of θ. In their AML example, TNE use
informative priors on parameters that represent covariate effects on outcomes, re-
flecting historic published data. In contrast, they use uninformative priors on the
dose-effects. Their objective is to identify the optimal dose of an experimental agent
whilst controlling for baseline heterogeneity. They have deployed uninformative
priors on the parameters that are the primary subject of investigation, and informa-
tive priors on those that they concede to be “nuisance parameters...for the purposes
of dose-finding”[89]. They describe an algorithm for establishing hyperparameters
of normal priors. To establish prior means, they elicit expected event rates for at least
two dose-levels and solve for the expected values of the dose coefficients α in (5.1)
after assuming that dose-covariate parameters γ have expected value zero. They
also describe a potential algorithm for establishing prior variances. This method
controls the effective sample size (ESS) by equating the first two moments of the
πk(τ,Z,θ) to beta distributions and exploiting the fact that the ESS of a beta(a, b)
distribution is a + b. They advocate that each of the a + b should be small to reflect
the limited prior knowledge about dose-effects.
Our primary objective is to estimate the efficacy and toxicity of a treatment in
each distinct cohort of patients. Thus, the covariates in our setting are rather more
than nuisances because they determine these groups. Having observed data in the
Garon[37] and Herbst[44] trials, we naturally anticipate that those with higher PD-
L1 scores will more likely achieve our efficacy outcome. Likewise, we anticipate that
PT patients will be modestly less likely to have the efficacy event.
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5.3.3.1 Informative priors
We could develop an analogue of TNE’s method described above to establish priors
in our setting. Instead, however, we consider different priors based on the event
rates they generate. Gelman et al.[39] encourage us to think “generatively” in our se-
lection of priors, explaining that “a prior is generative if the prior predictive distribu-
tion generates only data deemed consistent with our understanding of the problem.”
In this spirit, we are motivated to select informative priors on model parameters so
that the expected efficacy rate in high PD-L1 patients exceeds that of medium pa-
tients, which in-turn exceeds that of low patients; and that TN patients are slightly
more likely to experience efficacy than PT patients. Furthermore, we may reflect in
our priors, information not reported in the Garon and Herbst studies, like the log-
ical expectation that previously treated patients who are further down the disease
pathway, may be more likely to experience toxicity because they are more vulnera-
ble than TN patients. We discriminate the priors not by their notional ESS but by the
event rates they generate and the associated uncertainty intervals they provide.
Our efficacy outcome in PePS2, repeated here for convenience, is the occurrence of
CR, PR or SD, without prior PD, assessed by RECIST v1.1[35], at or after the second sched-
uled CT scan expected to occur at 18 weeks. This outcome is essentially a dichotomisa-
tion of progression-free survival (PFS), an outcome used in many cancer trials. We
can inform our expectations of our efficacy outcome by analysing PFS reported by
PD-L1 and pretreatment status by Garon et al.[37]. They do not explicitly report PFS
rates at 18 weeks, but in their Figure 3, they show Kaplan-Meier curves that allow
us to interpolate values. Their plot of PFS in PT patients includes approximately 300
patients at risk at time = 0, so we expect that the estimates will be relatively pre-
cise. In the PT subset, PFS at 18 weeks is approximately 36% in low, 37% in medium
and 55% in high PD-L1 patients, as shown in Table 5.4. We expect outcomes in the
PS2 population to be similar to PS0/1 but the lower overall level of health suggests
considering a modest penalty. To identify prior mean efficacy probabilities in PT pa-
tients that reflect a modest penalty, we subtract 15% from the PD-L1-matched PS0/1
groups, as demonstrated in column B of Table 5.4.
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Column A B C D E
Derivation Garon et al.[37] A - 15 B + 5 B ±2 C ±2
Interpretation PT (PS 0/1) PT (PS2) TN (PS2) PT target TN target
Low PD-L1 36 21 26 19-23 24-28
Medium PD-L1 37 22 27 20-24 25-29
High PD-L1 55 40 45 38-42 43-47
TABLE 5.4: Derivation of prior mean efficacy rates to motivate in-
formative parameter priors. We start in column A with the PS0/1
efficacy rate observed by Garon et al. in PT patients. We subtract 15%
from this in column B to reflect that we expect PS2 PT patients to be
weaker and have worse chances of efficacy than PS0/1 PT patients. In
column C we add 5% to B to reflect that we expect PS2 TN patients to
do slightly better than PS2 PT patients. In columns D and E, we create
target ranges for the expected efficacy rates by adding and subtract-
ing 2% to B and C, knowing that we will not obtain parameter priors
that yield efficacy means that exactly match B and C. Parameters in
Table 5.5 were chosen so that the expected efficacy rates fell in the
ranges in D and E. Numbers are %.
Garon et al.’s subset of TN patients is much smaller, however, with only 62 sub-
jects at time = 0 split between the three subgroups. The Kaplan-Meier plot for TN
patients shows large decreases in PFS for each single event, with large changes in
the survival curve being associated with small changes in time. This prohibits read-
ing off accurate values. We can see from the summary statistics they report that TN
patients generally do slightly better than PD-L1-matched PT patients. To identify
suitable prior efficacy estimates, we instead estimate the TN efficacies to be a mod-
est improvement on the PT efficacies. We increase the PD-L1-matched PT estimates
by 5%, as shown in column C. These coarse adjustments are intended only to iden-
tify plausible expected values. Neighbouring efficacy rates will be facilitated by the
uncertainty parameters in our normal parameter priors.








Having identified candidate prior mean efficacy rates in each cohort, we add
and subtract 2% from each to generate a target range, as shown in columns D and E.
We then select by trial-and-error hyperparameters that achieve means in the target
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FIGURE 5.2: Informative prior distributions on the parameters.
range. We have described this logic to give transparent justification to the prior mean
efficacy probabilities generated by our informative priors. We feel transparency is
important here given how contentious informative priors are.
Our chosen hyperparameters for our informative priors are shown in Table 5.5
and the prior parameter densities are shown in Figure 5.2. The event rates they
generate with credible intervals (CI) are shown in Table 5.6. The upper case L and U
adorn the 90% CI and lower case letters adorn the 50% CI. The variability parameters
were selected to yield 50% and 90% prior predictive CIs that felt appropriate. For
instance, efficacy probabilities over 40% are possible in TN low and medium PD-L1
patients, but not particularly likely. Likewise, we would not want to rule out an
efficacy probability in high PD-L1 patients that exceeds 70%, but it is much more
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likely to be lower.
Treatment status PD-L1 EffL Effl Eff Effu EffU
TN Low 0.00 0.01 0.24 0.40 0.91
TN Med 0.00 0.01 0.25 0.40 0.91
TN High 0.03 0.16 0.46 0.74 0.95
PT Low 0.00 0.00 0.22 0.34 0.94
PT Med 0.00 0.00 0.22 0.34 0.94
PT High 0.00 0.05 0.38 0.72 0.97
Treatment status PD-L1 ToxL Toxl Tox Toxu ToxU
TN/PT Low-High 0.01 0.03 0.18 0.26 0.64
TABLE 5.6: Credible intervals for events rates drawn from the prior
predictive distribution of the informative priors in Table 5.5. Eff and
Tox show the probability of efficacy and toxicity, respectively. Lower-
case l and u show the central 50% credible interval and upper-case L
and U show the central 90% credible interval.
We now consider priors on our toxicity outcome, again repeated for convenience:
treatment delay or discontinuation caused by an adverse event related to pembrolizumab.
Garon et al.[37] refer to only a solitary incident of treatment discontinuation after
an infusion reaction. Although they do not report treatment delays arising from
pembrolizumab-emergent adverse events, it is likely that they occurred. In stark
contrast, Herbst et al[44] report that 34 / 345 (9.9%) of patients allocated to pem-
brolizumab 2 mg/kg and 32 / 346 (9.2%) of patients allocated to pembrolizumab
10 mg/kg discontinued due to an adverse event. These events may have mani-
fested primarily because of treatment or disease. We are not told which but, for the
purposes of forming prior beliefs on our toxicity outcome, it is sensible to assume
that some are down to disease and some down to treatment. Once again, treatment
delays are not explicitly described or quantified but will almost certainly have oc-
curred. With three-weekly administrations in sick patients, treatment-related delays
could be very common. For example, it is highly likely that treatment delays will oc-
cur in patients that do not eventually discontinue. Our priors should reflect this level
of ignorance. We expect a toxicity rate approximately twice that reported by Herbst
but admit that the rate could plausibly be higher. Our hyperparameter choices for
the sole parameter in our toxicity model are shown in Table 5.5 and the generated
toxicity rates and CIs, assumed the same in each cohort, are shown in Table 5.6.
For illustration, the predictive event densities under our informative priors are
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FIGURE 5.3: Prior predictive distributions of the probabilities of effi-
cacy and toxicity in all cohorts under our informative priors.
shown in Figure 5.3. Contrast the high PD-L1 cohorts to the others. The efficacy dis-
tribution for the TN, high PD-L1 cohort, for instance, relocates a lot of the probabil-
ity mass along the entire range of estimates, producing a quasi-uniform distribution
that admits the potential for very high efficacy rates. There is much more probabil-
ity mass in the left-hand tail at the lower efficacy rates in the other cohorts, leading
to lower estimated means. We describe two further sets of priors in the following
sections.
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5.3.3.2 Regularising priors
Informative priors have the benefit of encapsulating beliefs based on some body of
knowledge. However, they can be contentious in clinical trial settings, and else-
where, because of their ability to influence posterior beliefs in ways not reflected in
the data. The PePS2 results will ultimately be published in a journal for the benefit
of the medical community. Reviewers will have to be satisfied that the data have
been analysed and reported in a fair way and in this regard, informative priors may
hinder publication. We anticipate resistance and provide alternative analyses under
different prior schemes.









As a measure against the charge of providing a favourable analysis, we consider
in this section regularising priors, chosen to prevent over-fitting. Listed in Table 5.7
and shown in Figure 5.4, these priors anticipate the same efficacy and toxicity event
rates of approximately 20% in each cohort. This efficacy rate is close to that seen in
the overall population in Garon et al and the toxicity rate is slightly higher. These
priors could be interpreted as being sceptical with respect to the effect of our co-
variates, anticipating no benefit to having a higher PD-L1 score or being TN. These
priors generate fairly wide credible intervals, as shown in Table 5.8.
These priors generate the types of outcomes we expect when all patients are anal-
ysed together without adjustment for covariates, so can only be considered generative
under certain circumstances. However, they do not bias the analysis towards accept-
ing the treatment in high PD-L1 cohorts, for instance, by assuming a high efficacy
rate.
Figure 5.5 shows that the priors support a wide range of outcomes, evocative
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FIGURE 5.4: Regularising prior distributions on the parameters.
of so-called spike-and-slab and horseshoe priors. There is a large probability mass al-
located to low event rates, reflecting the sceptical belief that most treatments are
ineffective. However, the relatively flat, wide right tail of the prior facilitates the pos-
sibility of high event rates if the data are strong enough to overcome the prior scep-
ticism. Regularising priors dissuade the model from over-fitting to small, chance
events, but do not categorically rule out large effects. In our situation, we expect
the priors to allow baseline effects like association of high efficacy with high PD-L1
scores to manifest through the data via the likelihood.
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Treatment status PD-L1 EffL Effl Eff Effu EffU
TN Low 0.00 0.01 0.21 0.31 0.87
TN Med 0.00 0.01 0.21 0.31 0.87
TN High 0.00 0.03 0.20 0.30 0.75
PT Low 0.00 0.00 0.21 0.30 0.92
PT Med 0.00 0.00 0.21 0.30 0.92
PT High 0.00 0.01 0.21 0.32 0.87
Treatment status PD-L1 ToxL Toxl Tox Toxu ToxU
TN/PT Low-High 0.00 0.03 0.20 0.30 0.75
TABLE 5.8: Credible intervals for events rates drawn from the prior
predictive distribution of the regularising priors in Table 5.7. Eff and
Tox show the probability of efficacy and toxicity, respectively. Lower-
case l and u show the central 50% credible interval and upper-case L
and U show the central 90% credible interval.
5.3.3.3 Diffuse priors
Despite the encouragement for researchers to use priors that truly reflect their be-
liefs, it is still fairly common for diffuse priors to be used. This could be motivated
by the desire that the data should speak for themselves. To convey the performance of
our P2TNE model with very diffuse prior information, we also consider the prior
parameters listed in Table 5.9 and shown in Figure 5.6.








The notable flaw with such diffuse priors is that they rarely reflect the researchers’
beliefs. The statement X ∼ N(0, σ2) generates the inference that Prob(|X| > σ2 ) >
Prob(|X| < σ2 ). In the context of the priors in Table 5.9, this implies that the absolute
value of each parameter is more likely to exceed 5 than to reside in the interval (-5,
5). The phenomenon is exacerbated with larger values of σ.
This folly is illustrated by the generated CIs in Table 5.10 and the prior predic-
tive densities shown in Figure 5.7. The prior predictive distributions are horseshoe-
shaped. The interaction of the normal prior with very wide tails, and the logit like-
lihood, which maps continuous real numbers to (0, 1), puts an inordinate amount of
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FIGURE 5.5: Prior predictive distributions of the probabilities of effi-
cacy and toxicity in all cohorts under our regularising priors.
prior mass at the extremes. For each event rate in each cohort, 40% of the probability
mass resides in the extremely narrow intervals very close to 0 and 1. Ultra-diffuse
priors may sometimes be described as uninformative, but this example shows that the
name is a misnomer when a sigmoidal link function is used. These priors absolutely
do not reflect our genuine prior expectations.




FIGURE 5.6: Diffuse prior distributions on the parameters.
5.4 Simulation Study
We conduct simulation studies to assess the operating characteristics of P2TNE im-
plementations. The parameters chosen will affect performance so they should be
driven by the clinical scenario, wherever possible. Sample size will naturally play
a large part in determining performance. Increasing the number of patients is the
typical method for providing more information to a clinical trial design with which
to appraise treatments. In PePS2, the sample size is fixed at 60 patients because
that is felt to be the most we could feasibly recruit in one year, so we demonstrate
simulations at that level of accrual. However, we demonstrate further model embel-
lishments and higher sample sizes in the following chapter.
At the very minimum in a simulation study, we are interested in estimating the
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Treatment status PD-L1 EffL Effl Eff Effu EffU
TN Low 0.000 0.000 0.499 1.000 1.000
TN Med 0.000 0.000 0.500 1.000 1.000
TN High 0.000 0.001 0.500 0.999 1.000
PT Low 0.000 0.000 0.501 1.000 1.000
PT Med 0.000 0.000 0.502 1.000 1.000
PT High 0.000 0.000 0.501 1.000 1.000
Treatment status PD-L1 ToxL Toxl Tox Toxu ToxU
TN/PT Low-High 0.000 0.001 0.498 0.999 1.000
TABLE 5.10: Credible intervals for events rates drawn from the prior
predictive distribution of the diffuse priors in Table 5.9. Eff and Tox
show the probability of efficacy and toxicity, respectively. Lower-case
l and u show the central 50% credible interval and upper-case L and
U show the central 90% credible interval.
probability that a design will correctly approve a treatment in a favourable scenario
(analogous to power in a frequentist analysis) and incorrectly approve a treatment
in an adverse scenario (analogous to statistical significance). Building on this mini-
mum, we will be interested to estimate the performance of a design over a range of
scenarios appropriate for the clinical setting.
5.4.1 Simulating cohort membership and outcomes
In the PePS2 trial, patients will belong to one of the six cohorts enumerated 1,..,6 in
Table 5.3. For brevity and clarity, when discussing the parameterisation of cohorts,
we present parameters that have different values for each cohort in that order. For
example, a true efficacy vector (0.1, 0.2, 0.3, 0.4, 0.5, 0.6) represents an efficacy rate of
0.2 in cohort 2, the cohort of patients that have not previously received treatment
and have a medium PD-L1 score.
In our simulations, we will randomly sample cohort membership and this re-
quires estimates of the cohort prevalences. In Table S9 of the supplementary in-
formation to Garon et al.[37], 39% of the 824 patients screened with evaluable tu-
mour sample had low PD-L1 expression, 38% medium and 23% high. Amongst TN
patients, these percentages were 31%, 44% and 25%. Amongst PT patients, they
were 41%, 36% and 23%. Testing for association between the two categories by chi-
squared test yields p = 0.049, so there is reasonable evidence to suspect that PD-L1
expression level is not identically distributed for TN and PT patients. Low PD-L1
scores appear to be less prevalent amongst TN patients.
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FIGURE 5.7: Prior predictive distributions of the probabilities of effi-
cacy and toxicity in all cohorts under our diffuse priors.
The chief investigator of PePS2 expects approximately 50% of patients to have
been previously treated, based on their experience with the patient population. Scal-
ing the PD-L1 prevalences observed by Garon et al. in the TN and PT groups, we
expect cohort membership probabilities
ρ̃ = (0.157, 0.218, 0.124, 0.207, 0.180, 0.114)
For iteration j, we randomly sampled cohort membership probabilities, ρj ∼ Dirichlet(ρ̂),
for j = 1, ..., J , where ρ̂ = (15.7, 21.8, 12.4, 20.7, 18.0, 11.4) and J is the number of
simulated trial iterations. In Appendix C.1, we investigate the effect of alternative
cohort prevalences.
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This yielded 95% confidence intervals for ρj given in Table 5.11. For each j,
patient-level allocations to cohorts 1, ..., 6 were randomly sampled from multinomial
distributions with probability vector ρj . The mean cohort sizes and 95% confidence
intervals are also shown in Table 5.11. These statistics are based on 100,000 random
samples. The distribution of these cohort sizes approximately concurred with our
expectations.
ρ Num patients
Cohort 95% CI Mean 95% CI
1 (0.093, 0.234) 9.4 (3, 17)
2 (0.143, 0.304) 13.1 (6, 17)
3 (0.067, 0.195) 7.4 (2, 14)
4 (0.134, 0.291) 12.4 (5, 21)
5 (0.111, 0.261) 10.8 (4, 19)
6 (0.060, 0.182) 6.8 (2, 14)
TABLE 5.11: Simulated cohort prevalences and cohort sizes, based on
100,000 replicates.
The variance of Dirichlet random variables is determined by the size of the ele-
ments of the parameter vector, ρ. To consider alternatives and verify that we were
using approximately the correct order of magnitude of randomness in our cohort al-
locations, we repeated the same exercise with Dirichlet parameter vectors ρ̂/10 and
10ρ̂. The vector ρ̂/10 yielded cohort sizes that were too wide, e.g. cohort sizes of zero
were observed too frequently. The vector 10ρ̂ yielded cohort sizes that exhibited less
variation, but looked plausible nonetheless. It is conservative to prepare for more
variability rather than less, so we resolved to use ρ̂.
A simulation scenario requires the specification of true efficacy and toxicity prob-
abilities in each cohort, and the level of association between efficacy and toxicity
events. In each scenario, we simulated J = 10, 000 iterations. In each iteration,
we randomly sampled N = 60 patients belonging to the six PePS2 cohorts using
the method described above. We then randomly sampled binary efficacy and tox-
icity events with probabilities driven by the cohort memberships. We simulated
correlated efficacy and toxicity events mirroring the method used in the R package
binarySimCLF [21], itself based on the work of Qaqish[75]. The level of association
is measured by odds-ratio. At the null value 1.0, efficacy is no more or less likely in
the presence of toxicity. With values less than 1, the events are negatively associated,
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i.e. the presence of one event makes the other event less likely.
5.4.2 Using simulation to select pE and pT
We desire that the design approve the treatment in each cohort: (i) with at least
80% probability in each cohort in a benchmark favourable scenario where πE = 0.3
and πT = 0.1 throughout; and (ii) with no more than 5% probability in any cohort
in a benchmark adverse scenario where πE = 0.1 and πT = 0.3 throughout. To
demonstrate the process of choosing pE and pT for use in (5.12), Table 5.12 shows
the combinations of pE and pT that we considered using the regularising priors.
Parameters Scenario 1 2 3 4 5 6
pE = 0.7, pT = 0.7 Favourable 0.90 0.92 0.91 0.91 0.91 0.89
Adverse 0.06 0.06 0.07 0.06 0.06 0.07
pE = 0.7, pT = 0.8 Favourable 0.90 0.92 0.91 0.91 0.91 0.89
Adverse 0.04 0.05 0.05 0.04 0.04 0.05
pE = 0.7, pT = 0.9 Favourable 0.90 0.92 0.91 0.91 0.91 0.89
Adverse 0.02 0.03 0.03 0.02 0.02 0.02
TABLE 5.12: Probabilities of approving treatment in two key bench-
mark scenarios under different values for pE and pT using the regu-
larising priors, based on 10,000 simulated trial runs. The favourable
and adverse scenarios eventually became 1 & 2 in Table 5.13.
Initially, we tried pE = pT = 0.7. In the favourable scenario, the design reli-
ably approves in all cohorts with a margin of at least 9% above our required prob-
ability of 80%. However, in the adverse scenario, the design does not reject often
enough. PePS2 is an early-phase study and patients are potentially near end-of-life
so we wanted to be quite confident when we say a treatment is tolerable. We can be
slightly less stringent in our choice of pE because of the relative dearth of alternative
treatments. To systematically arrive at an acceptable pair, we held one of pE and
pT fixed, and adjusted the other. We increased pT to 0.8 so that the design would
be more demanding when it infers the treatment is tolerable, and held pE constant.
This reduced the probability of wrongly accepting in the adverse scenario to approx-
imately 5% in all cohorts and did not perceptibly change the probability of accept-
ing in the favourable scenario. The apparent ability to improve the probability in the
adverse scenario without impacting the favourable scenario motivated investigation
of a further increase in pT to 0.9, yielding the final two rows in Table 5.12. Again,
probabilities in the favourable scenario did not change using 2 decimal places. With
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pE = 0.7 and pT = 0.9, the design rejects in all cohorts in the adverse scenario at
least 97% of the time, and approves in all cohorts in the favourable scenario at least
89% of the time. This was deemed a desirable compromise that addresses the two
competing goals represented by the two scenarios.
The different sets of priors required their own values for pE and pT . Similar
processes showed that those same values would achieve the same under the diffuse
priors; and that a small adjustment to pE = 0.7 and pT = 0.95 would achieve the
same under the informative priors. Even though pE and pT took different values for
different priors, the values for πE and πT were the same throughout.
In the next section, we assess performance over a wider range of scenarios. The
favourable scenario above became scenario 1 and the adverse scenario became sce-
nario 2 in the broad simulation study described below.
5.4.3 Main simulation study
Table 5.13 shows simulated performance in six scenarios. The scenarios chosen
broadly reflect our expectations, driven by the Garon study, and the range of sce-
narios over which the design should perform well. The simulated mean number of
patients, and efficacy and toxicity events, are presented for each cohort. The proba-
bilities of approving treatment using P2TNE models under the informative, regular-
ising, and diffuse priors are shown.
In scenarios 1 - 3, the rates of efficacy and toxicity are uniform across the cohorts.
Scenario 1 is our benchmark favourable scenario. It shows that if the true probabil-
ity of efficacy is 30% and toxicity is 10%, we can expect all designs to approve the
treatment with at least 80% probability in all cohorts, irrespective the priors used.
The cohorts have different approval probabilities because the average cohort sizes
are different. Under the diffuse priors, cohorts 3 and 6 have the smallest approval
probabilities because they have the fewest patients. In contrast, those same proba-
bilities are very high under the informative priors because the observed data concur
with the prior expectation, confirming that efficacy is good throughout. A key bene-
fit of the P2TNE design is the sharing of information across cohorts via the Bayesian
regression model. For instance, designs will quite reliably approve the treatment in
scenario 1 in cohorts 3 and 6, even though they each only receive approximately 7
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Sc Coh PrEff PrTox Odds N Eff Tox Inf Reg Diffuse BetaBin
1 1 0.300 0.1 1.0 9.3 2.8 0.9 0.883 0.896 0.878 0.540
2 0.300 0.1 1.0 13.1 3.9 1.3 0.906 0.920 0.905 0.658
3 0.300 0.1 1.0 7.5 2.3 0.8 0.980 0.909 0.816 0.473
4 0.300 0.1 1.0 12.5 3.7 1.2 0.875 0.912 0.896 0.635
5 0.300 0.1 1.0 10.8 3.2 1.1 0.873 0.909 0.890 0.590
6 0.300 0.1 1.0 6.8 2.0 0.7 0.959 0.893 0.819 0.459
2 1 0.100 0.3 1.0 9.3 0.9 2.8 0.012 0.025 0.019 0.035
2 0.100 0.3 1.0 13.1 1.3 3.9 0.013 0.028 0.023 0.032
3 0.100 0.3 1.0 7.5 0.8 2.3 0.038 0.029 0.021 0.034
4 0.100 0.3 1.0 12.5 1.2 3.7 0.009 0.024 0.021 0.034
5 0.100 0.3 1.0 10.8 1.1 3.2 0.009 0.024 0.022 0.032
6 0.100 0.3 1.0 6.8 0.7 2.0 0.027 0.025 0.019 0.041
3 1 0.300 0.1 0.2 9.3 2.8 0.9 0.884 0.897 0.879 0.562
2 0.300 0.1 0.2 13.1 3.9 1.3 0.906 0.920 0.904 0.667
3 0.300 0.1 0.2 7.5 2.3 0.8 0.981 0.909 0.818 0.494
4 0.300 0.1 0.2 12.5 3.7 1.2 0.877 0.913 0.897 0.652
5 0.300 0.1 0.2 10.8 3.2 1.1 0.874 0.908 0.889 0.605
6 0.300 0.1 0.2 6.8 2.0 0.7 0.960 0.893 0.820 0.478
4 1 0.167 0.1 1.0 9.3 1.5 0.9 0.408 0.451 0.398 0.293
2 0.192 0.1 1.0 13.1 2.5 1.3 0.651 0.690 0.633 0.432
3 0.500 0.1 1.0 7.5 3.8 0.8 0.993 0.981 0.974 0.622
4 0.091 0.1 1.0 12.5 1.1 1.3 0.208 0.277 0.215 0.131
5 0.156 0.1 1.0 10.8 1.7 1.1 0.405 0.493 0.419 0.298
6 0.439 0.1 1.0 6.8 3.0 0.7 0.961 0.930 0.931 0.581
5 1 0.167 0.3 1.0 9.3 1.5 2.8 0.027 0.063 0.039 0.071
2 0.192 0.3 1.0 13.1 2.5 3.9 0.046 0.099 0.066 0.084
3 0.500 0.3 1.0 7.5 3.8 2.3 0.071 0.141 0.102 0.159
4 0.091 0.3 1.0 12.5 1.1 3.7 0.014 0.037 0.021 0.028
5 0.156 0.3 1.0 10.8 1.7 3.2 0.030 0.071 0.045 0.065
6 0.439 0.3 1.0 6.8 3.0 2.0 0.070 0.135 0.099 0.163
6 1 0.167 0.1 0.2 9.3 1.5 0.9 0.408 0.451 0.396 0.308
2 0.192 0.1 0.2 13.1 2.5 1.3 0.651 0.689 0.633 0.447
3 0.500 0.1 0.2 7.5 3.8 0.8 0.993 0.981 0.974 0.627
4 0.091 0.1 0.2 12.5 1.1 1.3 0.208 0.278 0.212 0.139
5 0.156 0.1 0.2 10.8 1.7 1.1 0.402 0.493 0.415 0.313
6 0.439 0.1 0.2 6.8 3.0 0.7 0.962 0.929 0.930 0.589
TABLE 5.13: A summary of simulated trials. Sc is scenario number
and Coh the cohort number. Patient cohorts are defined in Table
5.3. PrEff and PrTox are the true probabilities of efficacy and toxicity.
Odds denotes the ratio of odds of efficacy in patients that experience
toxicity to those that do not. Odds=1 corresponds to no association;
values less than one convey that efficacy is less likely when toxicity
is observed; and vice-versa. N is the mean number of patients in a
cohort; Eff and Tox the mean number of events. Inf is the probabil-
ity the treatment is approved by the P2TNE model using informative
priors; Reg and Diffuse are probabilities of approval under the regu-
larising and diffuse priors. BetaBin is the approval probability using
cohort-specific beta-binomial models. 10,000 iterations were used in
each scenario.
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patients who experience 2 efficacies. The high efficacy rate observed in other cohorts
informs the posterior inference.
To give measure to the benefit of information sharing in P2TNE, we also present
in the final column in Table 5.13 the approval probabilities under cohort-specific
beta-binomial Bayesian conjugate models that assume the efficacy and toxicity events
are independent. With prior π ∼ Beta(α, β), the posterior beliefs are π|r, n ∼
Beta(α + r, β + n − r) where n is the number of patients in a cohort and r is the
number of events observed. Inferences are made on the posterior distribution. Re-
implementing the same decision criteria, the beta-binomial models approve the treat-
ment in a given cohort if Pr(πE > 0.1|rE , n) > 0.7 and Pr(πT < 0.3|rT , n) > 0.9.
Diffuse Beta(0.001, 0.001) priors on the rates of efficacy and toxicity were used. The
beta-binomials models make decisions in each cohort singly and do not share infor-
mation. Comparing the performances of the P2TNE model with diffuse priors to the
beta-binomial models shows the benefit to sharing information.
In scenario 1, for instance, the P2TNE model with diffuse priors outperforms the
beta-binomial model by at least 25% in each cohort. The beta-binomial model would
approve the treatment less than 50% of the time in cohort 3 in scenario 1. With ex-
actly 7 patients, being the median size of this cohort, the beta-binomial model must
observe at least rE = 2 efficacy events and exactly rT = 0 toxicities to conclude that
the treatment is acceptable. With event probabilities 0.3 and 0.1 respectively, the joint
probability of this occurring is 0.32 using exact binomial probabilities, assuming in-
dependence. The individual cohorts are simply too small with the overall sample
size n = 60 to achieve in a cohort-by-cohort analysis error rates typically used in
clinical trials. However, information sharing can have adverse consequences too.
The chances of erroneously approving in subgroups with poor efficacy will be in-
flated when positive effects are observed in other subgroups. We demonstrate an
example of this in scenario 4 below.
Scenario 2 is our benchmark adverse scenario, where toxicity is 30% and efficacy
is 10% in all cohorts. The designs should reject because the efficacy probability is
undesirably low and the toxicity probability is undesirably high. As required, we
see that all designs are very likely to reject. This was ensured by the selection of pE
and pT , as described above. Once again, it is revealing to compare P2TNE to the
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FIGURE 5.8: Performance of the P2TNE model in scenario 4 under
informative priors.
beta-binomial alternative. Despite leveraging information to approve the treatment
with small cohort sizes when performance is good, it does not show a predisposi-
tion to approve the treatment when outcomes are poor. In fact, the P2TNE design
is generally more likely than the cohort-specific beta-binomial models to reject the
treatment in scenario 2, irrespective the priors, because it uses information from all
60 patients.
One of the features of P2TNE is that it models the association between efficacy
and toxicity. Scenario 3 shows performance when efficacy events are highly neg-
atively associated with toxicity. Here, the ability of patients to achieve efficacious
outcomes are strongly hindered if they experience a toxicity event. In every other
regard, the parameterisation of scenario 3 is the same as scenario 1. We see that per-
formance barely differs. This calls into question the benefit of modelling associated
co-primary outcomes, a topic we return to in the Discussion and investigate further
in the next chapter.
Scenario 4 uses efficacy probabilities that match the response rates observed in
Garon et al.[37], with a uniform toxicity probability of 10%. This reflects the type of
scenario we expect to observe in PePS2. A notable aspect is the apparent interaction
yielded by simultaneous low PD-L1 and pre-treated status so that the PD-L1-efficacy
curves are not piecewise-parallel, as depicted in Figure 5.1. Performance is shown
in Figure 5.8 under the informative priors. Our design is overwhelmingly likely to
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approve treatment in cohorts 3 and 6 where efficacy is high.
Cohort 2 in scenario 4 is an intermediate case. Whilst the toxicity rate is manage-
able at only 10%, the efficacy rate of 19.2% is attractive. However, 30% is the efficacy
rate that we would not like to miss, so we do not necessarily demand that the designs
offer 80% approval probabilities here. We see that the P2TNE designs are 60-70%
likely to approve treatment here, an improvement over the beta-binomial model of
at least 20%. P2TNE manages this, despite an average cohort size of 13.1 patients
and efficacy rate only 9.2% above the 10% threshold by leveraging the information
observed in other cohorts. Naturally, the opposite effect occurs too. The design is
20-30% likely to approve in cohort 4, and 7-15% more likely than the beta-binomial
analyses, even though the true efficacy probability is insufficient. The model has in-
flated expectations of the efficacy probability because of the good efficacy observed
in other cohorts. The natural solution to this flaw is to introduce interaction terms
between the independent variables, a topic we develop in the next chapter
Scenario 5 shows the same efficacy probabilities as scenario 4 combined with a
high toxicity probability of 30%. All approaches are now much less likely to approve
the treatment. All analyses except the P2TNE method with informative priors show
approval probabilities in excess of 10% in cohorts 3 and 6 where efficacy is highest.
Here, the methods are overwhelmingly inclined to accept the treatment from an
efficacy stance, but lack sufficient information on toxicity in a noteworthy percentage
of simulations to correctly reject the treatment. This can be addressed by using the
informative priors.
Finally, scenario 6 shows the same efficacy and toxicity rates as scenario 4, where
the events are now strongly negatively associated. Once again, we see that perfor-
mance under P2TNE barely changes, challenging the benefit of modelling associated
co-primary outcomes in this trial. We see from Figure 5.9 that the estimation of ψ
adapts to the prevailing scenario. For instance, the estimates are clustered around
zero when efficacy and toxicity are genuinely independent in scenario 4, but over-
whelming negative in scenario 6. We revisit this in the next chapter.
The trial design yields simple dichotomous decisions on whether there exists
sufficient evidence to warrant further study. To make this decision, the underlying
statistical model produces estimates of the probabilities of efficacy and toxicity in
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FIGURE 5.9: Simulated end-of-trial estimates of ψ in scenarios 4 & 6.
each cohort. In simulations, we know the underlying values that generated the hy-
pothetical trial outcomes so it is possible to assess the numerical performance of the
model. The following definitions are adapted from Morris et al.[66].






θ̂k − θ (5.14)
Bias measures whether the estimator targets the true value, on average, and an
unbiased estimator has bias equal to zero. Let θ̄ be the sample mean of the θ̂k. The





(θ̂k − θ̄)2 (5.15)
and measures the standard deviation of the estimates.
Finally, the coverage of an estimator reflects the percentage of iterations in which
an uncertainty interval of given width contains the true value. Let the equal-tailed
90% credible interval of estimate θ̂k have lower bound θ̂low,k and upper bound θ̂upp,k.





I(θ̂low,k ≤ θ ≤ θ̂upp,k) (5.16)
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By our definition, we expect coverage values of 90%.
Scenario Cohort EffBias EffEmpSE EffCov ToxBias ToxEmpSE ToxCov
1 1 -0.006 0.113 0.882 0.001 0.037 0.910
2 -0.008 0.104 0.879 0.001 0.037 0.910
3 -0.004 0.108 0.912 0.001 0.037 0.910
4 -0.007 0.107 0.884 0.001 0.037 0.910
5 -0.004 0.109 0.882 0.001 0.037 0.910
6 0.001 0.116 0.905 0.001 0.037 0.910
2 1 0.004 0.069 0.865 -0.006 0.058 0.894
2 0.001 0.063 0.864 -0.006 0.058 0.894
3 0.015 0.063 0.951 -0.006 0.058 0.894
4 -0.007 0.064 0.827 -0.006 0.058 0.894
5 -0.004 0.065 0.834 -0.006 0.058 0.894
6 0.012 0.070 0.909 -0.006 0.058 0.894
3 1 -0.007 0.113 0.882 0.000 0.037 0.913
2 -0.009 0.104 0.879 0.000 0.037 0.913
3 -0.004 0.107 0.912 0.000 0.037 0.913
4 -0.008 0.106 0.885 0.000 0.037 0.913
5 -0.005 0.109 0.883 0.000 0.037 0.913
6 0.000 0.116 0.905 0.000 0.037 0.913
4 1 -0.008 0.085 0.866 0.001 0.037 0.908
2 0.009 0.089 0.892 0.001 0.037 0.908
3 -0.072 0.126 0.867 0.001 0.037 0.908
4 0.030 0.066 0.902 0.001 0.037 0.908
5 0.007 0.082 0.887 0.001 0.037 0.908
6 -0.075 0.132 0.844 0.001 0.037 0.908
5 1 -0.008 0.085 0.864 -0.005 0.058 0.892
2 0.009 0.089 0.892 -0.005 0.058 0.892
3 -0.072 0.126 0.867 -0.005 0.058 0.892
4 0.030 0.066 0.901 -0.005 0.058 0.892
5 0.007 0.082 0.887 -0.005 0.058 0.892
6 -0.075 0.132 0.842 -0.005 0.058 0.892
6 1 -0.009 0.084 0.866 0.001 0.037 0.911
2 0.009 0.088 0.893 0.001 0.037 0.911
3 -0.072 0.126 0.867 0.001 0.037 0.911
4 0.030 0.066 0.903 0.001 0.037 0.911
5 0.007 0.082 0.886 0.001 0.037 0.911
6 -0.075 0.132 0.842 0.001 0.037 0.911
TABLE 5.14: The prefixes Eff and Tox denote the estimates of the
probability of efficacy and toxicity under regularising priors. The suf-
fix Bias denotes bias; EmpSE denotes the empirical standard error;
and Cov denotes 90% credible interval coverage.
The bias, empirical standard error and coverage of the P2TNE estimators of the
probabilities of efficacy and toxicity under our regularising, informative and diffuse
priors are given in Tables 5.14, 5.15 and 5.16. Furthermore, Table 5.17 summarises
the mean performance by each measure for each model.
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Firstly, we observe that the bias in the estimated probabilities of toxicity are low,
the empirical standard errors are relatively low, and the coverages are close to 90%
throughout. This is not particularly surprising given that the toxicity probabilities
do not vary by group and the analysis model uses only an intercept parameter. That
single parameter is estimated well with n = 60 and there is no cohort heterogeneity
to contend with.
Under the regularising priors, Table 5.14 shows noteworthy negative bias in the
estimation of πE in scenarios 4-6 in the high PD-L1 cohorts, i.e. the model esti-
mates efficacies in cohorts 3 and 6 that are habitually lower than the underlying
truth. Correspondingly, we see under-coverage in these cohorts. As we saw in Table
5.13, however, this does not adversely impair the approval probabilities. In contrast,
the model with regularising priors correctly approves with high probability in these
cohorts in scenario 4 despite the negative bias, and correctly rejects in scenario 5.
Downward bias in cohorts 3 and 6 in scenarios 4-6 is associated with modest upward
bias in the efficacy estimate in cohort 4. This stems from the absence of interaction
terms in the efficacy sub-model. We investigate this further in the next chapter. Table
5.14 shows that the other cohorts are largely unaffected. The regularising priors an-
ticipated efficacy probabilities of 20% in all cohorts. The shrinkage in cohorts 3 and 6
demonstrates an attractive aspect of regularisation. The model is dissuaded from fit-
ting values that diverge substantially from the population mean, particularly when
sample sizes are small, as a conservative measure to guard against over-fitting. We
see that the overall analysis objective is not impaired by this shrinkage
Table 5.15 essentially shows the complementary phenomenon that arises from
using our informative priors. Here, there is little bias in the estimation of efficacy
in scenario 4-6. There is, however, material upward bias in the high PD-L1 cohorts
in scenarios 1-3, as the observed efficacy rates diverge from those generated by the
priors. Once again, Table 5.13 confirms that this does not adversely affect operat-
ing performance, with the error rates in the desired range in attractive and adverse
scenarios.
Table 5.16 shows numerical performance under the diffuse priors. We see that
bias is typically low throughout. Comparing to Tables 5.14 and 5.15, the standard
errors are greater with less prior information available to keep the estimates in the
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Scenario Cohort EffBias EffEmpSE EffCov ToxBias ToxEmpSE ToxCov
1 1 -0.012 0.113 0.876 0.001 0.036 0.911
2 -0.014 0.104 0.873 0.001 0.036 0.911
3 0.073 0.115 0.889 0.001 0.036 0.911
4 -0.026 0.105 0.859 0.001 0.036 0.911
5 -0.023 0.107 0.861 0.001 0.036 0.911
6 0.062 0.123 0.892 0.001 0.036 0.911
2 1 -0.001 0.068 0.843 -0.008 0.058 0.885
2 -0.004 0.062 0.846 -0.008 0.058 0.885
3 0.078 0.078 0.897 -0.008 0.058 0.885
4 -0.019 0.060 0.769 -0.008 0.058 0.885
5 -0.017 0.060 0.782 -0.008 0.058 0.885
6 0.056 0.086 0.910 -0.008 0.058 0.885
3 1 -0.012 0.113 0.877 0.000 0.036 0.915
2 -0.015 0.104 0.873 0.000 0.036 0.915
3 0.072 0.114 0.890 0.000 0.036 0.915
4 -0.026 0.105 0.859 0.000 0.036 0.915
5 -0.024 0.107 0.862 0.000 0.036 0.915
6 0.061 0.122 0.893 0.000 0.036 0.915
4 1 -0.017 0.085 0.841 0.001 0.036 0.909
2 0.002 0.089 0.883 0.001 0.036 0.909
3 0.010 0.127 0.917 0.001 0.036 0.909
4 0.015 0.063 0.887 0.001 0.036 0.909
5 -0.010 0.079 0.852 0.001 0.036 0.909
6 -0.020 0.137 0.894 0.001 0.036 0.909
5 1 -0.017 0.085 0.839 -0.007 0.058 0.885
2 0.002 0.089 0.884 -0.007 0.058 0.885
3 0.010 0.127 0.915 -0.007 0.058 0.885
4 0.015 0.063 0.886 -0.007 0.058 0.885
5 -0.010 0.079 0.852 -0.007 0.058 0.885
6 -0.020 0.137 0.893 -0.007 0.058 0.885
6 1 -0.017 0.084 0.839 0.001 0.036 0.912
2 0.002 0.089 0.885 0.001 0.036 0.912
3 0.010 0.126 0.918 0.001 0.036 0.912
4 0.015 0.063 0.886 0.001 0.036 0.912
5 -0.010 0.078 0.852 0.001 0.036 0.912
6 -0.021 0.137 0.894 0.001 0.036 0.912
TABLE 5.15: The prefixes Eff and Tox denote the estimates of the
probability of efficacy and toxicity under informative priors. The suf-
fix Bias denotes bias; EmpSE denotes the empirical standard error;
and Cov denotes 90% credible interval coverage.
expected ranges. Given the low bias, we might be surprised to see that coverage
of the efficacy probabilities is typically lowest under the diffuse priors. Reasons for
under-coverage are given by Morris et al.[66], with the applicable explanation here
being the excess variability in the estimates.
These general observations are reflected in the mean measures presented in Table
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Scenario Cohort EffBias EffEmpSE EffCov ToxBias ToxEmpSE ToxCov
1 1 0.002 0.125 0.866 0.001 0.039 0.898
2 -0.002 0.113 0.866 0.001 0.039 0.898
3 0.003 0.140 0.861 0.001 0.039 0.898
4 -0.002 0.114 0.873 0.001 0.039 0.898
5 0.001 0.119 0.867 0.001 0.039 0.898
6 0.004 0.142 0.861 0.001 0.039 0.898
2 1 0.004 0.085 0.785 0.000 0.060 0.890
2 -0.000 0.074 0.804 0.000 0.060 0.890
3 0.005 0.095 0.734 0.000 0.060 0.890
4 -0.003 0.076 0.787 0.000 0.060 0.890
5 0.003 0.081 0.790 0.000 0.060 0.890
6 0.008 0.099 0.748 0.000 0.060 0.890
3 1 0.000 0.123 0.869 -0.000 0.038 0.901
2 -0.004 0.112 0.869 -0.000 0.038 0.901
3 0.001 0.139 0.864 -0.000 0.038 0.901
4 -0.004 0.113 0.875 -0.000 0.038 0.901
5 -0.001 0.117 0.870 -0.000 0.038 0.901
6 0.002 0.141 0.862 -0.000 0.038 0.901
4 1 -0.017 0.098 0.803 0.000 0.039 0.898
2 0.005 0.099 0.863 0.000 0.039 0.898
3 0.009 0.162 0.867 0.000 0.039 0.898
4 0.014 0.071 0.841 0.000 0.039 0.898
5 -0.005 0.090 0.834 0.000 0.039 0.898
6 -0.016 0.163 0.860 0.000 0.039 0.898
5 1 -0.017 0.098 0.803 0.000 0.060 0.889
2 0.005 0.100 0.860 0.000 0.060 0.889
3 0.009 0.163 0.865 0.000 0.060 0.889
4 0.014 0.072 0.839 0.000 0.060 0.889
5 -0.005 0.090 0.831 0.000 0.060 0.889
6 -0.016 0.163 0.857 0.000 0.060 0.889
6 1 -0.018 0.097 0.805 0.000 0.039 0.901
2 0.004 0.098 0.864 0.000 0.039 0.901
3 0.007 0.161 0.871 0.000 0.039 0.901
4 0.013 0.071 0.843 0.000 0.039 0.901
5 -0.006 0.089 0.834 0.000 0.039 0.901
6 -0.018 0.161 0.863 0.000 0.039 0.901
TABLE 5.16: The prefixes Eff and Tox denote the estimates of the
probability of efficacy and toxicity under diffuse priors. The suffix
Bias denotes bias; EmpSE denotes the empirical standard error; and
Cov denotes 90% credible interval coverage.
5.17. The diffuse priors produce the most variable estimates and coverage suffers
as a result. Bias is greater under our regularising and informative priors, but only
noteworthy in an isolated number of instances. The cases of noteworthy bias can be
understood with reference to the priors or the sub-model forms.
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Priors EffBias EffEmpSE EffCov ToxBias ToxEmpSE ToxCov
Sceptical -0.010 0.096 0.881 -0.001 0.044 0.905
Informative 0.004 0.097 0.871 -0.002 0.043 0.903
Diffuse -0.001 0.113 0.840 0.000 0.046 0.896
TABLE 5.17: Means of numerical performance measures from Tables
5.14, 5.15 and 5.16 to 3 d.p.
5.5 Discussion
The proposed P2TNE design has many benefits.
Firstly, it makes efficient use of the available information because the predictive
variables contribute to the modelling of the trial outcomes and ultimately to the ap-
proval decision. The effect of each variable is refined by regression. By adjusting
for these sources of variability that are predictive of patient outcomes, the trial anal-
ysis gains in accuracy. We see this when comparing the P2TNE model to a simple
beta-binomial alternative that makes decisions cohort by cohort.
Another key feature is that this design allows an acceptance / rejection deci-
sion for each permutation of the predictive variables via (5.12). Thus, it is feasible
to approve the treatment in only the cohorts where it is shown to work. Without
this facility, the undesirable risk is that the treatment is approved in cohorts where
it is not appropriate or the treatment is rejected universally because the poor per-
formance in some cohorts obscures the good performance in others. For instance,
Thatcher [95] studied the effect on survival of Gefitinib in non-small cell lung cancer
patients. Overall, they found that the treatment was not associated with a significant
improvement in survival in the general population but that there was pronounced
heterogeneity in survival in patient subgroups. In particular, there was evidence of
benefit in patients of Asian origin and in those that have never smoked. Ultimately,
it was determined that EGFR mutation was the factor that predicted benefit of the
drug. If these predictive factors are known or even just suspected a priori, it is ad-
vantageous to be able to incorporate this information and retain the ability to tailor
the acceptance / rejection decision using predictive variables. P2TNE provides this
facility.
P2TNE explicitly models the association between the efficacy and toxicity out-
comes. In real trials, as with PePS2, it is too simplistic to assume that efficacy and
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toxicity are independent because severe toxicity partially precludes the scope for
therapeutic benefit. In a model with co-primary outcomes of efficacy and toxicity, it
is desirable that this important relationship be modelled. Asserting that there is no
relationship (either explicitly or implicitly) risks spurious inference. We saw that the
performance of P2TNE does not degrade when efficacy and toxicity are associated.
We should stress that the level of association in our model is assumed to be constant
amongst the cohorts. A more general (and complicated) model might allow each
cohort to have its own association parameter but we do not consider that scenario
here. In the next chapter, we look at removing the association parameter.
P2TNE is Bayesian and thus admits prior information. In a clinical trial, we
usually want the data to speak for itself. However, in phase II trials with limited
time and patients, we can gain efficiency by incorporating prior information. We
saw here the benefit to using informative priors because overall the performance
of the design was enhanced compared to the regularising and diffuse alternatives.
However, each of the priors considered was sufficiently weak to be overwhelmed by
the information in the data when the trial decision was clear as in scenarios 1 and 2.
Efficacy is seen in Garon to increase with PD-L1 score. It is a limitation of our
analysis that we have implemented PD-L1 status as a categorical variable rather
than an ordinal one. There are a number of ways that an ordinal PD-L1 variable
could have been used in our model, each amounting to fixing the sign of coefficients
in the efficacy sub-model. The signs of parameters can be fixed using exponential
transforms or priors. For instance, a Gamma prior does not admit negative values,
effectively guaranteeing a positive posterior estimate. We do not investigate this
further here. More generally, we investigate the use of continuous PD-L1 in the next
chapter.
In PePS2, we have not sought to model how the rate of toxicity might vary from
cohort to cohort. We have omitted this potential complexity because we do not ex-
pect it to manifest in our clinical setting and expect no reward for the extra computa-
tional burden. However, the labels “efficacy" and “toxicity" are arbitrary so cohort-
varying toxicity could easily be achieved in the same manner we have analysed ef-
ficacy here. In general, the principle of parsimony suggests not including too many
parameters in θ. However, cohort-varying toxicity could easily be incorporated via
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extra terms in (5.13) and θ in a more fully-specified model. In the following chapter,
we consider a fully-specified model that allows cohort-varying efficacy and toxicity
and how a Bayesian information criterion can be used to choose amongst our default
‘modestly-specified‘ model and the fully-specified model.
We have not considered an interim analysis in the simulation study because it is
not required in our trial. The expected cohort size at final analysis is already small
at 60 / 6 = 10 patients. Nevertheless, the P2TNE design easily facilitates an arbi-
trary number of interim analyses by repeated invocations of (5.12), potentially with
different values for π∗E , π
∗
T , pE and pT . Indeed, in a larger trial than we have con-
sidered, interim analyses would be preferable to allow early rejection of treatments
that are inactive or excessively toxic in certain cohorts. If interim analyses are used,
the statistician should choose values of pE and pT mindful of the effect of repeated
testing, that lead to attractive operating characteristics overall.
Naturally, this design presents its challenges too. In some scenarios, the shar-
ing of information could lead to questionable behaviour. For instance, when the
P2TNE model specified observes requisite efficacies across the cohorts, it some-
times approves the treatment in a cohort that happened to observe zero efficacy
events. When this happens in cohort l, the number of responses observed in cohorts
i = 1, .., 6, i 6= l compensate the lack of efficacy in l to nevertheless yield a view that
the true efficacy rate in l is probably greater than π∗E = 0.10. This is less likely to
occur for larger values of π∗E . If we wish to avoid this behaviour, we can use more
stringent criteria than (5.12). For example, we could additionally require that the
number of efficacies in a cohort must be greater than zero for the treatment to be
approved.
Our P2TNE model is implemented in the Bayesian statistical language Stan[22]
and made available in the trialr package[16] of Bayesian clinical trial designs. It uses
Hamiltonian Monte Carlo to obtain samples from the posterior distributions. The
calculations are reasonably demanding and a computer simulation takes approxi-
mately 3-4 hours to perform 10,000 iterations. More complicated specifications with
more parameters will likely take longer.
It is problematic that there is no way to determine the required sample size with-
out running computer simulations. A pragmatic solution to this specific problem is
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to calculate a initial estimate of sample size using something like a Bryant & Day de-
sign or simple beta-binomial models and refining as the situation demands. Sample
size, pE and pT are chosen to achieve acceptable operating characteristics. If truly
predictive variables are introduced, the performance of P2TNE should be superior
to the beta-binomial method, as demonstrated, and this will improve the statistical
efficiency for the selected sample size..
When considering the predictive variables to include, there might appear to be a
problem of circularity. It could be considered unreasonable to expect trialists to have
knowledge of predictive variables at the start of a trial. Whilst this is sometimes
true, often it is not. Trials are inherently sequential, each building on what is already
known. P2TNE is a phase II design and phase II trials build on the results garnered
in other early phase trials. For instance, we believe PD-L1 score to be predictive in
PePS2 because it was demonstrated so by Garon et al.[37] in a closely-related patient
population. However, this remains to be demonstrated in the PS2 population and
this is the purpose of our trial.
Lastly, selecting sensible, modestly-informative joint priors is not a trivial task.
Thall et al.[94] provide a general method for equating the amount of information
in a multivariate normal prior to an hypothetical equivalent number of patient ob-
servations, a quantity they call the effective sample size. Priors can be as informative
as the existing data allows, but sufficiently vague to justify the clinical trial under
consideration.
In summary, we feel that the many benefits provided by P2TNE are attractive
enough to warrant the effort to overcome the challenges, as we have in PePS2.
5.5.1 Further Development
Our predictive variables in PePS2 are binary. We have not considered a continu-
ous predictive variable in PePS2 but the method described here needs only minimal
changes to accommodate it. This makes sense in scenarios like PePS2 where the ma-
jor predictive variable is a categorised mapping of an underlying continuous vari-
able, PD-L1 score. It is likely that information is lost in the dichotomisation process
and that using the continuous PD-L1 variable in 5.3 enhances the performance of the
design. As with the binary variables, the effect of a continuous predictive variable x.i
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would be governed by coefficient η, for instance, in θ. The posterior mean of exp (η)
would be the odds ratio for an event given a one unit increase in x.i. One potential
complication is that (5.12) would need to be resolved for each distinct value of x.i.
For a truly continuous explanatory variable, this would be the same as the number
of patients. Although this may sound prohibitively costly, the posterior parameter
samples provided by Stan make this trivial. We develop this idea in the following
chapter.
We have presented P2TNE in a single arm setting but there is no reason why
it could not be immediately applied in a multi-arm trial using dummy variables in
(5.3) and (5.4) to reflect allocation to treatment arms. We have discussed the problem
of having many components in θ and adding variables for treatment arms would
seem to exacerbate that problem. However, the inclusion of randomisation would
abrogate the need for some other explanatory markers. For instance, if PePS2 were
a randomised trial, we would have less need to include pre-treatment status as a
predictive variable because the proportions of previously treated patients would be
broadly balanced between the treatment arms. In a randomised controlled trial, the
decision criteria (5.12) would instead accept the experimental treatment if it is likely
that efficacy and/or toxicity are superior (or not-inferior) to the reference treatment,
a posteriori.
Lastly, P2TNE uses a binary efficacy outcome that is dichotomised from the un-
derlying continuous tumour size ratio variable. Wason et al.[100–102] have shown
that the efficiency of clinical trials can be significantly increased by using all the in-
formation in a continuous response variable. In place of RECIST[35], a preferable
design would use tumour size ratio and binary variables for non-shrinkage failures
(e.g. the appearance of new lesions) to measure efficacy. This would require an
analogue of (2.4) in the continuous setting.
5.6 Conclusions
It is a tremendous advantage to be able to tailor the clinical trial decision to patient
cohorts where there is evidence that efficacy and/or toxicity is associated with pre-
dictive variables, especially when separate trials in cohorts are infeasible. This is
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one of the primary goals of stratified medicine. The design presented, P2TNE, satis-
fies an unmet need by incorporating predictive information to jointly model efficacy
and toxicity and selectively approve a treatment only in the patient cohorts where
it is shown to be efficacious and tolerable, a posteriori. We demonstrate the method
in the context of PePS2, a phase II trial of pembrolizumab in performance status 2
patients with non-small cell lung cancer. Our predictive variables are PD-L1 expres-
sion level and pretreatment status. The model described is flexible enough to admit
arbitrary binary and continuous predictive variables. We demonstrate that model
performance is good across a wide range of scenarios. Key to this is that P2TNE
shares information across related cohorts to improve statistical performance. In con-
trast, benchmark beta-binomial designs that operate on cohorts singly perform rel-
atively poorly because they use the available information less efficiently. In PePS2,
P2TNE has allowed us to avoid the unappealing prospect of running parallel trials
in cohorts. The main limitation of our method is that it is computationally intensive.
The P2TNE phase II design provides researchers with an early opportunity to eval-
uate potentially predictive variables for stratified medicine that can be important to




Further Embellishments to the
Statistical Design in PePS2
Background: We noted various assumptions in our P2TNE efficacy and toxicity
sub-models used in Chapter 5 that had the potential to yield poor inferences.
Furthermore, we observed that our model could potentially be simplified by re-
moving the association parameter.
Notable methods in this chapter: We investigated various adaptations to the
models proposed for PePS2, including more complexity in the efficacy model,
and the facility of cohort-varying toxicity.
The implications on efficiency: We learned that additional parameters in the ef-
ficacy and toxicity sub-models require greater trial sample size to maintain the
statistical performance presented in Chapter 5. Competing goals exist to con-
duct trials quickly and accurately, and the motivation to meet the extra resource
burden of a more complex model should be appraised in the clinical context, in
light of existing information and alternative treatments. In PePS2, the modest
enhancement to inference in peripheral areas is unlikely to warrant recruiting at
least 40 extra patients and materially delaying the dissemination of trial results.
6.1 Introduction
In the previous chapter, we presented a novel adaptation of the TNE trial design[89]
for studying associated co-primary binary outcomes in the presence of predictive
covariates. We did this in the context of PePS2, a phase II trial of pembrolizumab in
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performance status 2 non-small-cell lung cancer patients. Our co-primary outcomes
were efficacy and toxicity. Our predictive variables were PD-L1 score (Low, Medium
or High) and pre-treatment status (TN or PT), each categorical in nature. We demon-
strated that the P2TNE method with predictive baseline covariates was far more ef-
ficient than a model-free technique that used a conjugate beta-binomial approach in
cohorts separately. Overall, we demonstrated that typical phase II error rates were
possible in six cohorts using only 60 patients in total. Nevertheless, we noted a num-
ber of limitations in our chosen model specifications, (5.13). Specifically, our efficacy
model lacked interactions and our toxicity model was very simplistic, containing
only an intercept term. Our model choices were motivated by the published data,
and sought a balance of efficiency and realism. We anticipate that more elaborate
models with extra parameters will be more flexible but will require greater sample
sizes. In this chapter, we consider the impact of embellishments to the model forms,
specifically with respect to the trade-off between performance and sample size.
The lack of interactions in the efficacy model in (5.13) effectively assumes that the
log-odds of efficacy in each PD-L1 cohort for PT patients was a common linear shift
of that for TN patients, an assumption we referred to as piecewise parallelism. This
assumption was pertinent because the data presented by Garon et al.[37] suggested
that the log-odds of objective response in a closely-related patient population were
perhaps not strictly piecewise parallel with respect to these covariates, as shown in
Figure 5.1. In Section 6.2, we relax this assumption by adding interaction terms to
our efficacy model.
Our toxicity model too was simplistic in that it assumed a common probabil-
ity of toxicity in all cohorts, despite the acknowledgements that efficacy varied and
toxicity and efficacy were plausibly associated. Our justification, again, was the pub-
lished data[37, 44], collectively reporting the outcomes of over 1,000 NSCLC patients
on pembrolizumab monotherapy, without noting toxicity that varied with pretreat-
edness or PD-L1 status. This does not, however, rule out heterogeneity in toxicity in
the lower performance status population in PePS2. Furthermore, in other trial sce-
narios, the information to anticipate homogeneity in toxicity may not be available.
In Section 6.3, we examine the effect on overall design performance by allowing tox-
icity to vary across cohorts by adding extra terms to the toxicity model.
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TNE use a bivariate model that associates efficacy and toxicity outcomes. They
consider the Gumbel model and a Gaussian copula. We use the Gumbel model (2.4)
with association parameter ψ. We demonstrated in Table 5.13 that model perfor-
mance barely differs when comparing scenarios that vary only in the presence of a
strong negative association between efficacy and toxicity. This questions the useful-
ness of the association parameter. In Section 6.4, we examine the effect of removing
it.
Finally, we have hitherto treated PD-L1 as a categorical variable because the three
PD-L1 cohorts were defined and validated in Garon et al.[37]. This is perhaps regret-
table, given that PD-L1 proportion score, the variable that determines PD-L1 cate-
gory, is effectively continuous on [0, 1]. Dichotomising a continuous variable leads
to loss of efficiency in analysis[2]. In this regard, we are motivated to research how
the continuous PD-L1 proportion score, hitherto referred to as PD-L1 score, can be
used in place of the categorised alternative variable to further enhance efficiency in
the PePS2 setting. This ongoing work is introduced in Appendix D.
6.2 Interaction-terms in the efficacy model
Adding interaction terms for PD-L1 and pre-treatedness to the marginal efficacy
model yields:
logitπE(xi,θ) = α+ βx1i + γx2i + ζx3i + ηx1ix2i + κx1ix3i
logitπT (xi,θ) = λ
(6.1)
As before, x1i, ..., x3i are the baseline covariates for patient i as described in Table
5.3, and θ is the vector of all parameters in the model. Here, θ = (α, β, γ, ζ, η, κ, λ, ψ),
and (2.4) is used to model the joint probability of πE and πT .
We refer to this as model 611, because there are 6 parameters in the efficacy model,
one in the toxicity model, and a single extra parameter for association in the joint
model. Using this nomenclature, the model in the previous chapter is model 411.
Table 6.1 shows the operating performance of model 611 in our previous scenar-
ios 1, 4 and 5, with increasing sample size, hitherto italicised and referred to simply
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Sc TotN Coh PrEff PrTox N Eff Tox Diffuse EffBias EffEmpSE EffCov ToxBias ToxEmpSE ToxCov
1 60 1 0.300 0.1 9.3 2.8 0.9 0.754 0.001 0.162 0.836 0.000 0.039 0.892
2 0.300 0.1 13.1 3.9 1.3 0.839 -0.002 0.132 0.856 0.000 0.039 0.892
3 0.300 0.1 7.5 2.3 0.8 0.716 0.006 0.171 0.839 0.000 0.039 0.892
4 0.300 0.1 12.5 3.7 1.2 0.826 -0.002 0.136 0.862 0.000 0.039 0.892
5 0.300 0.1 10.8 3.2 1.1 0.797 -0.000 0.147 0.852 0.000 0.039 0.892
6 0.300 0.1 6.8 2.0 0.7 0.683 0.003 0.185 0.816 0.000 0.039 0.892
1 80 1 0.300 0.1 12.6 3.8 1.2 0.829 -0.001 0.138 0.856 0.000 0.034 0.866
2 0.300 0.1 17.4 5.2 1.7 0.904 0.001 0.114 0.875 0.000 0.034 0.866
3 0.300 0.1 9.9 3.0 1.0 0.788 0.003 0.151 0.856 0.000 0.034 0.866
4 0.300 0.1 16.5 4.9 1.7 0.886 -0.001 0.118 0.871 0.000 0.034 0.866
5 0.300 0.1 14.4 4.3 1.4 0.859 -0.003 0.127 0.861 0.000 0.034 0.866
6 0.300 0.1 9.1 2.7 0.9 0.753 0.001 0.161 0.843 0.000 0.034 0.866
1 100 1 0.300 0.1 15.6 4.7 1.6 0.879 0.000 0.123 0.865 0.001 0.030 0.898
2 0.300 0.1 21.9 6.5 2.2 0.936 -0.001 0.101 0.878 0.001 0.030 0.898
3 0.300 0.1 12.4 3.7 1.3 0.833 0.002 0.137 0.862 0.001 0.030 0.898
4 0.300 0.1 20.7 6.2 2.1 0.927 -0.001 0.105 0.877 0.001 0.030 0.898
5 0.300 0.1 18.0 5.4 1.8 0.906 0.002 0.113 0.873 0.001 0.030 0.898
6 0.300 0.1 11.4 3.4 1.1 0.808 0.001 0.144 0.859 0.001 0.030 0.898
4 60 1 0.167 0.1 9.3 1.5 0.9 0.406 0.000 0.130 0.751 0.000 0.039 0.890
2 0.192 0.1 13.1 2.5 1.3 0.560 -0.001 0.112 0.847 0.000 0.039 0.890
3 0.500 0.1 7.5 3.8 0.8 0.929 -0.003 0.190 0.854 0.000 0.039 0.890
4 0.091 0.1 12.5 1.1 1.3 0.175 0.001 0.083 0.646 0.000 0.039 0.890
5 0.156 0.1 10.8 1.7 1.1 0.408 0.001 0.114 0.773 0.000 0.039 0.890
6 0.439 0.1 6.8 3.0 0.7 0.863 -0.005 0.202 0.840 0.000 0.039 0.890
4 80 1 0.167 0.1 12.6 2.1 1.3 0.469 0.001 0.110 0.810 0.000 0.033 0.866
2 0.192 0.1 17.4 3.4 1.7 0.640 0.002 0.098 0.855 0.000 0.033 0.866
3 0.500 0.1 9.9 5.0 1.0 0.962 -0.003 0.167 0.869 0.000 0.033 0.866
4 0.091 0.1 16.5 1.5 1.6 0.176 0.001 0.072 0.738 0.000 0.033 0.866
5 0.156 0.1 14.4 2.2 1.4 0.444 -0.000 0.100 0.826 0.000 0.033 0.866
6 0.439 0.1 9.1 4.0 0.9 0.917 -0.003 0.177 0.856 0.000 0.033 0.866
4 180 1 0.167 0.1 28.4 4.7 2.8 0.637 0.001 0.073 0.864 0.000 0.022 0.875
2 0.192 0.1 39.3 7.5 3.9 0.819 -0.000 0.065 0.879 0.000 0.022 0.875
3 0.500 0.1 22.3 11.2 2.2 0.999 -0.001 0.112 0.879 0.000 0.022 0.875
4 0.091 0.1 37.2 3.4 3.7 0.189 0.000 0.049 0.856 0.000 0.022 0.875
5 0.156 0.1 32.2 5.0 3.2 0.595 0.000 0.066 0.869 0.000 0.022 0.875
6 0.439 0.1 20.6 9.1 2.0 0.991 -0.001 0.116 0.880 0.000 0.022 0.875
4 300 1 0.167 0.1 47.5 7.8 4.7 0.749 -0.002 0.053 0.903 -0.000 0.018 0.868
2 0.192 0.1 65.6 12.6 6.5 0.934 -0.000 0.047 0.898 -0.000 0.018 0.868
3 0.500 0.1 36.7 18.4 3.7 1.000 0.001 0.091 0.872 -0.000 0.018 0.868
4 0.091 0.1 62.0 5.6 6.2 0.157 -0.000 0.036 0.884 -0.000 0.018 0.868
5 0.156 0.1 53.9 8.5 5.4 0.738 0.002 0.050 0.889 -0.000 0.018 0.868
6 0.439 0.1 34.4 15.0 3.3 1.000 -0.003 0.092 0.886 -0.000 0.018 0.868
5 60 1 0.167 0.3 9.3 1.5 2.8 0.041 0.000 0.130 0.752 0.000 0.060 0.887
2 0.192 0.3 13.1 2.5 3.9 0.059 -0.001 0.112 0.844 0.000 0.060 0.887
3 0.500 0.3 7.5 3.8 2.3 0.099 -0.003 0.190 0.849 0.000 0.060 0.887
4 0.091 0.3 12.5 1.1 3.7 0.018 0.001 0.084 0.648 0.000 0.060 0.887
5 0.156 0.3 10.8 1.7 3.2 0.044 0.001 0.115 0.772 0.000 0.060 0.887
6 0.439 0.3 6.8 3.0 2.0 0.093 -0.005 0.202 0.836 0.000 0.060 0.887
5 180 1 0.167 0.3 28.4 4.7 8.5 0.071 0.001 0.073 0.864 -0.000 0.034 0.891
2 0.192 0.3 39.3 7.5 11.8 0.092 -0.001 0.065 0.878 -0.000 0.034 0.891
3 0.500 0.3 22.3 11.2 6.7 0.111 -0.001 0.113 0.876 -0.000 0.034 0.891
4 0.091 0.3 37.2 3.4 11.2 0.022 0.000 0.049 0.854 -0.000 0.034 0.891
5 0.156 0.3 32.2 5.0 9.6 0.066 0.000 0.066 0.868 -0.000 0.034 0.891
6 0.439 0.3 20.6 9.1 6.2 0.110 -0.001 0.116 0.877 -0.000 0.034 0.891
TABLE 6.1: Operating performance of model 611 in selected scenarios
from Chapter 5 using increasing total sample sizes, TotN . Columns
Sc to Tox have the same definitions as Table 5.3. Diffuse shows ap-
proval probability under diffuse priors. Columns EffBias to ToxCov
have the same definitions as Table 5.14.
asN . For parsimony, we do not show performance in all scenarios. Scenario 1 shows
performance in our benchmark scenario analogous to an analysis of power. Scenar-
ios 4 and 5 illustrate performance in plausible efficacy scenarios where toxicity is
acceptable and not, respectively. Scenarios 3 and 6 were excluded because Table 5.13
revealed that they add little beyond scenarios 1 and 4. Scenario 2 was excluded for
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brevity but simulations revealed that the false approval rate was not increased. Co-
hort memberships are simulated using the same method described in Section 5.4.1.
Diffuse N(0, 102) priors on each element of θ were used in Table 6.1. We did this
so that the performance mainly reflects the observed data and the specified model
forms, and not the prior information. As such, we compare to the ‘Diffuse’ perfor-
mance under model 411 in Table 5.13. This is purely to aid comparison. Were we
to use model 611 in a trial, we would specify prior distributions less diffuse than
N(0, 102).
We see in Table 6.1 that the two extra parameters are associated with a reduction
in the probability of approving the treatment with N = 60. The probabilities of
approval fall to 68.3 - 83.8% in scenario 1. These are absolute reductions of 6 - 13%
compared to model 411, but still compare favourably to the performance of the beta-
binomial analyses with n = 60 in Table 5.13. The extra parameters have reduced
performance because there are now more ways the model can err when fitting the
data. There is also less opportunity to borrow information across cohorts in the
efficacy model. We see that bias is not generally a problem. However, comparing
to Table 5.16, efficacy coverage of the 90% CIs has now fallen below 85% in three of
the six cohorts. Furthermore, empirical standard error has increased in each cohort
by approximately 2 to 4%, in absolute terms. Standard error of efficacy estimates is
particularly high in the small high-PD-L1 cohorts.
Generally, models that estimate more parameters require a greater sample size
than models that estimate few parameters. As N increases to 100 in scenario 1, the
probability of approval is generally within a few percent of that under model 411
and N = 60, with performance slightly better in some cohorts and slightly worse in
others. The performance of the beta-binomial models also improves as n increases
(data not shown), but the performance of 611 is always superior. Likewise, the em-
pirical standard errors of efficacy estimates have fallen to approximately the same
levels, and coverages are now all between 85% and 90%. These qualities were not
achieved withN = 80. We may regard the extra 40 patients required by model 611 as
the approximate cost of supporting 2 extra parameters in the efficacy model in this
scenario and maintaining a similar level of operating performance and accuracy.
In scenario 4, the efficacy probabilities show a more plausible relationship with
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the baseline covariates. The observations highlighted above are again evident. At
N = 60, the probabilities of approval have generally fallen because the model is
under-informed. The efficacy coverages are particularly low in the small cohorts.
Once again, approval probabilities and coverages improve as N increases. To match
the approval probability of model 411 in the medium and high PD-L1 cohorts, a
sample size of N = 80 is approximately sufficient in this scenario. However, even
with this increase in N , we see that efficacy coverage is still poor.
As Figure 5.1 shows, Scenario 4 contains an interaction between PD-L1 and pre-
treatedness. The correct decision in cohort 4 is to reject the treatment because the
efficacy rate is marginally below the minimum threshold, 10%. The 411 model in-
correctly approved with probability 21.5%. We attributed some of this failure to the
high efficacy seen in other cohorts and the lack of interaction terms required to pre-
cisely estimate efficacy in this particular cohort. The approval rate is only slightly
lower in model 611 with the interaction terms. Increasing N from 60 to 180, we see
that the approval probability actually increases from 17.5% to 18.9% despite the fact
that coverage improves from 64.6% to 85.6% and empirical standard error falls. The
interaction terms in 611 have not overcome one of the notable shortcomings of model
411, even with triple the sample size. Increasing sample size further to N = 300, the
90% efficacy coverage moves to over 88%, the variability of estimates falls, and the
approval probability in cohort 4 falls to 15.7%. However, the benefits are very small.
The approval decision is made with reference to the model-estimated rates of effi-
cacy and toxicity using (5.12). With the interaction terms included, those efficacy
and toxicity rates are estimated by (6.1).
Other authors have highlighted the great demands in sample size to estimate in-
teraction effects. Schmoor et al.[80] demonstrate that at least four times the sample
size is required to detect a prognostic effect via interaction of a binary covariate in
a two-arm trial with a time-to-event outcome analysed by Cox model. The exact
multiplier is affected by the nature and prevalence of the covariate, but this gen-
eral result offers an insight into why model 611 performs relatively poorly despite a
greatly-increased sample size.
In scenario 5, we see that model 611 correctly rejects approximately as often as
model 411 with N = 60. However, coverage is particularly poor in some cohorts
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and this is rectified by increased N . With sample size as high as N = 180, coverage
is above 85% in all cohorts.
The unifying theme from these simulations is that greater sample size is required
to estimate the extra parameters in model 611 and to have confidence in the inference
it yields. We saw that 20 - 40 additional patients would allow this model to perform
similarly to model 411 in scenarios 1 and 4. However, merely replicating what we
had before will not provide justification. We saw that far more patients would be
required for model 611 to provide sufficient additional accuracy to materially im-
prove the extent to which the analysis makes the correct decision in cohort 4. The
potential to justify this drives at the heart of this thesis. The biological plausibility
of the interaction efficacy model is far from clear, and the data represented in Figure
5.1 support piecewise parallelism as a reasonable working assumption. In PePS2,
the extra time, money and effort that would be required to recruit these patients in
a phase II clinical trial would almost certainly not be warranted given the need to
conduct trials quickly to give patients a chance of tolerable and effective treatments.
Rather than increase the sample size fivefold, when efficacy under a targeted ther-
apy can be so profoundly associated with a biomarker, it would clearly be preferable
to run multiple trials of modest size in a wide variety of treatments.
In each of the scenarios considered hitherto, the toxicity coverage has been stable
and accurate. However, there are no variables beyond an intercept in the toxicity
model and there is no heterogeneity by cohort. We demand more from the toxicity
model in the next section.
6.3 Covariate terms in the toxicity model
The extra terms in the efficacy model in the previous section did not materially im-
prove operating performance but did incur material penalty in terms of greater re-
quired sample size. In this section, we revert to a four parameter efficacy model and
add parameters to the toxicity model so that it has the same freedom to estimate a
different toxicity rate in each cohort:
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FIGURE 6.1: Posterior mean estimates of Prob(Tox) with 90% CIs for
cohort 6 in scenario 1 using models 411 and 441 and a total N = 60.
The red intervals exclude the true value, 10%, shown by purple dot-
ted line.
logitπE(xi,θ) = α+ βx1i + γx2i + ζx3i
logitπT (xi,θ) = λ+ µx1i + νx2i + ξx3i
(6.2)
In this model that we will refer to as model 441, we are effectively assuming that
the log-odds of efficacy and toxicity are each piecewise parallel across the cohorts.
Once again, an indicative subset of scenarios is shown and to aid comparability,
diffuse N(0, 102) priors on each element of θ were used.
Table 6.2 shows that, as with model 611, the extra terms in model 441 have eroded
operating performance when N = 60 such that we can no longer expect at least 80%
approval probabilities in scenario 1. Operating performance improves with 40 extra
patients but not enough to attain 80% approval in all cohorts. Performance still
lags in the high PD-L1 cohorts, where the empirical standard error of the estimated
efficacy probabilities is highest.
Coverage is particularly poor in the estimated toxicity probabilities. The extra
terms in the toxicity model have increased the opportunity for the model to overfit
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Sc TotN Coh PrEff PrTox N Eff Tox Diffuse EffBias EffEmpSE EffCov ToxBias ToxEmpSE ToxCov
1 60 1 0.300 0.1 9.3 2.8 0.9 0.677 0.002 0.125 0.868 0.006 0.087 0.776
2 0.300 0.1 13.1 3.9 1.3 0.762 -0.002 0.113 0.865 -0.001 0.074 0.799
3 0.300 0.1 7.5 2.3 0.8 0.611 0.003 0.140 0.860 0.005 0.093 0.740
4 0.300 0.1 12.5 3.7 1.2 0.752 -0.002 0.114 0.873 -0.002 0.076 0.786
5 0.300 0.1 10.8 3.2 1.1 0.721 0.001 0.119 0.866 0.002 0.080 0.790
6 0.300 0.1 6.8 2.0 0.7 0.597 0.004 0.142 0.864 0.007 0.097 0.745
1 100 1 0.300 0.1 15.6 4.7 1.6 0.853 0.000 0.094 0.882 0.003 0.064 0.847
2 0.300 0.1 21.9 6.5 2.2 0.913 -0.001 0.086 0.887 -0.000 0.057 0.845
3 0.300 0.1 12.4 3.7 1.3 0.785 0.001 0.108 0.876 0.003 0.072 0.822
4 0.300 0.1 20.7 6.2 2.1 0.906 -0.001 0.088 0.881 -0.002 0.058 0.839
5 0.300 0.1 18.0 5.4 1.8 0.884 0.002 0.091 0.880 0.001 0.061 0.840
6 0.300 0.1 11.4 3.4 1.1 0.770 0.002 0.109 0.882 0.004 0.074 0.819
2 100 1 0.100 0.3 15.6 1.6 4.7 0.029 0.003 0.064 0.846 0.001 0.095 0.877
2 0.100 0.3 21.9 2.2 6.6 0.025 -0.002 0.056 0.849 0.001 0.088 0.875
3 0.100 0.3 12.4 1.2 3.7 0.029 0.003 0.071 0.816 0.002 0.108 0.874
4 0.100 0.3 20.7 2.1 6.2 0.030 -0.000 0.059 0.837 -0.001 0.088 0.881
5 0.100 0.3 18.0 1.8 5.4 0.028 0.002 0.061 0.842 0.002 0.091 0.882
6 0.100 0.3 11.4 1.2 3.5 0.031 0.004 0.073 0.819 0.004 0.109 0.879
4 60 1 0.167 0.1 9.3 1.5 0.9 0.310 -0.017 0.098 0.803 0.005 0.086 0.783
2 0.192 0.1 13.1 2.5 1.3 0.531 0.005 0.099 0.861 -0.000 0.074 0.801
3 0.500 0.1 7.5 3.8 0.8 0.727 0.009 0.162 0.864 0.005 0.092 0.744
4 0.091 0.1 12.5 1.1 1.3 0.179 0.014 0.071 0.841 -0.003 0.076 0.786
5 0.156 0.1 10.8 1.7 1.1 0.339 -0.005 0.090 0.831 0.002 0.081 0.788
6 0.439 0.1 6.8 3.0 0.7 0.681 -0.016 0.162 0.860 0.006 0.096 0.751
4 110 1 0.167 0.1 17.3 2.9 1.7 0.460 -0.018 0.071 0.826 0.003 0.061 0.846
2 0.192 0.1 24.0 4.6 2.4 0.763 0.006 0.073 0.878 -0.001 0.054 0.850
3 0.500 0.1 13.7 6.8 1.4 0.871 0.013 0.120 0.875 0.001 0.067 0.830
4 0.091 0.1 22.8 2.1 2.3 0.239 0.015 0.051 0.874 -0.002 0.055 0.841
5 0.156 0.1 19.8 3.1 2.0 0.504 -0.006 0.066 0.854 0.001 0.057 0.853
6 0.439 0.1 12.5 5.5 1.2 0.851 -0.014 0.120 0.871 0.002 0.069 0.825
4 180 1 0.167 0.1 28.4 4.7 2.8 0.587 -0.019 0.055 0.836 0.002 0.047 0.867
2 0.192 0.1 39.3 7.5 3.9 0.897 0.006 0.057 0.882 -0.000 0.042 0.868
3 0.500 0.1 22.3 11.2 2.2 0.956 0.013 0.093 0.879 -0.000 0.052 0.854
4 0.091 0.1 37.2 3.4 3.7 0.282 0.015 0.040 0.874 -0.001 0.043 0.868
5 0.156 0.1 32.2 5.0 3.2 0.621 -0.008 0.051 0.863 0.001 0.045 0.866
6 0.439 0.1 20.6 9.1 2.0 0.949 -0.016 0.093 0.875 0.000 0.053 0.857
5 60 1 0.167 0.3 9.3 1.5 2.8 0.059 -0.017 0.098 0.802 0.002 0.125 0.868
2 0.192 0.3 13.1 2.5 3.9 0.093 0.005 0.099 0.863 -0.000 0.114 0.870
3 0.500 0.3 7.5 3.8 2.3 0.144 0.009 0.162 0.867 0.003 0.138 0.861
4 0.091 0.3 12.5 1.1 3.7 0.032 0.014 0.072 0.841 -0.003 0.115 0.868
5 0.156 0.3 10.8 1.7 3.2 0.061 -0.005 0.090 0.833 0.002 0.119 0.867
6 0.439 0.3 6.8 3.0 2.0 0.144 -0.016 0.162 0.860 0.004 0.141 0.862
5 110 1 0.167 0.3 17.3 2.9 5.2 0.066 -0.018 0.071 0.826 0.003 0.090 0.880
2 0.192 0.3 24.0 4.6 7.2 0.099 0.006 0.072 0.878 -0.000 0.082 0.885
3 0.500 0.3 13.7 6.8 4.1 0.132 0.013 0.120 0.874 0.000 0.102 0.879
4 0.091 0.3 22.8 2.1 6.9 0.032 0.015 0.051 0.874 0.001 0.085 0.879
5 0.156 0.3 19.8 3.1 5.9 0.067 -0.006 0.066 0.855 0.002 0.088 0.881
6 0.439 0.3 12.5 5.5 3.8 0.133 -0.014 0.120 0.872 0.001 0.103 0.878
7 60 1 0.167 0.1 9.3 1.5 0.9 0.332 -0.017 0.098 0.805 0.005 0.075 0.822
2 0.192 0.1 13.1 2.5 1.3 0.553 0.005 0.099 0.864 0.000 0.068 0.825
3 0.500 0.1 7.5 3.8 0.8 0.765 0.009 0.162 0.864 0.006 0.082 0.808
4 0.091 0.3 12.5 1.1 3.7 0.035 0.014 0.071 0.839 -0.003 0.125 0.864
5 0.156 0.3 10.8 1.7 3.2 0.066 -0.005 0.090 0.832 0.001 0.132 0.860
6 0.439 0.3 6.8 3.0 2.0 0.150 -0.016 0.162 0.861 0.002 0.160 0.844
7 110 1 0.167 0.1 17.3 2.9 1.7 0.478 -0.018 0.071 0.826 0.002 0.053 0.859
2 0.192 0.1 24.0 4.6 2.4 0.778 0.006 0.073 0.878 -0.001 0.049 0.859
3 0.500 0.1 13.7 6.8 1.4 0.906 0.013 0.120 0.875 0.003 0.060 0.853
4 0.091 0.3 22.8 2.1 6.9 0.034 0.015 0.051 0.874 0.001 0.092 0.881
5 0.156 0.3 19.8 3.1 5.9 0.068 -0.006 0.066 0.853 0.002 0.097 0.878
6 0.439 0.3 12.5 5.5 3.8 0.142 -0.014 0.120 0.872 -0.000 0.118 0.870
TABLE 6.2: Operating performance of model 441 in selected scenarios
from Chapter 5, and the new scenario 7. Diffuse shows probability of
approval under diffuse priors. Bias, SE and coverage columns retain
the definitions already given.
chance occurrences at small sample sizes. Figure 6.1 illustrates this. The dots show
the posterior mean probability of toxicity in cohort 6 of scenario 1 and the horizon-
tal lines show 90% credible intervals. For clarity, we show only estimates from the
first 100 simulated iterations. The vertical purple dotted lines show the true toxicity
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probability, 10%, and the orange dashed lines show the mean of the posterior mean
estimates. The blue intervals contain the true value but the red intervals do not.
The left-hand panel shows those estimates by model 411 and the right-hand panel
model 441. For model 411, the orange and purple lines are so close as to be barely
distinguishable but there is a small amount of bias visible for model 441.
We see that the intervals for model 411 are generally narrower. This is not sur-
prising because each uses the full sample size of 60 patients to estimate only the
intercept parameter. In contrast, the extra parameters in model 441 admit much
more uncertainty at this modest sample size. Incongruously, even though the CIs
are generally wider in the 441 model, they are less likely to contain the true toxicity
value. We see a relative abundance of very low estimates with unduly narrow CIs.
The tenth iteration from the bottom is an extreme example. Having observed 0 tox-
icities in cohorts 4, 5 and 6 with sizes 14, 9 and 9 respectively, the posterior mean
toxicity estimates are very low. The posterior mean probabilities of toxicity in these
cohorts are all estimated to be less than 1% and 95th percentiles are each less than
4%. Faced with a chance occurrence, the model has produced parameter estimates
that are not only erroneous, but also unjustifiably precise.
The priors are partly to blame. The horseshoe-shaped prior distributions on the
event probability similar to those demonstrated in Figure 5.7, generated by the dif-
fuse parameter priors, are having an excessively adverse effect. In the chance neg-
ative example identified above, the data agree strongly with the large prior mass
placed close to the probability zero, pinning undue posterior mass to that boundary.
The combined effect of the priors and logit likelihood is to have removed too much
uncertainty from the posterior estimate. In contrast, a regularising effect could have
been provided by modestly informative priors, like our regularising priors in Chap-
ter 5, that prevent the model from over-fitting to chance events[64]. Unfortunately,
this particular example illustrates how diffuse priors can be inadvertently informa-
tive, and reflects what a misnomer ‘uninformative’ can be.
Whilst the example highlighted above leads to an erroneously low estimate of
toxicity, an error that Figure 6.1 shows is relatively common in model 441 compared
to model 411 under diffuse priors, we see from the locations and frequency of the
red lines that erroneously high estimates of toxicity are relatively common too. It
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is the coverage and variability of the toxicity estimates that have become impaired,
rather than the introduction of bias.
An alternative to changing the priors, naturally, is that we may recruit so many
patients that our posterior beliefs are dominated by the likelihood. However, once
again we are mindful that this thesis concerns itself with efficiency in clinical tri-
als. It is expedient to see priors as part of the overall model, chosen with similar
motivation as the likelihood function and the explanatory variables, to provide the
best inference possible. Priors that promote pathological behaviour like that demon-
strated above are a detriment to efficiency because they necessitate patients, who
themselves necessitate time and money, in order to counteract the misleading infor-
mation endowed in the posterior. Clinical trials provide a rare but costly opportu-
nity to make a decision that will impact the lives of many patients. It is preferable
to use priors that help the analysis to achieve its objectives. This does not mean
forcing the model to produce estimates that we expect a-priori. It means producing
estimates from the trial data that contain appropriate uncertainty, and stopping the
model from over-fitting.
It is interesting in scenario 2 to examine the coverages of estimates. In this sce-
nario, efficacy is low and toxicity is high in every cohort, and the correct decision is
to reject throughout. Coverage is now relatively poor for efficacy and acceptable in
toxicity. This is the opposite of what we saw in scenario 1, even though each sub-
model uses four parameters in each scenario. This suggests that bias is a greater risk
in logistic models when the true event rate is close to 0 or 1, as contraction in the
credible interval will occur at the boundary. As discussed above, this is exacerbated
by the diffuse priors.
In scenario 4, we see that performance is again relatively poor at N = 60. In
this scenario, raising N as high as 110 yields approval probabilities at least as high
as model 411 in cohorts 1, 2, 4 and 5. However, model 441 remains less likely to
approve in the high PD-L1 cohorts, 3 and 6. The toxicity coverage remains low in
these cohorts despite the comparatively high sample size. Overall sample size of the
order of N = 180 is required to restore the approval probabilities in these cohorts
close to those seen in model 411.
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In scenario 5 with N = 60, model 441 inflates the probability of incorrectly ap-
proving in cohorts 3 and 6 by approximately 4%. Even with sample size as high as
N = 110, this flaw is not completely rectified.
In Table 6.2, we have also added a new scenario 7 to test the discriminatory
power of the toxicity model. It uses the same efficacy probabilities as scenarios 4
and 5, but the rate of toxicity is low in TN patients and high in PT patients. We see
that the model is now very unlikely to approve in cohorts 4, 5, and 6, despite the
high efficacy in cohort 6. We see that N = 60 does not yield our desired approval
probability of 80% in cohort 3 but N = 110 raises the approval probability above
90%.
Overall, we have demonstrated that extra terms in the toxicity model will im-
prove inference as expected when toxicity varies by cohort. However, the extra pa-
rameters demand a greater sample size. To reproduce in scenarios 1-6 the operating
performance seen with model 411, up to N = 180 patients may be required. Once
again, the appetite for satisfying this burden will be driven by the clinical scenario.
Given the data already presented on pembrolizumab in a related patient group, the
motivation will not exist in PePS2 to triple the sample size to use model 441.
The previous two sections have concerned adding parameters in the effort to
produce a better model. Keeping all else constant, we saw that adding parameters
increases the amount of uncertainty in a model and reduces the statistical efficiency
of the method, a situation that can be rectified by recruiting more patients. This
forces us to contemplate that fewer parameters might be appropriate if it increases
statistical efficiency. We investigate that in the next section.
6.4 Removing the association between efficacy and toxicity
In the previous chapter, we saw evidence that questioned the benefit of modelling
associated co-primary outcomes. Scenarios 3 and 6 in Table 5.13 simulated efficacy
and toxicity events that were strongly negatively associated. These mirrored scenar-
ios 1 and 4 respectively in every other regard with the exception that the outcomes in
scenarios 1 and 4 were not associated, on average. Comparing scenario 1 to 3 and 4
to 6 in Table 5.13, model performance is practically unchanged. Here we investigate
178
6.4. Removing the association between efficacy and toxicity
further the benefit of ψ in the joint model by considering an alternative model with
no association parameter:
logitπE(xi,θ) = α+ βx1i + γx2i + ζx3i
logitπT (xi,θ) = λ
πa,b(πE , πT ) = π
a
E(1− πE)(1−a)πbT (1− πT )(1−b)
(6.3)
Once again, a takes the value 1 for a patient if the efficacy event happened, else
0, and b plays the equivalent role for the toxicity event. This joint model assumes the
two events are independent. In Table 6.3, we simulate the effect of this assumption.
To provide comparability, we have once again used diffuse N(0, 102) priors on each
element of θ in Table 6.3.
Sc Coh PrEff PrTox Odds N Eff Tox Diffuse EffBias EffEmpSE EffCov ToxBias ToxEmpSE ToxCov
1 1 0.300 0.100 1.0 9.3 2.8 0.9 0.877 0.002 0.125 0.867 0.001 0.039 0.901
2 0.300 0.100 1.0 13.1 3.9 1.3 0.904 -0.002 0.113 0.866 0.001 0.039 0.901
3 0.300 0.100 1.0 7.5 2.3 0.8 0.816 0.002 0.140 0.859 0.001 0.039 0.901
4 0.300 0.100 1.0 12.5 3.7 1.2 0.897 -0.003 0.114 0.876 0.001 0.039 0.901
5 0.300 0.100 1.0 10.8 3.2 1.1 0.890 0.000 0.119 0.868 0.001 0.039 0.901
6 0.300 0.100 1.0 6.8 2.0 0.7 0.818 0.003 0.142 0.862 0.001 0.039 0.901
2 1 0.100 0.300 1.0 9.3 0.9 2.8 0.019 0.004 0.085 0.785 0.000 0.060 0.892
2 0.100 0.300 1.0 13.1 1.3 3.9 0.023 -0.001 0.074 0.806 0.000 0.060 0.892
3 0.100 0.300 1.0 7.5 0.8 2.3 0.021 0.005 0.094 0.737 0.000 0.060 0.892
4 0.100 0.300 1.0 12.5 1.2 3.7 0.021 -0.002 0.075 0.789 0.000 0.060 0.892
5 0.100 0.300 1.0 10.8 1.1 3.2 0.023 0.003 0.080 0.792 0.000 0.060 0.892
6 0.100 0.300 1.0 6.8 0.7 2.0 0.018 0.007 0.098 0.746 0.000 0.060 0.892
3 1 0.300 0.100 0.2 9.3 2.8 0.9 0.878 0.002 0.125 0.867 0.000 0.039 0.905
2 0.300 0.100 0.2 13.1 3.9 1.3 0.904 -0.002 0.113 0.868 0.000 0.039 0.905
3 0.300 0.100 0.2 7.5 2.3 0.8 0.817 0.002 0.140 0.861 0.000 0.039 0.905
4 0.300 0.100 0.2 12.5 3.7 1.2 0.897 -0.003 0.114 0.877 0.000 0.039 0.905
5 0.300 0.100 0.2 10.8 3.2 1.1 0.890 0.000 0.119 0.868 0.000 0.039 0.905
6 0.300 0.100 0.2 6.8 2.0 0.7 0.817 0.003 0.142 0.863 0.000 0.039 0.905
4 1 0.167 0.100 1.0 9.3 1.5 0.9 0.397 -0.017 0.098 0.806 0.000 0.039 0.900
2 0.192 0.100 1.0 13.1 2.5 1.3 0.635 0.005 0.099 0.864 0.000 0.039 0.900
3 0.500 0.100 1.0 7.5 3.8 0.8 0.974 0.009 0.162 0.869 0.000 0.039 0.900
4 0.091 0.100 1.0 12.5 1.1 1.3 0.214 0.014 0.071 0.842 0.000 0.039 0.900
5 0.156 0.100 1.0 10.8 1.7 1.1 0.417 -0.005 0.090 0.833 0.000 0.039 0.900
6 0.439 0.100 1.0 6.8 3.0 0.7 0.930 -0.017 0.162 0.861 0.000 0.039 0.900
5 1 0.167 0.300 1.0 9.3 1.5 2.8 0.038 -0.017 0.098 0.807 0.000 0.060 0.891
2 0.192 0.300 1.0 13.1 2.5 3.9 0.064 0.005 0.099 0.864 0.000 0.060 0.891
3 0.500 0.300 1.0 7.5 3.8 2.3 0.100 0.009 0.162 0.867 0.000 0.060 0.891
4 0.091 0.300 1.0 12.5 1.1 3.7 0.020 0.014 0.071 0.842 0.000 0.060 0.891
5 0.156 0.300 1.0 10.8 1.7 3.2 0.043 -0.005 0.090 0.833 0.000 0.060 0.891
6 0.439 0.300 1.0 6.8 3.0 2.0 0.098 -0.017 0.162 0.863 0.000 0.060 0.891
6 1 0.167 0.100 0.2 9.3 1.5 0.9 0.396 -0.017 0.098 0.806 0.001 0.039 0.902
2 0.192 0.100 0.2 13.1 2.5 1.3 0.633 0.005 0.099 0.866 0.001 0.039 0.902
3 0.500 0.100 0.2 7.5 3.8 0.8 0.974 0.009 0.162 0.869 0.001 0.039 0.902
4 0.091 0.100 0.2 12.5 1.1 1.3 0.214 0.014 0.071 0.841 0.001 0.039 0.902
5 0.156 0.100 0.2 10.8 1.7 1.1 0.417 -0.005 0.090 0.831 0.001 0.039 0.902
6 0.439 0.100 0.2 6.8 3.0 0.7 0.929 -0.017 0.162 0.861 0.001 0.039 0.902
TABLE 6.3: Operating performance of model 410 in scenarios from
Chapter 5 with total sample size 60. Diffuse shows probability of ap-
proval under diffuse priors. Bias, SE and coverage columns retain the
definitions already given.
Comparing Table 6.3 to Tables 5.13 and 5.16, we see that performance is virtually
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identical. The differences in approval probabilities are of the order of 0.1%. Likewise,
the coverages of the 90% CIs are practically identical, as are the estimates of bias and
standard error. When appraising the model by its ability to correctly approve or
reject a treatment, there is no benefit in estimating the association parameter. We
note that ψ does not appear in either of the marginal models for πE or πT (6.3),
and thus does not determine the marginal probability of either event or affect the
approval determined by (5.12). However, as we noted above, performance is driven
not naively by the number of parameters, but by the scope for borrowing and how
this is impacted by the arrangement of parameters. We know from Figure 5.9 that
model 411 received information on the prevailing association between efficacy and
toxicity and adapted its estimation of ψ.
The ψ parameter appears in the general joint-likelihood (2.4) and thus also in the
conditional density of πE given πT , for instance. In the remainder of this section, we
demonstrate how ψ would affect inference on unobserved efficacy after confirmed
presence or absence of toxicity.
Imagine a trial scenario where a set of complete patient outcomes X has been
observed. Suppose also that the toxicity status for a further patient with baseline
covariate vector xi is known but their efficacy status is not. Let T be a Bernoulli
random variable taking values ∈ {0, 1}, representing the patient’s toxicity outcome.
Using the identity that links conditional and joint probability for events A and
B:
Pr(A|B) = Pr(A ∩B)
Pr(B)
(6.4)
we can estimate the posterior conditional probability of efficacy for this patient
given that toxicity occurred as:
πE(xi,θ|X, T = 1) =
π1,1(πE(xi,θ|X), πT (xi,θ|X), ψ)
πT (xi,θ|X)
(6.5)
and given that toxicity has not occurred as:
πE(xi,θ|X, T = 0) =
π1,0(πE(xi,θ|X), πT (xi,θ|X), ψ)
1− πT (xi,θ|X)
(6.6)
To illustrate this, we sampled a single trial dataset with N = 60 using event rates
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FIGURE 6.2: Posterior conditional Prob(Eff) under two models using
diffuse priors, where toxicity status is categorically observed but effi-
cacy is unknown. The wider observed dataset that forms the posterior
distributions is described in the text.
and associations from scenario 6 in Table 6.3, i.e. efficacy is very likely with high
PD-L1, but efficacy and toxicity are strongly negatively associated.
In our simulated data, there were 3 efficacy events from 5 patients in cohort 3, the
cohort of TN patients with high PD-L1, so the observed efficacy rate slightly exceeds
the underlying true rate of 50%. This dataset was then fit using models 411 and 410,
each using their sets of diffuse priors.
Suppose that we wish to perform inference on an extra patient that has covariate
vector that would put them in cohort 3. A posteriori, model 411 estimates the effi-
cacy rate to be 63% and model 410 estimates it to be 64% in cohort 3. The posterior
densities for the probability of efficacy conditional on the confirmed presence and
absence of toxicity using both models are shown in Figure 6.2.
As expected, the densities under model 410 are identical because this model lacks
the association parameter and cannot reflect the partial information. The expected
probability of efficacy in this scenario is 64%, irrespective the observed toxicity out-
come.
In contrast, the posterior density for the efficacy probability is shifted to the left
under model 411 if toxicity is observed. This accurately reflects the underlying real-
ity that efficacy and toxicity are negatively correlated, so efficacy is less likely when
toxicity is observed. Here, the expected efficacy probability has fallen by 14% to 49%.
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When the absence of toxicity is observed, the expected efficacy probability increases
very modestly to 65%. The probability has increased to correctly reflect the nega-
tive association. However, the increase is relatively small because toxicity is rare -
the true underlying rate is 10%. Confirmation of the absence of toxicity provides
relatively little additional information on efficacy.
In Chapter 2 we introduced the notion of outcome ambiguity where only one of
the two co-primary outcomes is known. Our motivation then was dose selection but
this method of conditional inference is useful for making judgements when one of
the outcomes is missing.
We see that ψ performs a useful role in model 411 that will improve inference in
situations with partially observed outcomes. Table 6.3 shows that performance is not
improved by removing the parameter so it seems natural to retain it in the model.
However, it is important that performance of the model is appraised to carry out the
intended inference. If it is desired that conditional inference be reliable, simulations
should be used to assess the performance of the model at this particular task. For
instance, the sample size and the priors need to be sufficiently informative to iden-
tify ψ and provide reliable conditional inference. We stress this because with small
sample sizes, chance spurious associations could adversely impact inference. In this
situation, a regularising prior on ψ would likely be beneficial. This was not desired
in PePS2 and further investigation of parameterisation for reliable conditional infer-
ence is beyond the scope of this thesis.
We advocate retaining the association parameter.
6.5 Discussion
In this chapter, we have considered notable embellishments to the P2TNE model pre-
sented for PePS2 in Chapter 5. These embellishments all sought to alter the model
forms. By adding interaction terms to the efficacy sub-model to abrogate the piece-
wise parallel assumption, and terms to the toxicity sub-model to handle heterogene-
ity therein, we showed that more discriminative inference is possible. However, we
saw that materially greater sample size is required to inform estimation of the ex-
tra parameters and maintain the sought level of overall statistical performance. A
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unifying conclusion to these experiments in the context of PePS2 is that the poten-
tial inferential benefits were not particularly valuable and did not warrant greater
accrual and a longer trial.
The incremental information to estimate the extra parameters could have come
from the priors rather than the outcomes. In the examples presented in this chapter,
we used very diffuse priors for comparability. The information these priors and the
diffuse priors in the previous chapter contain can be legitimately said to be minimal,
allowing us to ascribe difference in performance to the model specifications. This
satisfies the objective of this chapter. If used in a real trial situation, we would use
more informative priors that generate outcomes that genuinely reflect our expecta-
tion.
Having observed the cost of parameters to performance, we then considered
whether our model could be improved by removing the association parameter that
appeared to provide little benefit. We found that performance did not improve when
this parameter was removed. Furthermore, we demonstrated how this parameter
could be used to improve conditional inference when the co-primary outcome mea-
sures were partly observed. In these circumstances, it is natural to retain the associ-
ation parameter.
An undesirable curiosity of the categorical model is that it offers the same ap-
proval probabilities to patients with PD-L1 equal to 50% and 100%. In ongoing work
in Appendix D, we explore the use of continuous PD-L1 as a baseline covariate, in





In this thesis, we have considered methods that enhance efficiency in clinical trials
with limited sample size. These methods have been operational and statistical, fa-
cilitating efficient clinical trial conduct and analysis. They broadly imply two over-
arching goals: i) use more outcomes to answer questions in trials; and ii) use all
available information. We provide concluding remarks below.
7.1 Use more outcomes to answer questions in trials
Seamless phase I/II designs like EffTox[92] allow us to add efficacy to the typical
toxicity outcome when selecting doses. This could be necessary if there is doubt
about the monotonicity of the dose-efficacy relationship. By additionally evaluating
short-term efficacy, a dose-finding trial can address the traditional phase I objective
of identifying a dose suitable for further research, and an objective typical of phase II
trials in assessing whether there is sufficient activity to warrant a randomised study.
It is likely that achieving both of these objectives in a single clinical trial will be faster
and cheaper than running separate trials.
In Chapter 2, we gave an in-depth account of our use of EffTox in Matchpoint.
Since writing the chapter, this work has been published by Brock et al.[17]. Based on
our experience implementing this infrequently-used design, we advocated practical
measures such as phase I/II dose transition pathways (DTPs) to check in advance
that a parameterisation behaves in a desirable and consistent way, and gave an il-
lustration of latent undesirable behaviour in our original parameterisation. We in-
troduced the phenomena of dose ambivalence, where different doses can be recom-
mended in response to identical outcomes because of the uncertainty inherent in the
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analysis and the imperfect calculation method. We overcame this challenge with re-
peated calculation of the dose decision. We also introduced the challenge presented
by outcome ambiguity and how it can be overcome using DTPs. Phase I/II trials
are efficient because they allow the objectives of two trial phases to be addressed
at once. However, the described phenomena can erode that efficiency by allowing
sub-optimal doses to be selected and causing delays in trial conduct. The methods
we introduce show how those complications can be managed and overcome.
In Chapter 3, we introduced a novel hybrid of EffTox and Wages & Tait’s (WT)
design for phase I/II trials[98]. We compared the hybrid to variants of EffTox and
WT in a simulation study. A version of WT that does not use randomisation showed
superior statistical performance, achieving our operational efficiency objective with-
out compromising statistical efficiency. Our hybrid achieved the same operational
objective but offered slightly inferior statistical performance and greater heterogene-
ity, whilst allocating marginally fewer patients at attractive doses.
We remarked that additional innovation of WT would allow further streamlining
of the trial objectives. In phase I/II trials, we already require that efficacy and tox-
icity can be evaluated over a similar, acceptable time horizon. In situations where
randomisation to either a trivial or non-trivial dose is ethical, the zero-dose cohort
may serve as a control arm. This potentially elevates a dose-finding trial to ran-
domised controlled trial status, thus facilitating causal inference. In such scenarios,
a single large dose-finding trial could be used to find the most promising dose of
an experimental treatment and provide a randomised comparison to a control, thus
achieving the objectives of phases I and II, requiring only a subsequent phase III trial
to compare long term clinical efficacy. This takes to the extreme the potential bene-
fits of answering more questions in clinical trials. Potential applications include where
an experimental agent is optionally added to the standard of care. Crucially, giv-
ing an experimental treatment instead of a standard therapy is unlikely to be ethical
when efficacy evidence exists for the latter but not the former. Thus, this method is
unlikely to yield a comparison of a novel therapy to a completely distinct standard
therapy.
These examples are part of a wider trend to combine the traditional phases in
search of efficiency. Beyond this thesis, multi-arm multi-stage (MAMS) designs[77]
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allow researchers to conduct seamless phase II/III trials. Further so-called platform
trials, such as basket trials that assess a single treatment in many diseases, and um-
brella trials that assess many treatments in a single disease, are becoming increasingly
common. These elaborate different aspects of the traditional Patient, Intervention,
Comparator, Outcome (PICO) paradigm that has formed the foundation of innumer-
able historic clinical trials. The innovations reflect the desire to answer more ques-
tions under one protocol, augment traditional trial methods to accommodate the
abundance of potential treatments and molecular stratifiers, and conduct trials that
accommodate the likely biological nature of contemporary experimental treatments.
7.2 Use all available information
The second of our overarching conclusions advocates the use of all available infor-
mation to maximise statistical efficiency.
In Chapter 4, we presented a design to conduct a pivotal randomised clinical
trial in an ultra-rare disease. We demonstrated by simulation that we could expect
to achieve conventional error rates using 70 patients assessed seven times through-
out the trial. Critical to our parameterisation of the simulations and our proposal to
analyse the repeated outcome measures by hierarchical model was the data on the
cohort of patients with Wolfram syndrome from St Louis. We were able to specify
a model that would plausibly test the presence of a treatment effect based on the St
Louis outcomes, and investigate the impact of longitudinal missing data on statis-
tical efficiency. We did not incorporate any information from the St Louis data into
the model, via priors, for example, because the trial seeks to be pivotal.
Efficiency was a factor in the choice of analysis method in TreatWolfram. We
demonstrated that an analysis of final visual acuity values alone was inefficient, re-
quiring an infeasibly high sample size. We expect to conduct a trial that will achieve
acceptable power with our constrained sample size by using a hierarchical model
to analyse the repeated measures data. We learned that patient-specific intercepts
and gradients would likely be required to account for patient heterogeneity. That
the outcome measures are subject to modest variability and are likely to be highly
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correlated within patient means that inflation factors to account for missing data are
relatively low, promoting an efficient analysis if up to 15% of data is missing.
There are other examples of structured outcomes that arise in clinical trials be-
yond repeated measures. Outcomes nested within individuals arise in crossover tri-
als, and in scenarios where randomisation can be conducted on experimental units
within individuals. Examples of the latter include trials of topical treatments like
dressings, drops, and ointments that can be randomly allocated to wounds, burns,
or diseased eyes within patients. Experimental designs that facilitate within-patient
randomisation are particularly efficient because they control for a practically un-
bounded and uncountable number of potential confounding variables. For instance,
lifestyle and environmental factors, concomitant medications, and every known and
unknown gene expression are generally controlled by comparing outcomes within in-
dividual. We noted that there was further opportunity to increase expected power in
TreatWolfram by analysing the repeated visual acuity outcomes within eye, nested
within individuals. This scenario does not permit within patient randomisation be-
cause the oral medication is systemic. However, it will generate approximately twice
the number of series, and increase statistical power. The expected gain will be much
less than that notionally generated by doubling the sample size however, because of
the anticipated high correlation between each individual’s eyes.
Efficient use of the available information was also the theme of Chapter 5. We in-
troduced a novel refinement of Thall, Nguyen & Estey’s dose-finding design[89] that
we called P2TNE. This design incorporates baseline covariates to assess co-primary
binary efficacy and toxicity outcomes. Our motivation was PePS2, a trial of pem-
brolizumab in performance status 2 non-small-cell lung cancer patients. Based on
the information reported in previous trials[37, 44] of the same treatment in closely-
related patient groups, we anticipate that PD-L1 expression and pretreatedness will
be predictive of efficacy but not toxicity in the PS2 patient population. We demon-
strated that including the baseline predictive variables in the analysis model im-
proved performance considerably compared to separate cohort-specific inferences
provided by beta-binomial models. This improvement was apparent under diffuse,
regularising and informative priors. We noted several assumptions implicit in our
marginal model forms that had the potential to bias conclusions. By considering
188
7.2. Use all available information
more complex model specifications in Chapter 6, we learned that covariate terms
in the toxicity sub-model and interaction terms in the efficacy sub-model required
substantial increases in sample size. This was considered unjustifiable given the out-
comes suggested by previous trials and the potential benefit to the PS2 population
of conducting a fast phase II trial. This illustrates a restriction of statistical analysis
pertinent to efficiency that is felt particularly strongly in clinical trials. The perfect
analysis1 does not exist: Inference can practically always be improved by collect-
ing more data. However, trials are expensive, arduous and numerous. Achieving
the trial objective in the agreed time-frame and avoiding the diversion of subsidiary
questions and elaborate flourishes is instrumental in a successful trial.
Another important source of information in the P2TNE example was our pa-
rameter priors. It is a pervasive belief in biostatistics that priors should be diffuse to
avoid biasing an analysis with external information. This view is seen to be question-
able when we consider the opportunity for influence stemming from investigator
degrees of freedom, like experimental design, choice of likelihood function, inclu-
sion and exclusion of explanatory variables, choice of statistical test, and method of
dealing with missing data. We demonstrated that the diffuse priors provided poor
posterior coverage and empirical standard error of estimated event rates, particu-
larly when the models contained many terms or underlying event rates were very
low. Our statistical model was more efficient under our regularising and informa-
tive priors. We advocate that priors are seen as any other part of an analysis that is
chosen to promote accuracy and efficiency, and requires justification in light of the
alternatives.
In Chapter 6, we demonstrated the role played by the association parameter in
conditional inference on partially observed outcomes in the EffTox, TNE and P2TNE
models. This further reiterated the benefit of using all available information.
In Appendix D, we considered the underlying continuous PD-L1 covariate in-
stead of the categorisation presented in [37]. We expected the continuous covariate
to be more efficient and yield superior inference because it can discriminate between
more cases than the categorisation. For instance, the continuous covariate can reflect
that a PD-L1 score of 40% is superior to a score of 5%, but the categorical variable
1also, the perfect thesis
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treats these as equal. Whilst we did improve inference using continuous PD-L1 in
some scenarios, we noted the care needed when specifying the model form and pri-
ors to avoid inadvertently coercing undesirable information that is detrimental to
analytical efficiency.
A topic largely absent from Chapters 5 and 6 is the potential benefit for the re-
sponse variables to be continuous rather than binary. Efficacy is naturally continuous
when we consider that tumour size underlies the response categories defined by
RECIST[35]. The toxicity outcome may seem more naturally dichotomous in that
a specific event either occurs or does not. However, methods have been proposed
that analyse the total toxicity burden, informed by the frequency and severity of all
adverse events sustained by patients. Evidence of the dominant culture treating effi-
cacy as categorical or binary is that the novel methods in this thesis are refinements
of previous methods[89, 92, 98] and that the RECIST[35] paper has been cited over
11,000 times (according to Google Scholar at 05-Sep-2018). Nevertheless, methods
have been introduced by Wason et al.[100–102] that demonstrate the benefit to ef-
ficiency from retaining the continuous tumour measurements. More recently, joint
modelling methods have been proposed[14] that use two-level hierarchical structure
to analyse the repeated measurements of tumour lesions nested within individual
(i.e. the constituent parts of the RECIST calculation) through time as an ongoing
mediator of the hazard of some time-to-event endpoint like death. These methods
present a desirable future direction for the methods presented herein in the pursuit
of further efficiency.
7.3 Final conclusion
This thesis has demonstrated that efficiency in clinical trials comes from a blend
of operational and statistical choices. Investigators seeking to improve efficiency
should consider how they may use multiple outcomes to address the objectives of
trials; and how they may use all available information, be that structured patient
data, association in outcome measures, baseline covariates or priors. The settings
for the contained methodological work have been the Matchpoint, TreatWolfram
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and PePS2 trials of the University of Birmingham’s Cancer Research UK Clinical
Trials Unit.
The Matchpoint trial started recruiting patients in 2015. Shortly after it opened,
the design parameterisation was slightly altered, as described in Section 2.3.2.6. Al-
most from the start, dose-transition pathways and repeated invocations of the dose-
update decision were used to detect dose ambivalence and routinely reported to the
data monitoring committee to help justify dose selections. By late 2018, the trial had
evaluated 17 patients and remained open to recruitment.
The TreatWolfram trial opened in the UK at the beginning of 2019 and imme-
diately started randomising patients. It seeks to recruit 70 patients and these are
being randomised to sodium valproate or placebo at a ratio of 2:1. The team intends
to open European sites in France, Spain and Poland in 2019. The primary outcome
measure is visual acuity and assessments are being taken at baseline and then every
six months for three years. The intended analysis model will use population-level ef-
fects for time and the interaction of time and treatment allocation, with patient-level
terms for intercepts and gradients with respect to time.
PePS2 opened for recruitment at the beginning of 2017 and recruited 63 patients
between then and February 2018. Baseline pretreatedness and PD-L1 status were
sought at registration for all patients. The intended primary analysis will use the
411 model using categorical PD-L1 and the Gumbel association function, expanded
at length in Chapter 5. This will be used to present the evidence on efficacy and
toxicity in the six cohorts in Table 5.3. Sensitivity analyses may be conducted using
the 611 and 441 models from Chapter 6. The association parameter is performing
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B.1 Literature review search strategy
On 08-March-2017, we searched PubMed with the search phrase “visual acuity sam-
ple size trial”. The PubMed search engine generalised this search string to be:
(“visual acuity”[MeSH Terms] OR (“visual”[All Fields] AND “acu-
ity”[All Fields]) OR “visual acuity”[All Fields]) AND (“sample size”[MeSH
Terms] OR (“sample”[All Fields] AND “size”[All Fields]) OR “sample
size”[All Fields]) AND (“clinical trials as topic”[MeSH Terms] OR (“clin-
ical”[All Fields] AND “trials”[All Fields] AND “topic”[All Fields]) OR
“clinical trials as topic”[All Fields] OR “trial”[All Fields])
The search returned 109 results.
Abstracts were reviewed for all results and full-texts were sought in all cases.
25 manuscripts were not immediately available through the University of Birming-
ham’s package of journal subscriptions. Of these 25, it was evident from the content
of the abstract alone in eight instances that the manuscript would not replicate our
method. This was because the abstract identified another method for calculating
sample size (n = 3), described a systematic review that did not require a prospec-
tive sample size estimate (n = 2), identified a non-longitudinal analysis method
(n = 2) or listed outcomes but omitted visual acuity (n = 1). In the remaining 17
cases, 16 were found to be listed on ResearchGate and a full-text copy was requested
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directly from the author(s). Six full-text manuscripts were obtained from Research-
Gate in this way and formed part of the review described below. We resigned that
the residual eleven manuscripts would remain unavailable but did not envisage that
it would impact the generalisability of our results. Ninety full-text manuscripts were
obtained and reviewed, summarised in Table 4.6.
B.2 Grading our efforts by framework of Parmar et al.
Whilst the TreatWolfram trial was being designed, Parmar et al.[72] published guid-
ance on sequential steps that may be taken to arrive at a defensible trial using a
feasible sample size when conducting randomised controlled trials in rare diseases.
Those steps, with the pertinent choice in TreatWolfram, are listed in Table B.1. We
discuss the most noteworthy of those points now.
We addressed each item listed under the objective of increasing what is feasible.
It became obvious relatively early on that repeated measures analysis and interna-
tional recruitment would be necessary to increase the information content. Widening
the eligibility criteria was not an option because the syndrome is genetically defined.
We also addressed most of the commonly considered approaches. As described, we
sought the outcomes with the highest information content. It was perhaps fortuitous
that the key outcome of visual acuity saw relatively large changes through time with
relatively modest variability, making it conducive to study. The trial and intended
analysis should have power of least approximately 80% to detect a treatment effect
of approximately 50% in VA.
Having reached a feasible and defensible design, we had no reason to explore
any of the less common approaches. It is reassuring to see that the decisions we took to
arrive at a feasible design bear a high affinity for the advice of Parmar et al.[72]
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Item Wolfram
1. Increase what is feasible
Increase accrual and / or follow-
up time
We increased trial to 3 years and
repeated measures to reach a
feasible experiment.
Broaden eligibility criteria This is not an option as the syn-
drome is monogenic




We will use international sites
2. Explore commonly-considered approaches to reducing sample size
Identify experimental arm
which starkly differs from
control arm
We only had one experimental
arm
Change outcome to one that is is
more information-heavy
VA & VPV were selected for
maximal information content.
Define target difference that is
realistic and worthwhile, which
might be larger
Targeting a 50% treatment effect
in VA was deemed worthwhile.
Slightly larger effect had to be
used in VPV considering the in-
vasive nature of frequent assess-
ment.
Relax power by a small amount Power stands at approximately
80%
3. Explore less common approaches to reducing sample size
Relax α a small amount We managed to retain the con-
ventional 5%
Move from two- to one-sided ef-
fects
For this pivotal study, conven-
tional two-sided test used. We
had no need to use a one-sided
test.
Include covariate information We considered some patient
characteristics in this chapter
but they appeared to yield little
benefit. No further prognostic
factors are known.
Re-randomise patients The duration of the trial was al-
ready quite long.
Use external information We had no need.
TABLE B.1: Our choices on TreatWolfram summarised according to






The following sections are included because they address potential questions that
the reader might have about the methods in the main text.
C.1 Alternative cohort prevalences in P2TNE simulations
In all of the simulations presented in the main body, we use the parameter vector
ρ̂ = (15.7, 21.8, 12.4, 20.7, 18.0, 11.4) to sample cohort memberships, for the reasons
described. For clarity in this section, we refer to that set of prevalences derived for
the PePS2 trial as ρ̂P . We investigate the sensitivity of our P2TNE implementation to
the prevalences used by comparing performance under the alternative vector ρ̂A =
(16.67, 16.67, 16.67, 16.67, 16.67, 16.67), labelled with subscript A to denote it as an
alternative. Under ρ̂A, patients are uniformly distributed amongst the six cohorts
and the expected size of each is 10 patients.
Table C.1 compares the performance of P2TNE designs using cohort prevalences
ρ̂P and ρ̂A in scenario 8 of our simulations in the main text. Once again, scenario 8
was chosen for its representativeness and variety. The first thing to note is that the
probability of approving treatment has changed by no more than 4% in any cohort.
In all cohorts except one, the probability of accepting treatment has increased where
N has increased, and vice-versa. This is what we would expect.
Somewhat curiously, the performance in cohort 4 has actually improved with
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TABLE C.1: Comparison of P2TNE performance in scenario 4 of
Table 5.13 using the cohort prevalences derived in the main body
and alternative, uniform prevalences. N is the expected cohort size.
Pr(Approve) is the probability of the P2TNE design approving the
treatment.
Scenario 8 ρ̂P ρ̂A
Cohort Pr(Eff) Pr(Tox) N Pr(Approve) N Pr(Approve)
1 0.167 0.1 9.5 0.457 10.0 0.483
2 0.192 0.1 13.1 0.681 10.0 0.654
3 0.500 0.1 7.4 0.979 10.0 0.989
4 0.091 0.1 12.4 0.299 10.0 0.330
5 0.156 0.1 10.8 0.493 10.0 0.511
6 0.439 0.1 6.8 0.924 10.0 0.961
fewer patients. This might seem counter-intuitive. However, in P2TNE, the prob-
ability of accepting a treatment in a cohort is affected by the outcomes in other co-
horts. By transitioning from ρ̂P to ρ̂A, we have effectively allocated more patients to
the high PD-L1 cohorts, specifically the cohorts with the highest response rates. This
has raised the expected baseline rate of response, i.e. efficacy is believed more likely
in all cohorts. This is felt most sensitively in the cohort with the lowest response
rate, namely cohort 4.
In the main text we showed via simulation that the P2TNE design has good op-
erating characteristics in a wide range of scenarios. All these simulations used a
common assumed set of cohort prevalences. In some trial scenarios where recruit-
ment is stratified by the predictive variables, there will be no uncertainty about the
realised cohort sizes. In “all-comers" trials like PePS2, where the cohort sizes will
be randomly determined, Table C.1 shows that P2TNE is robust to reasonable devi-





D.1 Continuous PD-L1 as a covariate
The process of categorisation throws away information. This is familiar to statisti-
cians[2]. For instance, with respect to a continuous outcome measure, the values for
individual patients can be ordered from smallest to largest. When this measure is
categorised to some scheme of ordered disjoint sets (e.g. “0-10”, “10-20”, etc), ties,
where two or more patients have the same score, are necessarily more common. For
instance, patients with scores 2 and 8 can be distinctly and unambiguously ordered
with respect to the continuous measure, but are treated as equal in a categorisation
scheme containing the set “0-10”. This inability to resolve ties is the essence of infor-
mation loss, and degrades the efficiency of a statistical analysis.
Much of the information that informed the design of PePS2 came from the KEYNOTE-
001 study published by Garon et al[37]. We have hitherto used the three-level cate-
gorical PD-L1 variable that they introduced and validated. However, it would theo-
retically benefit us to eschew the categorisation in favour of the underlying continu-
ous PD-L1 proportion, bounded on [0, 1].
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PD-L1 score Screened Treated
Limits (%) Mid-point (%) Prevalence Prob(OR)
k lk − uk mk N ρk N ωk
1 0 0 323 0.392 87 0.081
2 1-24 12.5 255 0.310 147 0.129
3 25-49 37 55 0.067 27 0.194
4 50-74 62 71 0.086 39 0.296
5 75-100 87.5 120 0.146 72 0.454
Total 824 372
TABLE D.1: Distribution of PD-L1 scores in screened patients and
probabilities of objective response (OR) in treated patients, repro-
duced from Figure S4 of the supplementary information of Garon et
al.[37]. The authors label the lowest category as “< 1”. For the pur-
poses of modelling, we have interpreted this as 0.
In the supplementary appendix, Garon et al. provide the prevalence information
in Table D.1, showing the distribution of the PD-L1 scores for all screened patients.
It is more granular than the data in the main paper, using k = 5 categories instead
of three. We infer from the boundaries that PD-L1 score is recorded to the nearest
whole percent, else it would be ambiguous to which category a score of 24.5% would
belong, for instance. For the purposes of modelling, we have given the mid-point of
the PD-L1 categories, mk in Table D.1.
The PD-L1 frequencies are plotted in Figure D.1. We see that the distribution of
scores is bimodal, non-normal and asymmetric. The most common category is the
biomarker-negative cohort, PD-L1 < 1%. There is another local peak in the category
PD-L1 > 75%, and relatively few patients in the third and fourth cohorts.
Garon et al. also present the observed probabilities of objective response (OR) in
those same PD-L1 categories. These are given in Table D.1 and plotted in Figure D.2.
As in the previous chapter, we see that the probability of response is convincingly
associated with PD-L1 score.
Garon et al. do not provide patient-level PD-L1 scores and responses. If they did,
we could fit a generalised linear model (GLM) using PD-L1 score as an independent
variable to explain the chances of OR. With the resulting model, we could infer the
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FIGURE D.1: Count of screened patients by PD-L1 score, reproduced
from Figure S4 of the supplementary information of Garon et al.[37].
FIGURE D.2: Probability of objective response by PD-L1 score, re-
produced from Figure S4 of the supplementary information of Garon
et al.[37]. The orange dots are the values estimated by the model in
(D.1).
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probability of OR at any PD-L1 score. Instead, we will improvise with the data we
have. The orange dots in Figure D.2 show the fitted values according to the GLM
with a logit link function given by
logitωk | mk = α+ βmk, k = 1, ..., 5
= −2.29 + 2.40mk
(D.1)
when fit using the glm function in R, where ωk andmk are given in Table D.1. We
see from Figure D.2 that the resulting fit is good, and that interpreting the probability
of response as a continuous function of PD-L1 is a plausible working model. There
are errors on the probability scale of approximately 1% in cohorts 1, 2 and 4, and very
small errors in cohorts 3 and 5. The intercept coefficient says that the probability of
OR when PD-L1 = 0 is logit−1 (−2.292) = expit(-2.292) = 9.2%. The slope coefficient
says that the odds of OR are scaled by exp (0.01× 2.40) = 1.024, i.e. increases by
2.4%, for each 1% absolute increase in PD-L1 score.
In following sections, we use a similar method of regressing response probabili-
ties against PD-L1 category mid-points, mk, to produce data-generating models that
match our simulation scenarios used hitherto.
D.1.1 P2TNE models to use continuous PD-L1 in PePS2
In this section, we consider models that facilitate the analysis of PePS2 outcomes
with continuous PD-L1 and binary pre-treatment status as baseline covariates. The
general P2TNE model presented in the previous chapter used logit models for the
marginal probabilities of efficacy and toxicity:
πE(x,θ) = g(x,θ) and πT (x,θ) = h(x,θ) (D.2)
We will use that general form again to investigate models with different choices
for g and h and re-use our shorthand to identify models by the number of parameters
in the three model components.
Once again, let us use x1i to designate pre-treatment status, with x1i = 1 sig-
nifying that patient i has been previously treated, else x1i = 0. Again, we refer to
204
D.1. Continuous PD-L1 as a covariate
those patients with x1 = 0 as TN for treatment naive, and those with x1 = 1 as PT for
pre-treated. In the previous chapter, we used dummy variables x2i and x3i that deter-
mined membership of the high, medium and low PD-L1 categories. Henceforth, let
us redefine x2i to be PD-L1 score for patient i, taking values on [0, 1].
We demonstrated previously that overall approval probability of the ensemble
model does not depend on the association parameter ψ. However, we identified
theoretical benefits and no evidence of detriment to performance, so we retain ψ
and use the association model (2.4).
We use the following marginal models:
logitπE(xi,θ) = α+ βx1i + γx2i + ζx1ix2i (D.3)
and
logitπT (xi,θ) = λ (D.4)
There is an interaction between pretreatedness and PD-L1 in the efficacy model.
Toxicity is assumed uniform. We refer to this as model 411c, with the suffix c reflect-
ing that the use of continuous PD-L1.
The posterior quantities (5.7) to (5.11), and the approval criteria (5.12) are re-used
in this study. Posterior sampling is again performed using Stan[22].
D.1.2 Randomly sampling covariates
Randomly sampling PD-L1 scores will allow us to assess the performance of our
models on unseen data. We will sample PD-L1 scores to mimic the distribution
presented in Table D.1 because we expect that this will reflect the distribution of
scores in the PePS2 population. We only have frequencies in five categories, and no
further information on the distribution of the individual scores. However, this is
enough to create a functional and plausible method for simulating PD-L1 data. We
propose to sample n PD-L1 scores that mimic the distribution in Table D.1 using the
following algorithm:
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FIGURE D.3: Two examples of n = 824 simulated PD-L1 samples
using the algorithm described above.
FIGURE D.4: Two examples of n = 60 simulated PD-L1 samples using
the algorithm described above.
1. Sample cohort sizes n1, n2, n3, n4, n5 from a multinomial distribution with prob-
ability parameter ρ = (ρ1, ..., ρ5), so that
∑5
i=1 ni = n;
2. Sample nk PD-L1 scores assumed to be uniformly distributed on [lk, uk], for
k = 1, ..., 5.
The values for ρk, lk and uk are given in Table D.1. PD-L1 scores in cohort 1 are taken
simply to be 0.
Figure D.3 shows two samples of n = 824 PD-L1 scores simulated by this algo-
rithm. The sample size was fixed to match that in Figure D.1. Many similarities and
some modest differences are immediately recognisable. Two further examples are
given in Figure D.4 with n = 60. Much more variability is now apparent.
Pretreatedness is sampled as a Bernoulli random variable with success parameter
0.5.
206
D.1. Continuous PD-L1 as a covariate
D.1.3 Sampling efficacy and toxicity events
In simulations in Chapter 5, we assumed true probabilities of efficacy and toxicity in
each of the six cohorts. With continuous PD-L1 scores, that simplicity is no longer
present1. Instead, we now assume that models determine the probabilities of efficacy
and toxicity from PD-L1 score and pre-treatment status. We refer to these as event
generating models (EGMs). Generating events in this way presents a methodological
challenge. The EGMs should be realistic in order to provide useful inferences on
performance of the analysis model on unseen data. However, we should be mindful
of the degree of similarity between the model used to simulate events and that used
to analyse them. If the two models are unjustifiably similar, simulations will make
the analysis method appear artificially good.
We address this potential hazard by using as EGMs saturated generalised linear
regression models that exactly match the event probabilities for a PD-L1 score in the
centre of the cohort range in the categorised setting. For example, the probability
of efficacy for a PT patient with PD-L1 score of 75% will match that of a patient in
cohort 6 in Chapter 5. The event probabilities at the other PD-L1 scores are interpo-
lated by the model. This approach has the benefit of allowing us to compare model
performance under categorised and continuous PD-L1.
Scenario Efficacy EGM Toxicity EGM Chapter 5 scenario
1c πE = 0.3 πT = 0.1 1
2c πE = 0.1 πT = 0.3 2
4c logitπE = −1.61− 0.69x1 − 0.05x2 + 2.93x22 + 2.36x1x2 − 2.35x1x22 πT = 0.1 4
5c logitπE = −1.61− 0.69x1 − 0.05x2 + 2.93x22 + 2.36x1x2 − 2.35x1x22 πT = 0.3 5
TABLE D.2: Simulation scenarios used in Section D.1. Coefficients are
expressed to two decimal places. Scenario descriptions are given in
the text.
The simulation scenarios are summarised in Table D.2. Scenarios 1c and 2c mimic
the benchmark favourable and adverse scenarios used to calibrate pE and pT with
the categorical model in Section 5.4.2. Again, the suffix c is for continuous PD-L1.
1Measured to the nearest percent, we could regard the integer-valued PD-L1 scores as forming
a stratification over the PD-L1 space with 101 mutually-exclusive and -exhaustive cohorts, but that
would be an unfortunate way to address this problem, not least because the efficacy model would
require more than 100 parameters.
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The parameters for the efficacy EGM in Scenario 4c were calculated by fitting the
following GLM model
logitπE = θ1 + θ2x1 + θ3x2 + θ4x
2
2 + θ5x1x2 + θ6x1x
2
2
= −1.61− 0.69x1 − 0.05x2 + 2.93x22 + 2.36x1x2 − 2.35x1x22
(D.5)
to the six points in Table D.3 using the glm function in R. The model uses 6
parameters to fit six points so that a perfect fit is guaranteed, as shown in Figure
D.5. The orange dots represent the binding values in Table D.3. We see that in this
scenario, efficacy in patients with high PD-L1 scores is highly likely, especially in TN
patients.
Pre-treatment status PD-L1 score Prob(Eff) Prob(Tox)
x1 x2 πE πT
0 0 0.167 0.1
0 25 0.192 0.1
0 75 0.500 0.1
1 0 0.091 0.1
1 25 0.156 0.1
1 75 0.439 0.1
TABLE D.3: Efficacy probabilities in scenario 4c were fit to intersect
these 6 points from scenario 4 in the Chapter 5.
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FIGURE D.5: Efficacy probabilities as functions of PD-L1 score in sce-
nario 4c. The curves were fit to the points in scenario 4 from Chapter
5, reproduced in Table D.3.
Scenario 5c is similar to 4c, albeit with high toxicity.
D.1.4 Simulations Analysing Continuous PD-L1









Regularising priors are shown in Table D.4 and the events rates that they gener-
ate are summarised in Table D.5. We see that the expected event rates and credible
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intervals are similar to those generated by the regularising priors in the categorical
model in Table 5.8 with only modest differences. Figure D.6 shows the prior predic-
tive densities for TN patients with PD-L1 = 75%, chosen to allow comparison to the
analogous cohort under the categorical specification, shown in Figure 5.5. The prior
predictive distributions are very similar.
PreTreat PDL1 ProbEffL ProbEffl ProbEff ProbEffu ProbEffU
TN 0 0.00 0.02 0.22 0.33 0.80
TN 0.25 0.00 0.02 0.21 0.31 0.80
TN 0.75 0.00 0.01 0.21 0.32 0.86
PT 0 0.00 0.01 0.22 0.34 0.90
PT 0.25 0.00 0.01 0.20 0.29 0.89
PT 0.75 0.00 0.00 0.20 0.27 0.93
PreTreat PDL1 ProbToxL ProbToxl ProbTox ProbToxu ProbToxU
TN 0 0.00 0.03 0.20 0.30 0.75
TN 0.25 0.00 0.03 0.20 0.30 0.75
TN 0.75 0.00 0.03 0.20 0.30 0.75
PT 0 0.00 0.03 0.20 0.30 0.75
PT 0.25 0.00 0.03 0.20 0.30 0.75
PT 0.75 0.00 0.03 0.20 0.30 0.75
TABLE D.5: Credible intervals for events rates drawn from the prior
predictive distribution of the regularising priors in Table D.4. Lower-
case l and u show the central 50% credible interval and upper-case L
and U show the central 90% credible interval.
FIGURE D.6: Prior predictive distributions of the probabilities of effi-
cacy and toxicity in TN patients with PD-L1 = 75% under regularising
priors.
Table D.6 shows operating characteristics for model 411c with n = 60 patients.
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Sc PreTreat PDL1 PrEff PrTox Reg EffBias EffEmpSE EffCov ToxBias ToxEmpSE ToxCov
1c 0 0.00 0.300 0.1 0.974 -0.002 0.086 0.910 0.001 0.037 0.909
0 0.25 0.300 0.1 0.977 -0.010 0.081 0.889 0.001 0.037 0.909
0 0.50 0.300 0.1 0.952 -0.010 0.093 0.899 0.001 0.037 0.909
0 0.75 0.300 0.1 0.883 -0.003 0.114 0.917 0.001 0.037 0.909
0 1.00 0.300 0.1 0.792 0.008 0.136 0.929 0.001 0.037 0.909
1 0.00 0.300 0.1 0.959 0.005 0.095 0.894 0.001 0.037 0.909
1 0.25 0.300 0.1 0.963 -0.013 0.085 0.872 0.001 0.037 0.909
1 0.50 0.300 0.1 0.899 -0.018 0.103 0.877 0.001 0.037 0.909
1 0.75 0.300 0.1 0.792 -0.012 0.130 0.888 0.001 0.037 0.909
1 1.00 0.300 0.1 0.684 -0.001 0.157 0.891 0.001 0.037 0.909
2c 0 0.00 0.100 0.3 0.029 0.009 0.051 0.921 -0.004 0.057 0.903
0 0.25 0.100 0.3 0.025 -0.003 0.046 0.896 -0.004 0.057 0.903
0 0.50 0.100 0.3 0.020 -0.004 0.051 0.893 -0.004 0.057 0.903
0 0.75 0.100 0.3 0.020 0.002 0.064 0.913 -0.004 0.057 0.903
0 1.00 0.100 0.3 0.021 0.014 0.081 0.936 -0.004 0.057 0.903
1 0.00 0.100 0.3 0.027 0.005 0.057 0.892 -0.004 0.057 0.903
1 0.25 0.100 0.3 0.017 -0.013 0.047 0.830 -0.004 0.057 0.903
1 0.50 0.100 0.3 0.014 -0.016 0.054 0.829 -0.004 0.057 0.903
1 0.75 0.100 0.3 0.016 -0.006 0.072 0.845 -0.004 0.057 0.903
1 1.00 0.100 0.3 0.017 0.011 0.096 0.871 -0.004 0.057 0.903
4c 0 0.00 0.167 0.1 0.650 0.002 0.062 0.921 0.001 0.037 0.909
0 0.25 0.192 0.1 0.921 0.049 0.075 0.852 0.001 0.037 0.909
0 0.50 0.289 0.1 0.975 0.051 0.101 0.872 0.001 0.037 0.909
0 0.75 0.500 0.1 0.981 -0.048 0.132 0.899 0.001 0.037 0.909
0 1.00 0.780 0.1 0.981 -0.224 0.155 0.703 0.001 0.037 0.909
1 0.00 0.091 0.1 0.226 0.017 0.051 0.928 0.001 0.037 0.909
1 0.25 0.156 0.1 0.638 0.013 0.067 0.899 0.001 0.037 0.909
1 0.50 0.268 0.1 0.882 0.002 0.104 0.883 0.001 0.037 0.909
1 0.75 0.439 0.1 0.928 -0.038 0.149 0.878 0.001 0.037 0.909
1 1.00 0.642 0.1 0.938 -0.115 0.182 0.870 0.001 0.037 0.909
5c 0 0.00 0.167 0.3 0.083 0.002 0.063 0.920 -0.004 0.057 0.901
0 0.25 0.192 0.3 0.121 0.049 0.075 0.850 -0.004 0.057 0.901
0 0.50 0.289 0.3 0.129 0.051 0.101 0.870 -0.004 0.057 0.901
0 0.75 0.500 0.3 0.130 -0.048 0.132 0.900 -0.004 0.057 0.901
0 1.00 0.780 0.3 0.130 -0.224 0.155 0.704 -0.004 0.057 0.901
1 0.00 0.091 0.3 0.028 0.017 0.051 0.927 -0.004 0.057 0.901
1 0.25 0.156 0.3 0.081 0.013 0.067 0.900 -0.004 0.057 0.901
1 0.50 0.268 0.3 0.117 0.002 0.104 0.885 -0.004 0.057 0.901
1 0.75 0.439 0.3 0.122 -0.038 0.149 0.878 -0.004 0.057 0.901
1 1.00 0.642 0.3 0.124 -0.115 0.182 0.871 -0.004 0.057 0.901
TABLE D.6: Operating performance of continuous PD-L1 model 411
in the scenarios in Table D.2 with total sample size 60. PreTreat re-
flects x1 and PDL1 x2. Reg shows approval probability under the
regularising priors. Eff and Tox are abbreviations for efficacy and
toxicity. EmpSE is empirical standard error and Cov is coverage of
90% posterior credible intervals.
In scenario 1c, we see that approval probability is unacceptable in some cohorts.
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FIGURE D.7: Probability of approval in scenario 4 under the 411 mod-
els that analyse continuous and categorical PD-L1.
Performance degrades as the two covariates take values further from zero. In gen-
eral, approval probability is always lower in PT (where PreTreat = 1) than TN pa-
tients (where PreTreat = 0) for matched PD-L1 and underlying event probabilities.
Furthermore as PD-L1 increases in scenario 1c, the approval probabilities fall, de-
spite the underlying event rates remaining constant. We revisit this below.
In scenario 2c, the model correctly disregards the treatment with high probability.
It is in scenario 4c that we see the real benefit of using continuous PD-L1. Fig-
ure D.7 shows the approval probability as a function of PD-L1 for models 411c and
411, the categorical model in Chapter 5. For model 411, the approval probabilities
increase in steps, as reflected by the coarse categorisation scheme. For instance, as
PD-L1 increases from 49% to 50%, the estimated probability of approval jumps by
approximately 40% in PT patients under the categorical model. This is clearly un-
desirable because it fails to reflect the underlying biological reality. In contrast, the
approval probability under the continuous model is a smooth increasing function of
PD-L1, which mirrors that efficacy is a smooth function of PD-L1 score, as demon-
strated in Figure D.2.
The PT cohort shows that the continuous model does not indiscriminately ap-
prove. Recall from Table D.6 that when PD-L1 is zero, the true efficacy probability is
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FIGURE D.8: Simulated posterior mean parameter estimates of model
411c in scenario 1c.
only 9.1% so it is incorrect to approve here. Model 411c is less likely to approve than
model 411. When PD-L1 is zero in TN patients, the efficacy probability is 16.7% and
it is acceptable to approve here.
There is notable negative bias in the estimations of efficacy at PD-L1 ≥ 75% in
scenarios 4c and 5c. This is because the analysis model is less complex than the EGM,
and the efficacy probability is underestimated at high PD-L1 values. Irrespective, the
approval probabilities are not unduly impaired.
The continuous model performs very similarly in scenario 5c as model 411 per-
formed in scenario 5, correctly rejecting with high probability.
Returning to scenario 1c, Figure D.8 illustrates why approval falls in PD-L1. It
shows the distribution of the final parameter estimates over the simulated trial iter-
ations. The expected values for β, γ & ζ are zero, as required. However, the distribu-
tions for γ & ζ are relatively wide. These are the two coefficients in (D.3) for terms
that contribute to the gradient with respect to PD-L1 score. If they are estimated to
be negative, which happens relatively frequently, the approval probability will de-
crease as PD-L1 increases. Nevertheless, the bias values are low throughout and the
coverage values close to the theoretical 90%.
A natural temptation is to use a prior that take only positive values, like beta
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or half-normal distributions. This would reflect our belief that efficacy is positively
associated with PD-L1. However, when regularising half-normal priors are used,
undesirable biases manifest elsewhere. In particular, material inflation occurs in the
estimated efficacy rate and approval probability when PD-L1 is 0% and the under-
lying true efficacy rate is only 9.1%.
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